omeprazole has been researched along with Gastroduodenal Ulcer in 742 studies
Omeprazole: A 4-methoxy-3,5-dimethylpyridyl, 5-methoxybenzimidazole derivative of timoprazole that is used in the therapy of STOMACH ULCERS and ZOLLINGER-ELLISON SYNDROME. The drug inhibits an H(+)-K(+)-EXCHANGING ATPASE which is found in GASTRIC PARIETAL CELLS.
omeprazole : A racemate comprising equimolar amounts of (R)- and (S)-omeprazole.
5-methoxy-2-{[(4-methoxy-3,5-dimethylpyridin-2-yl)methyl]sulfinyl}-1H-benzimidazole : A member of the class of benzimidazoles that is 1H-benzimidazole which is substituted by a [4-methoxy-3,5-dimethylpyridin-2-yl)methyl]sulfinyl group at position 2 and a methoxy group at position 5.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Poliprotect proved noninferior to standard-dose omeprazole in symptomatic patients with heartburn/epigastric burning without erosive esophagitis and gastroduodenal lesions." | 9.69 | Poliprotect vs Omeprazole in the Relief of Heartburn, Epigastric Pain, and Burning in Patients Without Erosive Esophagitis and Gastroduodenal Lesions: A Randomized, Controlled Trial. ( Annibale, B; Badiali, D; Bassotti, G; Bragazzi, MC; Ciacci, C; Cicala, M; Corazziari, ES; D'Alba, L; D'Ovidio, V; Di Sabatino, A; Gasbarrini, A; Iovino, P; Marazzato, M; Neri, M; Passaretti, S; Radocchia, G; Repici, A; Ribichini, E; Riggio, O; Schippa, S, 2023) |
| " Here, we compare the efficacy of the gastromucoprotective drug irsogladine with omeprazole in preventing NSAID-induced esophagitis, peptic ulcers, and small-intestinal mucosal injury in healthy subjects." | 9.17 | Preventive effect of irsogladine or omeprazole on non-steroidal anti-inflammatory drug-induced esophagitis, peptic ulcers, and small intestinal lesions in humans, a prospective randomized controlled study. ( Abe, Y; Higuchi, K; Inoue, T; Ishida, K; Kawakami, K; Kojima, Y; Kuramoto, T; Murano, M; Narabayashi, K; Nouda, S; Takeuchi, T; Tokioka, S; Umegaki, E; Yoda, Y, 2013) |
| "Melatonin and L-tryptophan (Trp) are highly gastroprotective in humans, but no study has assessed their impact on healing of chronic gastroduodenal ulcers in humans." | 9.15 | Melatonin or L-tryptophan accelerates healing of gastroduodenal ulcers in patients treated with omeprazole. ( Bielanski, W; Brzozowski, T; Celinski, K; Cichoz-Lach, H; Konturek, PC; Konturek, SJ; Malgorzata, P; Reiter, RJ; Slomka, M, 2011) |
| "Patients with Helicobacter pylori positive peptic ulcer disease were randomly allocated into two groups: amoxicillin 1 g b." | 9.15 | Furazolidone, amoxicillin and omeprazole with or without bismuth for eradication of Helicobacter pylori in peptic ulcer disease. ( Ghadir, MR; Iranikhah, A; Joukar, F; Mansour-Ghanaei, F; Pakdin, A; Shafaghi, A, 2011) |
| " The aim of this study was to evaluate the efficacy and tolerability of a levofloxacin-based regimen in patients with peptic ulcer after failure of the standard first-line H." | 9.15 | Second-line levofloxacin-based triple therapy's efficiency for Helicobacter pylori eradication in patients with peptic ulcer. ( Akyuz, F; Ermis, F; Kaymakoglu, S; Kurt, R; Mungan, Z; Nazik, H; Pinarbasi, B; Uyanikoglu, A, 2011) |
| "To establish the efficacy and safety of a 7-d therapeutic regimen using omeprazole, bismuth subcitrate, furazolidone and amoxicillin in patients with peptic ulcer disease who had been previously treated with other therapeutic regimens without success." | 9.13 | Quadruple therapy with furazolidone for retreatment in patients with peptic ulcer disease. ( Barbuti, RC; Eisig, JN; Felga, GE; Navarro-Rodriguez, T; Silva, FM; Zaterka, S, 2008) |
| "The remaining ratio of peptic ulcers after 1 week and the complete healing rate after 6 weeks in the rabeprazole versus omeprazole group were 45." | 9.12 | Comparison of the efficacy of rabeprazole 10 mg and omeprazole 20 mg for the healing rapidity of peptic ulcer diseases. ( Baik, SK; Jee, MK; Ji, S; Kim, HS; Kim, JW; Kwon, SO; Lee, DK; Park, KW; Song, JS; Uh, Y, 2006) |
| "Clopidogrel causes significantly less symptomatic peptic ulcer disease and gastrointestinal bleeding than low-dose aspirin in average-risk patients." | 9.11 | Clopidogrel plus omeprazole compared with aspirin plus omeprazole for aspirin-induced symptomatic peptic ulcers/erosions with low to moderate bleeding/re-bleeding risk -- a single-blind, randomized controlled study. ( Chang, CM; Chen, WH; Ng, FH; Wong, BC; Wong, SY, 2004) |
| " pylori-positive peptic ulcer were randomly divided into two groups, and accepted triple therapy with omeprazole 20 mg, amoxicillin 1000 mg and either clarithromycin 500 mg (OAC group, n = 58) or metronidazole 400 mg (OAM group, n = 45)." | 9.11 | Efficacy of omeprazole and amoxicillin with either clarithromycin or metronidazole on eradication of Helicobacter pylori in Chinese peptic ulcer patients. ( Cao, DZ; Fu, XL; Hu, JM; Ou, XL; Su, H; Sun, WH; Sun, YL; Yu, Q; Yu, T; Zhu, F, 2005) |
| "To study the efficacy and safety of rabeprazole in peptic ulcer patients alone or combined with anti-Helicobacter pylori (Hp) agents." | 9.11 | [The clinical applications of rabeprazole either alone or combined with anti-Helicobacter pylori agents in peptic ulcer patients]. ( Lin, SR, 2005) |
| "A total of 101 patients who had peptic ulcer bleeding based on endoscopic findings of nonbleeding visible vessels or fresh adherent clots were randomly assigned to receive omeprazole (40 mg p." | 9.10 | Comparison of oral omeprazole and endoscopic ethanol injection therapy for prevention of recurrent bleeding from peptic ulcers with nonbleeding visible vessels or fresh adherent clots. ( Jung, HK; Jung, SA; Kim, DY; Lee, HC; Moon, IH; Son, HY; Yi, SY; Yoo, K, 2002) |
| " pylori-positive patients with peptic ulcer bleeding (n = 101) were randomized to receive either a regular dose (20 mg/day for 3 days) (n = 51) or a high dose of omeprazole (80 mg bolus + 8 mg/h infusion/day for 3 days) (n = 50)." | 9.10 | Effect of short-term treatment with regular or high doses of omeprazole on the detection of Helicobacter pylori in bleeding peptic ulcer patients. ( Julkunen, R; Miettinen, P; Palmu, A; Udd, M, 2003) |
| " pylori-positive patients with peptic ulcer disease were received rabeprazole 10 mg bid, amoxicillin 1,000 mg bid and clarithromycin 500 mg bid for a week." | 9.10 | [A prospective study on rabeprazole-based triple therapy for Helicobacter pylori eradication in patients with peptic ulcer]. ( Choi, BK; Chung, JM; Jang, YS; Lee, SH; Lee, YJ; Park, ET; Seol, SY; Yang, SY, 2003) |
| "To compare the short-term (7-day) safety and efficacy of two triple-therapy regimens using pantoprazole with those of two dual-therapy regimens (one with pantoprazole and one without), for Helicobacter pylori eradication in patients with peptic ulcer disease." | 9.10 | Eradication of Helicobacter pylori by 7-day triple-therapy regimens combining pantoprazole with clarithromycin, metronidazole, or amoxicillin in patients with peptic ulcer disease: results of two double-blind, randomized studies. ( Bochenek, WJ; Davis, KD; El-Zimaity, HM; Fraga, PD; Graham, DY; Mack, ME; Osato, MS; Peters, S; Wang, W, 2003) |
| " pylori-infected peptic ulcer patients were randomly assigned to 1 of 3 groups: RAC4 (rabeprazole 20 mg, amoxicillin 1000 mg, and clarithromycin 500 mg twice daily for 4 days), RAC7 (rabeprazole 20 mg, amoxicillin 1000 mg, and clarithromycin 500 mg twice daily for 7 days), and OAC7 (omeprazole 20mg, amoxicillin 1000 mg, and clarithromycin 500 mg twice daily for 7 days)." | 9.10 | Comparison of rabeprazole-based four- and seven-day triple therapy and omeprazole-based seven-day triple therapy for Helicobacter pylori infection in patients with peptic ulcer. ( Chen, JH; Chen, TJ; Lee, SC; Wang, GM; Yang, KC, 2003) |
| "In this randomised, double-blind, multicentre study, conducted at 27 European sites, the efficacy and safety of rabeprazole and omeprazole were compared in patients with erosive or ulcerative gastro-oesophageal reflux disease (GERD)." | 9.09 | Double-blind comparison [correction of Double-blind, placebo-controlled comparison] of rabeprazole 20 mg vs. omeprazole 20 mg in the treatment of erosive or ulcerative gastro-oesophageal reflux disease. The European Rabeprazole Study Group. ( Beker, JA; Bell, NE; Dekkers, CP; Gabryelewicz, A; Humphries, TJ; Thjodleifsson, B, 1999) |
| "This study was a comparison of 1-week and 2-week triple therapies with omeprazole, amoxicillin, and clarithromycin (OAC) in patients with peptic ulcer disease and Helicobacter pylori infection." | 9.09 | Comparison of 1-week and 2-week triple therapy with omeprazole, amoxicillin, and clarithromycin in peptic ulcer patients with Helicobacter pylori infection: results of a randomized controlled trial. ( Habu, Y; Inokuchi, H; Kawai, K; Kimoto, K; Kiyota, K; Mizuno, S; Sugano, Y, 1999) |
| " pylori positive active peptic ulcer disease were randomly assigned to receive lansoprazole 30 mg o." | 9.09 | Effect of ornidazole and clarithromycin resistance on eradication of Helicobacter pylori in peptic ulcer disease. ( Beglinger, C; Drewe, J; Lehmann, FS; Terracciano, L, 2000) |
| "Lansoprazole 30 mg, amoxicillin 1000 mg, and tinidazole 500 mg were given twice daily to 39 peptic ulcer patients (26 duodenal and 13 gastric ulcer, mean age 52." | 9.09 | Eradication of Helicobacter pylori with lansoprazole based triple therapy in peptic ulcer disease. ( Gonlachanvit, S; Kladchareon, N; Kullavanijaya, P; Mahachai, V, 2000) |
| "After endoscopic treatment of bleeding peptic ulcers, a high-dose infusion of omeprazole substantially reduces the risk of recurrent bleeding." | 9.09 | Effect of intravenous omeprazole on recurrent bleeding after endoscopic treatment of bleeding peptic ulcers. ( Chan, AC; Chan, FK; Chung, SC; Lau, JY; Lee, CW; Lee, KK; Ng, EK; Sung, JJ; Wong, SK; Wu, JC; You, JH; Yung, MY, 2000) |
| "Little is known about the efficacy and safety of different formulations of omeprazole-based triple therapy regimens for the treatment of Helicobacter pylori-positive peptic ulcer." | 9.09 | Comparison of the efficacy and safety of different formulations of omeprazole-based triple therapies in the treatment of Helicobacter pylori-positive peptic ulcer. ( Baik, SK; Cho, MY; Jeong, YS; Kim, HS; Kim, JW; Kim, KH; Kwon, SO; Lee, DK; Seo, JI, 2001) |
| "This study reports preliminary results of a controlled, multicenter trial on the quality of ulcer healing induced by lansoprazole (LPZ) or roxatidine (R) in gastric ulcer (GU) or duodenal ulcer (DU) patients." | 9.08 | Quality of peptic ulcer healing induced by lansoprazole and roxatidine. ( Fujino, MA; Kobayashi, K; Morozumi, A; Ohtsuka, H; Sano, S; Suzuki, Y; Tachikawa, H; Uchida, N; Ueda, F; Yamamoto, Y, 1995) |
| "The clinical usefulness of lansoprazole in the healing of gastric and duodenal ulcers, the S2-stage shift rate (white scarring rate), and endoscopic healing rate with respect to degree of gastric mucosal atrophy were investigated." | 9.08 | Clinical evaluation of lansoprazole in the treatment of peptic ulcers: initial healing and prevention of relapse. Tohoku Peptic Ulcer Study Group. ( Asaki, S; Hongo, M; Sakurada, H; Sato, A; Takeda, T; Toyota, T, 1995) |
| "In the present study, the effects of short-term treatment with lansoprazole on healing and recurrence of peptic ulcer were investigated." | 9.08 | The effect of lansoprazole treatment on the healing and relapse of peptic ulcer and serum levels of IgG anti-Helicobacter pylori antibody. ( Akimoto, K; Fukujin, H; Katoaka, A; Mashima, H; Mine, T; Nagasawa, J; Tajima, A; Takano, T; Tsuchida, T; Yasuda, H, 1995) |
| "We studied the effects of lansoprazole on ulcer healing and Helicobacter pylori infection in elderly patients with peptic ulcers." | 9.08 | Therapeutic effects of lansoprazole on peptic ulcers in elderly patients. ( Asagoe, K; Dekigai, H; Kusaka, S; Maeda, S; Matsumoto, M; Mizuno, M; Murakami, M; Saita, H; Seki, M; Takahashi, Y, 1995) |
| "Patients with a history of dyspepsia or uncomplicated peptic ulcer disease and with a need for continuous NSAID treatment were randomized to receive either 20 mg omeprazole once daily or placebo." | 9.08 | Prevention of peptic ulcer and dyspeptic symptoms with omeprazole in patients receiving continuous non-steroidal anti-inflammatory drug therapy. A Nordic multicentre study. ( Anker-Hansen, O; Carling, L; Ekström, P; Lundegårdh, G; Thorhallsson, E; Unge, P; Wetterhus, S; Wingren, PE, 1996) |
| "In this prospective controlled study conducted in a single center, 78 symptomatic peptic ulcer patients were treated for 4 wk with omeprazole 40 mg o." | 9.08 | Does pretreatment with omeprazole decrease the chance of eradication of Helicobacter pylori in peptic ulcer patients? ( Anania, MC; Annibale, B; D'Ambra, G; Delle Fave, G; Iannoni, C; Luzzi, I; Marcheggiano, A; Marignani, M; Paoletti, M, 1997) |
| "The use of omeprazole is more effective than cimetidine in increasing intragastric pH and reducing rebleeding episodes in patients with bleeding peptic ulcers after successful endoscopic therapy." | 9.08 | A prospective randomized comparative trial showing that omeprazole prevents rebleeding in patients with bleeding peptic ulcer after successful endoscopic therapy. ( Lee, FY; Lin, HJ; Lo, WC; Perng, CL; Tseng, GY, 1998) |
| "One hundred and sixty-nine patients chronically ingesting diclofenac, ketoprofen, indomethacin or naproxen for osteoarthritis or rheumatoid arthritis, who had abdominal pain and an endoscopically proven gastroduodenal ulcer, were evaluated in a randomized, double-blind, dose regimen trial with omeprazole 20 mg o." | 9.08 | Omeprazole 20 or 40 mg daily for healing gastroduodenal ulcers in patients receiving non-steroidal anti-inflammatory drugs. ( Annibale, B; Capurso, L; Del Veccho Blanco, C; Fusillo, M; Massimo Claar, G; Monaco, S, 1998) |
| "Rabeprazole is a new fast acting proton pump inhibitor that has recently been proven to be effective in the treatment of peptic ulceration and reflux esophagitis." | 9.08 | Safety and efficacy of rabeprazole in combination with four antibiotic regimens for the eradication of Helicobacter pylori in patients with chronic gastritis with or without peptic ulceration. ( Atherton, JC; Cockayne, A; Hawkey, CJ; Jenkins, D; Knifton, A; Stack, WA; Thirlwell, D, 1998) |
| "Two 4-week triple-therapy treatment regimens, metronidazole+tetracycline+bismuth subcitrate and omeprazole+amoxycillin+bismuth subcitrate, were compared in a randomly allocated double-blind trial for their efficacy in eradicating Helicobacter pylori from the gastric mucosa of patients with gastritis and/or peptic ulcer disease." | 9.07 | Pharmacological effects of metronidazole+tetracycline+bismuth subcitrate versus omeprazole+amoxycillin+bismuth subcitrate in Helicobacter pylori-related gastritis and peptic ulcer disease. ( Hahm, JS; Kim, HJ; Park, KN, 1994) |
| "Patients (106) with peptic ulceration of the oesophagus, stomach and duodenum, unresponsive to 3 or more months of high-dose treatment with ranitidine, were initially given pantoprazole (40-80 mg, p." | 9.07 | Long-term therapy with pantoprazole in patients with peptic ulceration resistant to extended high-dose ranitidine treatment. ( Brunner, G; Harke, U, 1994) |
| "Forty-two patients with peptic ulceration of the duodenum, stomach or oesophagus, who had not responded to 3 or more months of high-dose treatment with ranitidine (450 or 600 mg/day), were treated with oral lansoprazole at 30-60 mg daily." | 9.07 | An open trial of long-term therapy with lansoprazole in patients with peptic ulceration resistant to extended high-dose ranitidine treatment. ( Arnold, R; Brunner, G; Fuchs, W; Hennig, U, 1993) |
| " Altogether 107 patients (duodenal ulcer, n = 88; prepyloric ulcer, n = 14; gastric ulcer, n = 3; mixed sites, n = 2) with refractory peptic ulcer - that is ulcer unhealed after at least two months' treatment with cimetidine 0." | 9.07 | Treatment of refractory peptic ulcer with omeprazole or continued H2 receptor antagonists: a controlled clinical trial. ( Bardhan, KD; Bianchi Porro, G; Carroll, NJ; Daly, MJ; Hinchliffe, RF; Lazzaroni, M; Morris, P; Naesdal, J; Petrillo, M; Thompson, M, 1991) |
| "Twenty-seven patients with peptic ulcer (19 with duodenal ulcer (DU) and eight with gastric ulcer (GU] refractory to H2-antagonists were treated with 40 mg of omeprazole once daily for 4-8 weeks, depending on the rate of ulcer healing." | 9.06 | Omeprazole in acute and long-term treatment of Asian patients with peptic ulcer refractory to H2-antagonists. ( Chelvam, P; Wong, EC, 1989) |
| " Recent randomized controlled trials in patients who are at moderately increased risk of ulcers have shown that the proton pump inhibitor esomeprazole (the S-isomer of racemic omeprazole) reduces the gastroduodenal ulcer incidence by approximately 70-85% and the gastrointestinal bleeding risk by as much as 90%." | 8.87 | Reducing the risk of gastroduodenal ulcers with a fixed combination of esomeprazole and low-dose acetyl salicylic acid. ( Yeomans, ND, 2011) |
| " pylori infection in active peptic ulcer in Korea (30 mg of lansoprazole, 250 mg of clarithromycin, and 400 mg of metronidazole, all twice daily)." | 7.70 | One-week triple therapy with lansoprazole, clarithromycin, and metronidazole to cure Helicobacter pylori infection in peptic ulcer disease in Korea. ( El-Zimaity, HM; Graham, DY; Kim, JG; Osato, MS; Perng, CL, 1998) |
| "Omeprazole, a substituted benzimidazole, is known to inhibit acid secretion from parietal cells in gastric glands, and is widely utilized as a drug for peptic ulcer." | 7.70 | Fine structural and morphometric studies on gastric parietal cells of peptic ulcer patients after long-term treatment with omeprazole. ( Kobayashi, H; Mutoh, H; Nakahara, A; Tanaka, N; Uchiyama, Y; Watanabe, T, 1998) |
| "To investigate whether CYP2C19 genotype status is associated with cure rates for Helicobacterpylori infection and peptic ulcer achieved by using dual therapy with omeprazole and amoxicillin." | 7.70 | Effect of genetic differences in omeprazole metabolism on cure rates for Helicobacter pylori infection and peptic ulcer. ( Furuta, T; Hanai, H; Ishizaki, T; Kamata, T; Kaneko, E; Kawasaki, T; Kosuge, K; Kubota, T; Ohashi, K; Takashima, M, 1998) |
| "A prospective trial was designed to study the effectiveness of the 1-week combination of lansoprazole, clarithromycin and amoxycillin in 102 consecutive patients with active peptic ulcer." | 7.70 | Impact of clarithromycin resistance on the effectiveness of a regimen for Helicobacter pylori: a prospective study of 1-week lansoprazole, amoxycillin and clarithromycin in active peptic ulcer. ( Ducóns, JA; Ferrero, M; Gomollón, F; Guirao, R; Montoro, M; Santolaria, S, 1999) |
| "Long-term omeprazole therapy in humans results in moderate hypergastrinemia and a significant argyrophil cell hyperplasia, which are correlated to the grade of corpus gastritis." | 7.68 | Long-term omeprazole therapy in peptic ulcer disease: gastrin, endocrine cell growth, and gastritis. ( Brunner, G; Creutzfeldt, W; Lamberts, R; Solcia, E; Strüber, HG, 1993) |
| "Thirty patients with peptic ulcers resistant to at least 8 weeks of continuous therapy with full-dose H2-receptor antagonists alone or followed by other anti-ulcer drugs, were treated with the gastric proton pump inhibitor omeprazole (40 mg), administered orally once daily for up to 8 weeks." | 7.68 | Omeprazole in the treatment of peptic ulcers resistant to H2-receptor antagonists. ( Guerreiro, AS; Neves, BC; Quina, MG, 1990) |
| "A total of 143 patients with peptic ulceration of the duodenum, stomach and oesophagus who did not respond to 3 or more months of high-dose treatment with ranitidine, 450 mg or more daily, were treated with oral omeprazole, 40 mg daily." | 7.68 | Efficacy and safety of omeprazole in the long-term treatment of peptic ulcer and reflux oesophagitis resistant to ranitidine. ( Brunner, GH; Creutzfeldt, W; Lamberts, R, 1990) |
| "Omeprazole is a proton pump inhibitor with proven efficacy in the prevention and treatment of PUD." | 6.76 | Prophylactic use of omeprazole associated with a reduced risk of peptic ulcer disease among maintenance hemodialysis patients. ( Chang, CT; Hsu, WM; Huang, CC; Kuo, HL; Liang, CC; Lin, HH; Liu, JH; Wang, IK; Yeh, HC, 2011) |
| "Omeprazole (OM) has been shown to be superior to H2-Blockers in terms of complete healing rates of gastric (GU) and duodenal ulcers (DU)." | 6.68 | [Treatment of acute peptic gastroduodenal ulcer: omeprazole is superior to ranitidine especially in the early phase of ulcer healing. A prospective controlled randomized serial endoscopy study]. ( Guthke, A; Hotz, J; Kark, W; Otten, O; Plein, K; Wiedbrauck, F, 1995) |
| "Lansoprazole 30 mg/day was administered to 124 gastric ulcer (GU) patients and 57 duodenal ulcer (DU) patients." | 6.68 | Peptic ulcer therapy with lansoprazole and Helicobacter pylori eradication. ( Kato, T; Ogoshi, K; Sakagawa, T, 1995) |
| "Lansoprazole is a potent antisecretory drug also possessing anti-Helicobacter pylori activity in vitro." | 6.68 | Lansoprazole capsules and amoxicillin oral suspension in the treatment of peptic ulcer disease. ( Bang, CJ; Berstad, A; Hatlebakk, JG; Hausken, T; Nesje, LB, 1995) |
| "Pirenzepine has been reported to inhibit gastrin secretion." | 6.68 | Effects of pirenzepine on omeprazole-induced hypergastrinemia and acid suppression in peptic ulcer patients. ( Fukino, Y; Hamada, M; Haruma, K; Inoue, M; Kajiyama, G; Kamiyasu, T; Sumii, K; Sumii, M; Tari, A, 1996) |
| "Omeprazole is a substituted benzimidazole derivative which markedly inhibits basal and stimulated gastric acid secretion." | 6.37 | Omeprazole. A preliminary review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in peptic ulcer disease and Zollinger-Ellison syndrome. ( Campoli-Richards, DM; Clissold, SP, 1986) |
| "Poliprotect proved noninferior to standard-dose omeprazole in symptomatic patients with heartburn/epigastric burning without erosive esophagitis and gastroduodenal lesions." | 5.69 | Poliprotect vs Omeprazole in the Relief of Heartburn, Epigastric Pain, and Burning in Patients Without Erosive Esophagitis and Gastroduodenal Lesions: A Randomized, Controlled Trial. ( Annibale, B; Badiali, D; Bassotti, G; Bragazzi, MC; Ciacci, C; Cicala, M; Corazziari, ES; D'Alba, L; D'Ovidio, V; Di Sabatino, A; Gasbarrini, A; Iovino, P; Marazzato, M; Neri, M; Passaretti, S; Radocchia, G; Repici, A; Ribichini, E; Riggio, O; Schippa, S, 2023) |
| "Omeprazole was superior to famotidine with less gastrointestinal symptoms and recurrent ulcers/erosions in patients using 24-week low-dose aspirin." | 5.40 | Comparison of proton pump inhibitor and histamine-2 receptor antagonist in the prevention of recurrent peptic ulcers/erosions in long-term low-dose aspirin users: a retrospective cohort study. ( Chan, HH; Chen, WC; Cheng, JS; Chiang, PH; Lai, KH; Li, YD; Tsai, TJ; Tsai, WL; Tsay, FW; Wang, EM, 2014) |
| "It was found that patients with gastroduodenal ulcer have metabolic, less frequently hypercapnic acidosis with suppressed gastric secretion of HCO3-." | 5.31 | [Relations of acid-base balance and gastric secretion of hydrogen carbonate ions in patients with peptic ulcer]. ( Ivashkina, TG; Kulikov, AN; Malov, IuS, 2001) |
| "Therefore, we diagnosed bronchial asthma associated with reflux esophagitis and gastroduodenal ulcer." | 5.29 | [A case of bronchial asthma associated with reflux esophagitis, whose peak expiratory flow rate improved with omeprazole and cisapride]. ( Arakawa, M; Fujimori, K; Suzuki, E, 1994) |
| "Pre-treatment metronidazole susceptible H pylori were significantly more likely to respond to the triple therapy used than those with the metronidazole resistant ones (14 of 15 v five of 10) (p = 0." | 5.29 | Prevalence of metronidazole resistant Helicobacter pylori strains among Chinese peptic ulcer disease patients and normal controls in Hong Kong. ( Ching, CK; Lai, CL; Lai, KC; Lam, SK; Leung, KP; Wong, BC; Yung, RW, 1996) |
| "Omeprazole is a potent and long-acting inhibitor of pentagastrin stimulated gastric acid secretion in normal subjects, and this prompted a study of the effect of omeprazole on gastric acid hypersecretion and acid peptic disease resulting from endogenous hypergastrinaemia in Zollinger-Ellison patients." | 5.27 | Present experiences with omeprazole in the Zollinger-Ellison syndrome. ( Lamers, CB, 1986) |
| " Here, we compare the efficacy of the gastromucoprotective drug irsogladine with omeprazole in preventing NSAID-induced esophagitis, peptic ulcers, and small-intestinal mucosal injury in healthy subjects." | 5.17 | Preventive effect of irsogladine or omeprazole on non-steroidal anti-inflammatory drug-induced esophagitis, peptic ulcers, and small intestinal lesions in humans, a prospective randomized controlled study. ( Abe, Y; Higuchi, K; Inoue, T; Ishida, K; Kawakami, K; Kojima, Y; Kuramoto, T; Murano, M; Narabayashi, K; Nouda, S; Takeuchi, T; Tokioka, S; Umegaki, E; Yoda, Y, 2013) |
| " Patients with Helicobacter pylori infection and a history of peptic ulcer were assigned dual antiplatelet combination with omeprazole." | 5.17 | Effect of clopidogrel with or without omeprazole in patients with carotid artery stenting. ( Chen, G; Du, Y; Hang, L; Ma, B, 2013) |
| "Melatonin and L-tryptophan (Trp) are highly gastroprotective in humans, but no study has assessed their impact on healing of chronic gastroduodenal ulcers in humans." | 5.15 | Melatonin or L-tryptophan accelerates healing of gastroduodenal ulcers in patients treated with omeprazole. ( Bielanski, W; Brzozowski, T; Celinski, K; Cichoz-Lach, H; Konturek, PC; Konturek, SJ; Malgorzata, P; Reiter, RJ; Slomka, M, 2011) |
| "Patients with Helicobacter pylori positive peptic ulcer disease were randomly allocated into two groups: amoxicillin 1 g b." | 5.15 | Furazolidone, amoxicillin and omeprazole with or without bismuth for eradication of Helicobacter pylori in peptic ulcer disease. ( Ghadir, MR; Iranikhah, A; Joukar, F; Mansour-Ghanaei, F; Pakdin, A; Shafaghi, A, 2011) |
| " The aim of this study was to evaluate the efficacy and tolerability of a levofloxacin-based regimen in patients with peptic ulcer after failure of the standard first-line H." | 5.15 | Second-line levofloxacin-based triple therapy's efficiency for Helicobacter pylori eradication in patients with peptic ulcer. ( Akyuz, F; Ermis, F; Kaymakoglu, S; Kurt, R; Mungan, Z; Nazik, H; Pinarbasi, B; Uyanikoglu, A, 2011) |
| "Adopting randomized and controlled principle, the 46 patients with active peptic ulcer were randomly allocated into the treated group and the control group, they received respectively the treatment of YHF + Omeprazole and Omeprazole alone for 5 weeks." | 5.14 | [Effect of yiqi huoxue formula on healing quality and recurrence rate of peptic ulcer]. ( Ge, HN; Guo, JW; Zhang, WP, 2009) |
| "Two hundred and forty Chinese with peptic ulcer disease were randomly assigned to the following regimens: amoxicillin and clarithromycin together with omeprazole (OAC) or rabeprazole (RAC)." | 5.14 | The effect of cytochrome P2C19 and interleukin-1 polymorphisms on H. pylori eradication rate of 1-week triple therapy with omeprazole or rabeprazole, amoxycillin and clarithromycin in Chinese people. ( Hu, YM; Li, QS; Mei, Q; Xu, JM; Zhang, L, 2010) |
| "To establish the efficacy and safety of a 7-d therapeutic regimen using omeprazole, bismuth subcitrate, furazolidone and amoxicillin in patients with peptic ulcer disease who had been previously treated with other therapeutic regimens without success." | 5.13 | Quadruple therapy with furazolidone for retreatment in patients with peptic ulcer disease. ( Barbuti, RC; Eisig, JN; Felga, GE; Navarro-Rodriguez, T; Silva, FM; Zaterka, S, 2008) |
| "The remaining ratio of peptic ulcers after 1 week and the complete healing rate after 6 weeks in the rabeprazole versus omeprazole group were 45." | 5.12 | Comparison of the efficacy of rabeprazole 10 mg and omeprazole 20 mg for the healing rapidity of peptic ulcer diseases. ( Baik, SK; Jee, MK; Ji, S; Kim, HS; Kim, JW; Kwon, SO; Lee, DK; Park, KW; Song, JS; Uh, Y, 2006) |
| "The study was performed in 137 patients with peptic ulcer who had undergone a 7-day course of eradication treatment with one of two sets of drugs: 1, omeprazole, amoxicillin, and tinidazole or 2, omeprazole, clarithromycin, and tinidazole." | 5.12 | Oral health status and oral hygiene practices of patients with peptic ulcer and how these affect Helicobacter pylori eradication from the stomach. ( Bucki, R; Gotebiewska, M; Kemona, A; Namiot, DB; Namiot, Z, 2007) |
| "Clopidogrel causes significantly less symptomatic peptic ulcer disease and gastrointestinal bleeding than low-dose aspirin in average-risk patients." | 5.11 | Clopidogrel plus omeprazole compared with aspirin plus omeprazole for aspirin-induced symptomatic peptic ulcers/erosions with low to moderate bleeding/re-bleeding risk -- a single-blind, randomized controlled study. ( Chang, CM; Chen, WH; Ng, FH; Wong, BC; Wong, SY, 2004) |
| "The purpose of this study was to compare the efficacy of tinidazole- versus clarithromycin-based triple regimens for eradication of Helicobacter pylori in North Indian patients of peptic ulcer disease, and to correlate the outcome with in vitro antibiotic susceptibility." | 5.11 | Use of imidazole-based eradication regimens for Helicobacter pylori should be abandoned in North India regardless of in vitro antibiotic sensitivity. ( Ahuja, V; Bal, C; Bhatia, V; Das, B; Sharma, MP, 2004) |
| " pylori positive peptic ulcer disease or functional dyspepsia were treated with two-day quadruple therapy (lansoprazole 30 mg twice daily, and colloidal bismuth subcitrate 120 mg, tetracycline 250 mg and metronidazole 250 mg, all eight times a day)." | 5.11 | The influence of pretreatment on cure rates of Helicobacter pylori eradication. ( de Boer, WA; Jansen, JB; Janssen, MJ; Laheij, RJ, 2004) |
| "We followed up 295 pregnancies exposed to omeprazole [233 in the first trimester (T1)], 62 to lansoprazole (55 in T1) and 53 to pantoprazole (47 in T1), and compared pregnancy outcome to that of 868 European Network of Teratology Information Services controls." | 5.11 | The safety of proton pump inhibitors in pregnancy: a multicentre prospective controlled study. ( Arnon, J; Clementi, M; De Santis, M; Diav-Citrin, O; Malm, H; Ornoy, A; Robert-Gnansia, E; Schaefer, C; Shechtman, S; Valti, E; van Tonningen, MR, 2005) |
| " pylori-positive peptic ulcer were randomly divided into two groups, and accepted triple therapy with omeprazole 20 mg, amoxicillin 1000 mg and either clarithromycin 500 mg (OAC group, n = 58) or metronidazole 400 mg (OAM group, n = 45)." | 5.11 | Efficacy of omeprazole and amoxicillin with either clarithromycin or metronidazole on eradication of Helicobacter pylori in Chinese peptic ulcer patients. ( Cao, DZ; Fu, XL; Hu, JM; Ou, XL; Su, H; Sun, WH; Sun, YL; Yu, Q; Yu, T; Zhu, F, 2005) |
| "To study the efficacy and safety of rabeprazole in peptic ulcer patients alone or combined with anti-Helicobacter pylori (Hp) agents." | 5.11 | [The clinical applications of rabeprazole either alone or combined with anti-Helicobacter pylori agents in peptic ulcer patients]. ( Lin, SR, 2005) |
| "Celecoxib was as effective as lansoprazole co-therapy in the prevention of recurrences of ulcer complications in subjects with a history of NSAID-related complicated peptic ulcers." | 5.11 | Celecoxib compared with lansoprazole and naproxen to prevent gastrointestinal ulcer complications. ( Chan, AO; Chu, KM; Hu, WH; Hui, WM; Lai, KC; Lam, SK; Wong, BC; Wong, J; Wong, WM, 2005) |
| "A total of 101 patients who had peptic ulcer bleeding based on endoscopic findings of nonbleeding visible vessels or fresh adherent clots were randomly assigned to receive omeprazole (40 mg p." | 5.10 | Comparison of oral omeprazole and endoscopic ethanol injection therapy for prevention of recurrent bleeding from peptic ulcers with nonbleeding visible vessels or fresh adherent clots. ( Jung, HK; Jung, SA; Kim, DY; Lee, HC; Moon, IH; Son, HY; Yi, SY; Yoo, K, 2002) |
| " pylori-infected peptic ulcer patients were randomly treated with either rabeprazole (10 mg b." | 5.10 | Effect of different proton pump inhibitors, differences in CYP2C19 genotype and antibiotic resistance on the eradication rate of Helicobacter pylori infection by a 1-week regimen of proton pump inhibitor, amoxicillin and clarithromycin. ( Habu, Y; Hayakumo, T; Inokuchi, H; Kawabata, H; Kawai, K; Kimoto, K; Kiyota, K; Kobayashi, M; Kutsumi, H; Mizuno, S; Nakajima, M; Oyasu, K; Tomioka, H, 2003) |
| " pylori-positive gastritis or peptic ulcers were randomly assigned to receive 30 mg lansoprazole twice daily (LAC group), 10 mg rabeprazole twice daily (RAC20 group), or 20 mg rabeprazole twice daily (RAC40 group), with 1000 mg amoxicillin twice daily and 400 mg clarithromycin twice daily for 1 week." | 5.10 | Impact of clarithromycin resistance and CYP2C19 genetic polymorphism on treatment efficacy of Helicobacter pylori infection with lansoprazole- or rabeprazole-based triple therapy in Japan. ( Aoyama, N; Kasuga, M; Kita, T; Kuroda, K; Maekawa, S; Miki, I; Okumura, K; Sakaeda, T; Sakai, T; Shirasaka, D; Tamura, T; Wambura, CM, 2003) |
| " pylori-positive patients with peptic ulcer bleeding (n = 101) were randomized to receive either a regular dose (20 mg/day for 3 days) (n = 51) or a high dose of omeprazole (80 mg bolus + 8 mg/h infusion/day for 3 days) (n = 50)." | 5.10 | Effect of short-term treatment with regular or high doses of omeprazole on the detection of Helicobacter pylori in bleeding peptic ulcer patients. ( Julkunen, R; Miettinen, P; Palmu, A; Udd, M, 2003) |
| "A randomized, placebo-controlled, treatment trial in Vietnam allocated 296 Helicobacter pylori-infected patients with peptic ulcer of >or= 5 mm to one of three regimens: (i) twice-daily: lansoprazole 30 mg, clarithromycin 250 mg and tinidazole 500 mg; (ii) once-daily: lansoprazole 60 mg, clarithromycin 500 mg and tinidazole 1000 mg; (iii) once-daily: placebo, clarithromycin 500 mg and tinidazole 1000 mg." | 5.10 | Helicobacter pylori eradication and peptic ulcer healing: the impact of deleting the proton pump inhibitor and using a once-daily treatment. ( Björkman, A; Granström, M; Hoang, TT; Phung, DC; Sörberg, M; Wheeldon, TU, 2003) |
| " pylori-positive patients with peptic ulcer disease were received rabeprazole 10 mg bid, amoxicillin 1,000 mg bid and clarithromycin 500 mg bid for a week." | 5.10 | [A prospective study on rabeprazole-based triple therapy for Helicobacter pylori eradication in patients with peptic ulcer]. ( Choi, BK; Chung, JM; Jang, YS; Lee, SH; Lee, YJ; Park, ET; Seol, SY; Yang, SY, 2003) |
| "To study whether prophylaxis with lansoprazole could prevent relapse of ulcers after eradication of Helicobacter pylori in patients with NSAID-related peptic ulcers." | 5.10 | Lansoprazole reduces ulcer relapse after eradication of Helicobacter pylori in nonsteroidal anti-inflammatory drug users--a randomized trial. ( Chan, CK; Chan, OO; Chu, KM; Hu, HC; Hui, WM; Kwok, KF; Lai, KC; Lam, SK; Wong, BC; Wong, WM, 2003) |
| "To compare the short-term (7-day) safety and efficacy of two triple-therapy regimens using pantoprazole with those of two dual-therapy regimens (one with pantoprazole and one without), for Helicobacter pylori eradication in patients with peptic ulcer disease." | 5.10 | Eradication of Helicobacter pylori by 7-day triple-therapy regimens combining pantoprazole with clarithromycin, metronidazole, or amoxicillin in patients with peptic ulcer disease: results of two double-blind, randomized studies. ( Bochenek, WJ; Davis, KD; El-Zimaity, HM; Fraga, PD; Graham, DY; Mack, ME; Osato, MS; Peters, S; Wang, W, 2003) |
| " pylori-infected peptic ulcer patients were randomly assigned to 1 of 3 groups: RAC4 (rabeprazole 20 mg, amoxicillin 1000 mg, and clarithromycin 500 mg twice daily for 4 days), RAC7 (rabeprazole 20 mg, amoxicillin 1000 mg, and clarithromycin 500 mg twice daily for 7 days), and OAC7 (omeprazole 20mg, amoxicillin 1000 mg, and clarithromycin 500 mg twice daily for 7 days)." | 5.10 | Comparison of rabeprazole-based four- and seven-day triple therapy and omeprazole-based seven-day triple therapy for Helicobacter pylori infection in patients with peptic ulcer. ( Chen, JH; Chen, TJ; Lee, SC; Wang, GM; Yang, KC, 2003) |
| "In this randomised, double-blind, multicentre study, conducted at 27 European sites, the efficacy and safety of rabeprazole and omeprazole were compared in patients with erosive or ulcerative gastro-oesophageal reflux disease (GERD)." | 5.09 | Double-blind comparison [correction of Double-blind, placebo-controlled comparison] of rabeprazole 20 mg vs. omeprazole 20 mg in the treatment of erosive or ulcerative gastro-oesophageal reflux disease. The European Rabeprazole Study Group. ( Beker, JA; Bell, NE; Dekkers, CP; Gabryelewicz, A; Humphries, TJ; Thjodleifsson, B, 1999) |
| "To evaluate the reliability of the omeprazole hydroxylation index as a marker for polymorphic CYP2C19 activity in a Japanese population of healthy young subjects (n = 78) and patients with peptic ulcer (n = 72)." | 5.09 | Reliability of the omeprazole hydroxylation index for CYP2C19 phenotyping: possible effect of age, liver disease and length of therapy. ( Higuchi, S; Ieiri, I; Iimori, E; Kimura, M; Mamiya, K; Otsubo, K; Sakai, T; Urae, A; Wada, Y, 1999) |
| "Helicobacter pylori-positive patients (224) with peptic ulcer disease or non-ulcer dyspepsia were randomized to receive one of three different omeprazole or lansoprazole-amoxycillin-clarithromycin (PPI/AC) regimens for 7 days: (1) OAC 20 regimen (n = 76), omeprazole (OPZ) 20 mg daily, amoxycillin (AMOX) 500 mg t." | 5.09 | Efficacy of 1 week omeprazole or lansoprazole-amoxycillin-clarithromycin therapy for Helicobacter pylori infection in the Japanese population. ( Miwa, H; Murai, T; Nagahara, A; Ohkura, R; Sato, K; Sato, N; Shimizu, H; Watanabe, S, 1999) |
| "We conducted a prospective, uncontrolled study of a consecutive series of 21 peptic ulcer patients with failure of 1-week lansoprazole, amoxicillin, and clarithromycin." | 5.09 | Quadruple therapy is effective for eradicating Helicobacter pylori after failure of triple proton-pump inhibitor-based therapy: a detailed, prospective analysis of 21 consecutive cases. ( Ducóns, JA; Ferrero, M; García Cabezudo, J; Gomollón, F; Guirao, R; Montoro, M; Simón, MA, 1999) |
| "This study was a comparison of 1-week and 2-week triple therapies with omeprazole, amoxicillin, and clarithromycin (OAC) in patients with peptic ulcer disease and Helicobacter pylori infection." | 5.09 | Comparison of 1-week and 2-week triple therapy with omeprazole, amoxicillin, and clarithromycin in peptic ulcer patients with Helicobacter pylori infection: results of a randomized controlled trial. ( Habu, Y; Inokuchi, H; Kawai, K; Kimoto, K; Kiyota, K; Mizuno, S; Sugano, Y, 1999) |
| " pylori positive active peptic ulcer disease were randomly assigned to receive lansoprazole 30 mg o." | 5.09 | Effect of ornidazole and clarithromycin resistance on eradication of Helicobacter pylori in peptic ulcer disease. ( Beglinger, C; Drewe, J; Lehmann, FS; Terracciano, L, 2000) |
| "Lansoprazole 30 mg, amoxicillin 1000 mg, and tinidazole 500 mg were given twice daily to 39 peptic ulcer patients (26 duodenal and 13 gastric ulcer, mean age 52." | 5.09 | Eradication of Helicobacter pylori with lansoprazole based triple therapy in peptic ulcer disease. ( Gonlachanvit, S; Kladchareon, N; Kullavanijaya, P; Mahachai, V, 2000) |
| "After endoscopic treatment of bleeding peptic ulcers, a high-dose infusion of omeprazole substantially reduces the risk of recurrent bleeding." | 5.09 | Effect of intravenous omeprazole on recurrent bleeding after endoscopic treatment of bleeding peptic ulcers. ( Chan, AC; Chan, FK; Chung, SC; Lau, JY; Lee, CW; Lee, KK; Ng, EK; Sung, JJ; Wong, SK; Wu, JC; You, JH; Yung, MY, 2000) |
| "To evaluate the efficacy of 3 days of azithromycin 500 mg od, 7 days of amoxycillin 750 mg tid and omeprazole, 20 (Group A) or 40 mg (Group B) on randomization, as a treatment for Helicobacter pylori infection in patients with endoscopically diagnosed peptic ulcer." | 5.09 | [Triple therapy of short-term with azithromycin, amoxycillin and omeprazole for the eradication of Helicobacter pylori]. ( Aguilera, R; Flores, S; Marchese, A; Opazo, H; Valderrama, D; Valderrama, S, 2000) |
| " pylori-positive patients who had peptic ulcers or reflux oesophagitis were treated for 3 years with either omeprazole (20 mg/day) alone (n=7) or with omeprazole for primary therapy (8 weeks), followed by famotidine (40 mg/day) for maintenance therapy (n=134)." | 5.09 | Changes in Helicobacter pylori-induced gastritis in the antrum and corpus during long-term acid-suppressive treatment in Japan. ( Mashiba, H; Matsumura, N; Okamoto, S; Sasaki, N; Taniyama, K; Uemura, N; Yamaguchi, S; Yamamoto, S, 2000) |
| " pylori who had functional dyspepsia were randomly assigned to 7 days of treatment with a lansoprazole-based triple therapy or placebo and then followed for 1 year." | 5.09 | Eradication of Helicobacter pylori prevents ulcer development in patients with ulcer-like functional dyspepsia. ( Chan, HH; Chen, W; Cheng, JS; Chien, EJ; Hsu, PI; Hsu, PN; Ku, MK; Lai, KH; Lin, CK; Lo, CC; Lo, GH; Peng, NJ; Tseng, HH, 2001) |
| "Little is known about the efficacy and safety of different formulations of omeprazole-based triple therapy regimens for the treatment of Helicobacter pylori-positive peptic ulcer." | 5.09 | Comparison of the efficacy and safety of different formulations of omeprazole-based triple therapies in the treatment of Helicobacter pylori-positive peptic ulcer. ( Baik, SK; Cho, MY; Jeong, YS; Kim, HS; Kim, JW; Kim, KH; Kwon, SO; Lee, DK; Seo, JI, 2001) |
| "Ninety patients with established peptic ulcer and NUD (with previously proven ulcer) were randomly assigned to receive either bismuth-subcitrate, amoxycillin and metrnidazole (BAM) or lansoprasole, clarithromycine and metronidazole (LCM) for 7 days." | 5.09 | The effect of culture results for Helicobacter pylori on the choice of treatment following failure of initial eradication. ( Avidan, B; Bar-Meir, S; Keller, N; Melzer, E, 2001) |
| "A total of 122 consecutive patients with peptic ulcer and Helicobacter pylori infection were treated with omeprazole 20 mg b." | 5.09 | Modified seven-day, quadruple therapy as a first line Helicobacter pylori treatment. ( Brullet, E; Calvet, X; Campo, R; Garcia, N; Gené, E; Sanfeliu, I, 2001) |
| "A total of 120 patients with peptic ulcer and non-ulcer dyspepsia were randomly assigned to a 2-week course of either: famotidine 40 mg twice a day, amoxycillin 1 g twice a day and tinidazole 500 mg twice a day (FAT group; n = 60); or omeprazole 20 mg twice a day, amoxycillin 1 g twice a day and tinidazole 500 mg twice a day (OAT group; n = 60)." | 5.09 | Famotidine versus omeprazole, in combination with amoxycillin and tinidazole, for eradication of Helicobacter pylori infection. ( Changchien, CS; Chen, JJ; Hsu, CC; Hu, TH; Lu, SN, 2001) |
| "The clinical efficacy of lansoprazole plus amoxicillin treatment in eradicating Helicobacter pylori was examined in peptic ulcer patients." | 5.08 | Clinical efficacy of lansoprazole-amoxicillin treatment in eradicating Helicobacter pylori: evaluation by the polymerase chain reaction method. ( Ogura, K; Ota, S; Shimada, T; Terano, A, 1995) |
| "A randomized, single-blind study was designed to assess the effect of lansoprazole alone and lansoprazole plus amoxicillin on the healing and eradication rates in Helicobacter pylori-associated peptic ulcer disease." | 5.08 | Clinical efficacy of lansoprazole in eradication of Helicobacter pylori. ( Asaka, M; Kagaya, H; Katagiri, M; Katoh, M; Kudoh, M; Takeda, H, 1995) |
| "This study reports preliminary results of a controlled, multicenter trial on the quality of ulcer healing induced by lansoprazole (LPZ) or roxatidine (R) in gastric ulcer (GU) or duodenal ulcer (DU) patients." | 5.08 | Quality of peptic ulcer healing induced by lansoprazole and roxatidine. ( Fujino, MA; Kobayashi, K; Morozumi, A; Ohtsuka, H; Sano, S; Suzuki, Y; Tachikawa, H; Uchida, N; Ueda, F; Yamamoto, Y, 1995) |
| "The clinical usefulness of lansoprazole in the healing of gastric and duodenal ulcers, the S2-stage shift rate (white scarring rate), and endoscopic healing rate with respect to degree of gastric mucosal atrophy were investigated." | 5.08 | Clinical evaluation of lansoprazole in the treatment of peptic ulcers: initial healing and prevention of relapse. Tohoku Peptic Ulcer Study Group. ( Asaki, S; Hongo, M; Sakurada, H; Sato, A; Takeda, T; Toyota, T, 1995) |
| "In the present study, the effects of short-term treatment with lansoprazole on healing and recurrence of peptic ulcer were investigated." | 5.08 | The effect of lansoprazole treatment on the healing and relapse of peptic ulcer and serum levels of IgG anti-Helicobacter pylori antibody. ( Akimoto, K; Fukujin, H; Katoaka, A; Mashima, H; Mine, T; Nagasawa, J; Tajima, A; Takano, T; Tsuchida, T; Yasuda, H, 1995) |
| "We studied the effects of lansoprazole on ulcer healing and Helicobacter pylori infection in elderly patients with peptic ulcers." | 5.08 | Therapeutic effects of lansoprazole on peptic ulcers in elderly patients. ( Asagoe, K; Dekigai, H; Kusaka, S; Maeda, S; Matsumoto, M; Mizuno, M; Murakami, M; Saita, H; Seki, M; Takahashi, Y, 1995) |
| "We investigated the effects of omeprazole or lansoprazole on peptic ulcer healing, eradication of Helicobacter pylori (Hp) and abdominal symptoms." | 5.08 | Proton pump inhibitors for Helicobacter pylori eradication in patients with peptic ulcer. ( Fukuda, Y; Okui, M; Shimoyama, T; Tamura, K; Yamamoto, I, 1995) |
| " pylori infection and peptic ulcer disease (n = 64) or functional dyspepsia (n = 16), with similar demographic and clinical characteristics, were treated for 1 week with either omeprazole 20 mg once in the morning and clarithromycin 250 mg and metronidazole 400 mg twice daily (OCM; n = 40) or with omeprazole 20 mg once in the morning and clarithromycin 250 mg and tetracycline 500 mg twice daily (OCT; n = 40)." | 5.08 | One-week low-dose triple therapy for the eradication of Helicobacter pylori infection. ( Becker, T; Börsch, G; Labenz, J; Rühl, GH; Sollböhmer, M; Stolte, M; Tillenburg, B, 1995) |
| "Eradication of Helicobacter pylori from the stomach by triple therapy with bismuth, tetracycline, and metronidazole cures peptic ulcer disease." | 5.08 | Effect of acid suppression on efficacy of treatment for Helicobacter pylori infection. ( de Boer, W; Driessen, W; Jansz, A; Tytgat, G, 1995) |
| "We report the results of seven therapeutic trials combining omeprazole, clarithromycin, amoxycillin, colloidal bismuth subcitrate and tinidazole in 198 patients (peptic ulcer disease/non-ulcerative dyspepsia, 137/61) to eradicate H." | 5.08 | Omeprazole-based antimicrobial therapies: results in 198 Helicobacter pylori-positive patients. ( Buset, M; De Koster, E; Deltenre, M; Jonas, C; Otero, J; van Gossum, M, 1995) |
| "Patients with a history of dyspepsia or uncomplicated peptic ulcer disease and with a need for continuous NSAID treatment were randomized to receive either 20 mg omeprazole once daily or placebo." | 5.08 | Prevention of peptic ulcer and dyspeptic symptoms with omeprazole in patients receiving continuous non-steroidal anti-inflammatory drug therapy. A Nordic multicentre study. ( Anker-Hansen, O; Carling, L; Ekström, P; Lundegårdh, G; Thorhallsson, E; Unge, P; Wetterhus, S; Wingren, PE, 1996) |
| "Eighty-two patients with severe peptic ulcer disease and concurrent Helicobacter pylori infection were treated with a two week regimen of omeprazole (40 mg once daily), amoxycillin (750 mg t." | 5.08 | Immediate repeat course of amoxycillin, metronidazole and omeprazole to eradicate Helicobacter pylori. ( Jönsson, KA; Sörberg, M; Ström, M, 1997) |
| "In this prospective controlled study conducted in a single center, 78 symptomatic peptic ulcer patients were treated for 4 wk with omeprazole 40 mg o." | 5.08 | Does pretreatment with omeprazole decrease the chance of eradication of Helicobacter pylori in peptic ulcer patients? ( Anania, MC; Annibale, B; D'Ambra, G; Delle Fave, G; Iannoni, C; Luzzi, I; Marcheggiano, A; Marignani, M; Paoletti, M, 1997) |
| "Patients with active HP infection and peptic ulcer, a history of peptic ulcer, or nonulcer dyspepsia were randomized to either lansoprazole 30 mg b." | 5.08 | Bismuth subsalicylate instead of metronidazole with lansoprazole and clarithromycin for Helicobacter pylori infection: a randomized trial. ( Barnett, JL; Chey, WD; DelValle, J; Elta, GH; Fisher, L; Hasler, WL; Nostrant, T; Scheiman, JM, 1997) |
| "In a prospective study, 113 patients with peptic ulcer (n = 36) or non-ulcer dyspepsia (n = 77) were randomized to receive 1-wk treatment, composed of omeprazole 20 mg b." | 5.08 | Omeprazole plus clarithromycin and either tinidazole or tetracycline for Helicobacter pylori infection: a randomized prospective study. ( Attili, AF; Diana, F; Pugliano, F; Rinaldi, V; Zullo, A, 1997) |
| " pylori-positive peptic ulcer received omeprazole 20 mg twice daily in combination with metronidazole 400 mg twice daily and clarithromycin 500 mg twice daily for seven days." | 5.08 | One week triple therapy for Helicobacter pylori: does high-dose clarithromycin confer additional benefit? ( Bhutta, AS; Bindel, H; Cunnane, K; Loane, J; O'Connor, HJ, 1997) |
| "The use of omeprazole is more effective than cimetidine in increasing intragastric pH and reducing rebleeding episodes in patients with bleeding peptic ulcers after successful endoscopic therapy." | 5.08 | A prospective randomized comparative trial showing that omeprazole prevents rebleeding in patients with bleeding peptic ulcer after successful endoscopic therapy. ( Lee, FY; Lin, HJ; Lo, WC; Perng, CL; Tseng, GY, 1998) |
| "In this study, the effect of different periods of amoxicillin (AMPC) treatment on the eradication rate of Helicobacter pylori in 173 patients with peptic ulcers (gastric ulcer, 109; duodenal ulcer, 64) was investigated." | 5.08 | Does Helicobacter pylori eradication depend on the period of amoxicillin treatment? A retrospective study. ( Abe, T; Asai, A; Goto, M; Ito, T; Kawano, S; Kubo, M; Tanabe, J; Tanimura, H, 1998) |
| " pylori-positive peptic ulcer received lansoprazole 30 mg twice daily in combination with metronidazole 400 mg twice daily and clarithromycin 250 mg twice daily for 5 days." | 5.08 | Lansoprazole triple therapy for Helicobacter pylori--is 5 days enough? ( Cunnane, K; Kelly, S; Laundon, J; McLoughlin, R; O'Connor, HJ, 1998) |
| "Although bismuth was both the first drug shown to alter the natural history of peptic ulcer disease and also a constituent of the first very effective eradication regimens, it has been excluded from the newer regimens, despite its safety and low cost, in favour of two antibiotics." | 5.08 | Bismuth-containing single-antibiotic 1-week triple therapy for Helicobacter pylori eradication. ( Scott, BB, 1998) |
| "One hundred and sixty-nine patients chronically ingesting diclofenac, ketoprofen, indomethacin or naproxen for osteoarthritis or rheumatoid arthritis, who had abdominal pain and an endoscopically proven gastroduodenal ulcer, were evaluated in a randomized, double-blind, dose regimen trial with omeprazole 20 mg o." | 5.08 | Omeprazole 20 or 40 mg daily for healing gastroduodenal ulcers in patients receiving non-steroidal anti-inflammatory drugs. ( Annibale, B; Capurso, L; Del Veccho Blanco, C; Fusillo, M; Massimo Claar, G; Monaco, S, 1998) |
| " pylori-associated gastritis, received seven days of lansoprazole, bismuth, tetracycline and metronidazole after three days of lansoprazole pretreatment." | 5.08 | Lansoprazole quadruple therapy is effective in curing Helicobacter pylori infection. ( Bolin, TD; Engelman, JL; Korman, MG; Nicholson, FB, 1998) |
| "Rabeprazole is a new fast acting proton pump inhibitor that has recently been proven to be effective in the treatment of peptic ulceration and reflux esophagitis." | 5.08 | Safety and efficacy of rabeprazole in combination with four antibiotic regimens for the eradication of Helicobacter pylori in patients with chronic gastritis with or without peptic ulceration. ( Atherton, JC; Cockayne, A; Hawkey, CJ; Jenkins, D; Knifton, A; Stack, WA; Thirlwell, D, 1998) |
| "To assess the effects of the mucoprotective drug sofalcone, which has direct and indirect effects on Helicobacter pylori in vitro, the eradication rate, adverse effects, and the quality of healing peptic ulcers were evaluated." | 5.08 | Preliminary study on a novel quadruple eradication therapy with a mucoprotective drug, sofalcone, for Helicobacter pylori infection. ( Arakawa, T; Kamisawa, T; Kato, H; Kozawa, H; Momma, K; Sakaki, N; Yamada, Y, 1998) |
| "Two 4-week triple-therapy treatment regimens, metronidazole+tetracycline+bismuth subcitrate and omeprazole+amoxycillin+bismuth subcitrate, were compared in a randomly allocated double-blind trial for their efficacy in eradicating Helicobacter pylori from the gastric mucosa of patients with gastritis and/or peptic ulcer disease." | 5.07 | Pharmacological effects of metronidazole+tetracycline+bismuth subcitrate versus omeprazole+amoxycillin+bismuth subcitrate in Helicobacter pylori-related gastritis and peptic ulcer disease. ( Hahm, JS; Kim, HJ; Park, KN, 1994) |
| "Serum gastrin levels in 44 peptic ulcer patients (26 gastric ulcer patients and 18 duodenal ulcer patients) were determined after they had been treated with omeprazole (OPZ) (20 mg/day) alone or in combination with pirenzepine (PZP) (100 mg/day)." | 5.07 | Serum gastrin levels following administration of omeprazole alone or in combination with pirenzepine. ( Arakawa, Y; Ito, K; Iwasaki, A; Kawamura, Y; Matsuo, Y; Miyazawa, K; Sakai, Y; Tashiro, Y, 1994) |
| "Patients (106) with peptic ulceration of the oesophagus, stomach and duodenum, unresponsive to 3 or more months of high-dose treatment with ranitidine, were initially given pantoprazole (40-80 mg, p." | 5.07 | Long-term therapy with pantoprazole in patients with peptic ulceration resistant to extended high-dose ranitidine treatment. ( Brunner, G; Harke, U, 1994) |
| "Thirty-five consecutive patients (median age: 50 years, 17 men and 18 women) suffering from Helicobacter pylori associated peptic ulcer disease (duodenal ulcer: n = 15, gastric ulcer: n = 13) or severe functional dyspepsia (n = 7) were enrolled in a two-center clinical trial and treated with omeprazole 20 mg bid preprandially and roxithromycin 300 mg bid postprandially over two weeks." | 5.07 | [Omeprazole modified antibiotic therapy of Helicobacter pylori infection: can clarithromycin be replaced by roxithromycin?]. ( Adamek, RJ; Börsch, G; Labenz, J; Opferkuch, W; Rühl, GH; Wegener, M, 1994) |
| " pylori-positive gastroduodenal ulcer disease were treated with a 14-day course of 20 mg omeprazole bid orally, combined with either 1 g amoxicillin tid intravenously (n = 15) or 500 mg amoxicillin six times daily orally (n = 16)." | 5.07 | Medium-term results of oral and intravenous omeprazole/amoxicillin Helicobacter pylori eradication therapy. ( Adamek, RJ; Freitag, M; Labenz, J; Opferkuch, W; Rühl, GH; Wegener, M, 1994) |
| "Forty-two patients with peptic ulceration of the duodenum, stomach or oesophagus, who had not responded to 3 or more months of high-dose treatment with ranitidine (450 or 600 mg/day), were treated with oral lansoprazole at 30-60 mg daily." | 5.07 | An open trial of long-term therapy with lansoprazole in patients with peptic ulceration resistant to extended high-dose ranitidine treatment. ( Arnold, R; Brunner, G; Fuchs, W; Hennig, U, 1993) |
| "In an open study, 62 patients with Helicobacter pylori-associated ulcer disease or functional dyspepsia were treated for two weeks with 2 x 20 mg omeprazole preprandially and 4 x 500 mg amoxicillin suspension one hour before meals and at night." | 5.07 | Two weeks treatment with amoxicillin/omeprazole for eradication of Helicobacter pylori. ( Börsch, G; Gyenes, E; Labenz, J; Rühl, GH, 1992) |
| " Altogether 107 patients (duodenal ulcer, n = 88; prepyloric ulcer, n = 14; gastric ulcer, n = 3; mixed sites, n = 2) with refractory peptic ulcer - that is ulcer unhealed after at least two months' treatment with cimetidine 0." | 5.07 | Treatment of refractory peptic ulcer with omeprazole or continued H2 receptor antagonists: a controlled clinical trial. ( Bardhan, KD; Bianchi Porro, G; Carroll, NJ; Daly, MJ; Hinchliffe, RF; Lazzaroni, M; Morris, P; Naesdal, J; Petrillo, M; Thompson, M, 1991) |
| "Twenty-seven patients with peptic ulcer (19 with duodenal ulcer (DU) and eight with gastric ulcer (GU] refractory to H2-antagonists were treated with 40 mg of omeprazole once daily for 4-8 weeks, depending on the rate of ulcer healing." | 5.06 | Omeprazole in acute and long-term treatment of Asian patients with peptic ulcer refractory to H2-antagonists. ( Chelvam, P; Wong, EC, 1989) |
| " Clinical trials of omeprazole, a substituted benzimidazole, indicate that it is safe and effective for short-term treatment of patients with duodenal or gastric ulcer, and it is highly effective for long-term treatment of patients with Zollinger-Ellison syndrome." | 5.06 | Treatment of acid-peptic diseases by inhibition of gastric H+,K+-ATPase. ( Gardner, JD; Jensen, RT; McArthur, KE, 1986) |
| " Recent randomized controlled trials in patients who are at moderately increased risk of ulcers have shown that the proton pump inhibitor esomeprazole (the S-isomer of racemic omeprazole) reduces the gastroduodenal ulcer incidence by approximately 70-85% and the gastrointestinal bleeding risk by as much as 90%." | 4.87 | Reducing the risk of gastroduodenal ulcers with a fixed combination of esomeprazole and low-dose acetyl salicylic acid. ( Yeomans, ND, 2011) |
| " pylori infection, a new one-week triple therapy regimen (lansoprazole or omeprazole + amoxicillin + clarithromycin) has been approved for use in patients with peptic ulcer disease in Japan." | 4.82 | Current consensus on the diagnosis and treatment of H. pylori-associated gastroduodenal disease. ( Hoshino, Y; Ishii, H; Kurabayashi, K; Masaoka, T; Minegishi, Y; Nomura, S; Suzuki, H; Suzuki, M, 2003) |
| " Pharmacodynamic results have also suggested that rabeprazole may be better suited than omeprazole as on-demand therapy for symptomatic gastro-oesophageal reflux disease." | 4.82 | Review article: relationship between the metabolism and efficacy of proton pump inhibitors--focus on rabeprazole. ( Horn, J, 2004) |
| "Two recently reported studies of nonsteroidal anti-inflammatory drugs (NSAIDs), the Omeprazole versus Misoprostol for NSAID-induced Ulcer Management and the Acid Suppression Trial: Ranitidine versus Omeprazole for NSAID-associated Ulcer Treatment studies, concluded that omeprazole was superior to a subtherapeutic misoprostol or an ineffective dose of ranitidine for the endpoint, prevention of gastroduodenal ulcers in chronic NSAID users." | 4.81 | Helicobacter pylori and nonsteroidal anti-inflammatory drugs: interaction with proton pump inhibitor therapy for prevention of nonsteroidal anti-inflammatory drug ulcers and ulcer complications--future research needs. ( Graham, DY, 2001) |
| "In uncontrolled clinical trials and case reports to date, omeprazole has been effective and well tolerated for the acute and chronic treatment of esophageal and peptic ulcer disease in children, particularly those who had failed to respond to previous treatment with histamine2-receptor antagonists." | 4.81 | A review of omeprazole use in the treatment of acid-related disorders in children. ( Katona, BG; Levine, D; Souney, PE; Walters, JK; Zimmermann, AE, 2001) |
| "Data from double-blind, placebo-controlled trials involving more than 1000 patients demonstrate that short-term, high-dose omeprazole therapy is effective for reducing bleeding and transfusion requirements in patients with acute peptic ulcer bleeding." | 4.81 | Proton-pump inhibitors for acute peptic ulcer bleeding. ( Erstad, BL, 2001) |
| " A daily dose of 30 mg lansoprazole reduced epigastric pain faster than omeprazole 20 mg daily in patients with peptic ulcer disease but healing rates at 4 and 8 weeks were similar with both agents at these dosages." | 4.81 | Lansoprazole: pharmacokinetics, pharmacodynamics and clinical uses. ( Gremse, DA, 2001) |
| "This meta-analysis reviewed all randomized, controlled clinical trials published as full text articles in English between 1993 and 1996 that reported the efficacy of lansoprazole treatment as monotherapy or in combination with antibiotics in the treatment of peptic ulcer and in eradicating H." | 4.80 | Efficacy of lansoprazole in eradicating Helicobacter pylori: a meta-analysis. ( Bazzoli, F; Berretti, D; De Luca, L; Fossi, S; Nicolini, G; Pozzato, P; Ricciardiello, L; Zagari, M, 1998) |
| " Early indications that acid suppression was effective in the management of NSAID-related peptic ulcers came from studies showing that gastric ulcers could be healed by omeprazole in patients who continued to take NSAIDs." | 4.80 | Management of nonsteroidal anti-inflammatory drug-induced gastroduodenal disease by acid suppression. ( Armstrong, D; Lad, R, 1999) |
| "Aim of this overview was to evaluate the main clinical trials with lansoprazole published from 1997 to 1999 in English-language journals, regarding gastroesophageal reflux disease, peptic ulcer, NSAID-induced ulcer, and ZES." | 4.80 | [Lansoprazole: an analysis of the clinical trials in the 3 years of 1997-1999]. ( Capurso, L; Dobrilla, G, 2000) |
| "To summarize the published data on lansoprazole, a proton pump inhibitor approved by the Food and Drug Administration for use in the treatment of duodenal ulcer, erosive esophagitis, and pathologic hypersecretory conditions (e." | 4.79 | Lansoprazole: a proton pump inhibitor. ( Garnett, WR, 1996) |
| "Omeprazole was administered for up to 6 years in 859 patients for 'prevention of relapse in patients with poorly responsive peptic ulcer or reflux oesophagitis'." | 4.78 | Safety experience from long-term treatment with omeprazole. ( Joelson, IB; Joelson, S; Lundborg, P; Walan, A; Wallander, MA, 1992) |
| "To investigate the effect of Anwei Qingyou formula on the clinical treatment of patients with peptic ulcer (PU) and its effect on the levels of epidermal growth factor (EGF) and prostaglandin E2 (PGE2)." | 4.12 | Clinical effect of Anwei Qingyou recipe on peptic ulcer and its effect on the levels of EGF and PGE2: A retrospective study. ( Bai, G; Du, H; Yi, J; Yu, Y, 2022) |
| "The efficacy of omeprazole in gastroesophageal reflux disease (GERD) and peptic ulcer disease (PUD), including those caused by non-steroidal antiinflammatory drugs (NSAIDs) is well documented." | 3.88 | Reliving 25 years of Experience with Omeprazole in Acid-peptic Diseases. ( Sharma, P, 2018) |
| "One of the most likely causes of the lack of effectiveness of eradication therapy of peptic ulcer associated with Helicobacter pylori, is a feature of omeprazole metabolism by cytochrome CYP2C19." | 3.81 | [THE EFFECTIVENESS OF ERADICATION IN PATIENTS WITH PEPTIC ULCER DISEASE ASSOCIATED WITH HELICOBACTER PYLORI, DEPENDING ON THE GENOTYPE OF THE DRUGMETABOLISM OF PROTON PUMP INHIBITORS]. ( Elokhina, EV; Kostenko, MB; Livzan, MA; Scalskiy, SV, 2015) |
| " pylori culture positive dyspeptic patients (64 patients with peptic ulcer, PU) completed a 2-week treatment with omeprazole, amoxicillin and metronidazole and underwent endoscopy again 6-8 weeks after the end of therapy." | 3.78 | Factors modulating the outcome of treatment for the eradication of Helicobacter pylori infection. ( Figura, N; Giordano, N; Langone, F; Moretti, E; Vaglio, L; Vernillo, R; Vindigni, C, 2012) |
| "Lansoprazole is an effective acid pump inhibitor acting at the final enzymatic step of the acid secretory pathway of the parietal cell, decreasing gastric acid secretion regardless of the primary stimulus." | 3.77 | Lansoprazole. A review of its pharmacodynamic and pharmacokinetic properties and its therapeutic efficacy in acid-related disorders. ( Barradell, LB; Faulds, D; McTavish, D, 1992) |
| "The aim of this study is to assess the prevalence of peptic ulcer rebleeding by comparing patients who received omeprazole versus pantoprazole i." | 3.76 | [Prevalence of rebleeding from peptic ulcer in patients treated with proton pump inhibitors]. ( de Sousa, M; Garrido, A; Iborra, MI; Saperas, E, 2010) |
| "Patients with peptic ulcer who failed with first-line triple eradication therapy containing clarithromycin received quadruple therapy with omeprazole (20 mg, twice daily), amoxicillin (750 mg, twice daily), metronidazole (500 mg, twice daily) and ecabet sodium (1000 mg, twice daily) for 14 days." | 3.76 | Quadruple therapy with ecabet sodium, omeprazole, amoxicillin and metronidazole is effective for eradication of Helicobacter pylori after failure of first-line therapy (KDOG0201 Study). ( Ae, T; Azuma, M; Higuchi, K; Ishido, K; Katada, C; Koizumi, W; Nakatani, K; Nakayama, N; Nishimura, K; Saigenji, K; Sasaki, T; Tanabe, S, 2010) |
| " Isolated, non-specific adverse events which might be attributable to omeprazole have included nausea, dizziness, headache and diarrhoea." | 3.76 | The clinical safety of omeprazole. ( Sölvell, L, 1990) |
| "Omeprazole has given healing rates of 58-83% after treatment for 2 weeks and 84-100% after 4 weeks." | 3.76 | Clinical experience with omeprazole: assessment of efficacy and safety. ( Walan, A, 1989) |
| "The aim of this study is to elucidate the effects and the mechanism of rebamipide, omeprazole, and their combination treatment on quality of peptic ulcer healing (QOUH)." | 3.75 | Effect of rebamipide on quality of peptic ulcer healing in rat. ( Haixia, C; Jie, L; Qi, Z; Xiaoying, Z, 2009) |
| "High-risk peptic ulcer bleeding patients received endoscopic therapy with epinephrine (adrenaline) injection plus intravenous omeprazole (40 mg bolus followed by 40 mg infusion every 12 h) for 3 days." | 3.75 | Efficacy of an intravenous proton pump inhibitor after endoscopic therapy with epinephrine injection for peptic ulcer bleeding in patients with uraemia: a case-control study. ( Cheng, YT; Fang, CT; Huang, CH; Liao, PC; Lin, HJ; Tseng, GC; Tseng, GY; Wang, PC; Yang, HB, 2009) |
| "This is our final report on the clinical effectiveness and safety of long-term pantoprazole in patients with severe peptic ulcer or reflux disease during continuous treatment for up to 5 years." | 3.73 | Pantoprazole in severe acid-peptic disease: the effectiveness and safety of 5 years' continuous treatment. ( Bardhan, KD; Bishop, AE; Luehmann, R; McCaldin, B; Morris, P; Polak, JM; Romanska, HM; Rowland, A; Schaefer-Preuss, S; Thompson, M, 2005) |
| "The present study was designed to investigate anti-ulcerogenic property of ethanolic extract of Desmodium gangeticum (DG) against cold restraint (CRU, 2 hr cold restraint stress), aspirin (ASP, 150 mg/kg orally), alcohol (AL, absolute alcohol 1 ml/200gm) and pyloric ligation (PL, 4 hr pylorus ligation) induced gastric ulcer models in Sprague Dawley rats, and histamine (HST, 0." | 3.73 | Desmodium gangeticum: a potent anti-ulcer agent. ( Chauhan, VS; Dharmani, P; Maurya, R; Mishra, PK; Palit, G, 2005) |
| " Patients with a history of peptic ulcers were randomized to 1-week omeprazole 20 mg, amoxicillin 1 g and clarithromycin 500 mg twice daily (eradication group; n = 51) or 1-week omeprazole 20 mg twice daily (omeprazole group; n = 49) before initiation of diclofenac 100 mg daily for 6 months." | 3.73 | Helicobacter pylori eradication prior to initiation of long-term non-steroidal anti-inflammatory drug therapy in Chinese patients-a cost-effectiveness analysis. ( Chan, FK; Ching, JY; Lau, W; Lee, IY; Lee, KK; You, JH; Yung, M, 2006) |
| ", omeprazole, misoprostol, and high-dose famotidine) in the prevention of NSAID-induced gastroduodenal ulcers will also be effective in this setting." | 3.71 | Current approaches to reducing gastrointestinal toxicity of low-dose aspirin. ( Lanas, AI, 2001) |
| "Pheripheral edema was observed in five female patients after taking proton pump inhibitors omeprazole, lansoprazole, or pantoprazole for 7-15 days for peptic acid diseases in recommended standard doses." | 3.71 | Reversible pheripheral edema in female patients taking proton pump inhibitors for peptic acid diseases. ( Athmann, C; Boldt, JH; Brunner, G, 2001) |
| " pylori infection in active peptic ulcer in Korea (30 mg of lansoprazole, 250 mg of clarithromycin, and 400 mg of metronidazole, all twice daily)." | 3.70 | One-week triple therapy with lansoprazole, clarithromycin, and metronidazole to cure Helicobacter pylori infection in peptic ulcer disease in Korea. ( El-Zimaity, HM; Graham, DY; Kim, JG; Osato, MS; Perng, CL, 1998) |
| "Thirty-eight clinical strains of Helicobacter pylori were isolated from patients with chronic gastritis and gastroduodenal ulceration, and their susceptibility to macrolide antibiotics (roxithromycin, flurithromycin, azithromycin, erythromycin) in combination with proton-pump inhibitors (lansoprazole and omeprazole) and bismuth subcitrate was assayed." | 3.70 | Synergic interactions of macrolides and proton-pump inhibitors against Helicobacter pylori: a comparative in-vitro study. ( Campa, M; Favini, P; Malizia, T; Marchetti, F; Pizzarelli, G; Senesi, S; Tejada, M, 1998) |
| "We isolated strains of Helicobacter pylori from gastric mucosa of patients with peptic ulcer before and after eradication therapy, and studied their sensitivity to amoxicillin (AMPC) and clarythromycin (CAM)." | 3.70 | [Sensitivity of Helicobacter pylori to amoxicillin and clarythromycin with special reference to eradication therapy]. ( Honda, T; Matsumoto, T; Mori, K; Nagatomi, Y; Takaba, M; Tsuneoka, H, 1998) |
| "Omeprazole, a substituted benzimidazole, is known to inhibit acid secretion from parietal cells in gastric glands, and is widely utilized as a drug for peptic ulcer." | 3.70 | Fine structural and morphometric studies on gastric parietal cells of peptic ulcer patients after long-term treatment with omeprazole. ( Kobayashi, H; Mutoh, H; Nakahara, A; Tanaka, N; Uchiyama, Y; Watanabe, T, 1998) |
| "To investigate whether CYP2C19 genotype status is associated with cure rates for Helicobacterpylori infection and peptic ulcer achieved by using dual therapy with omeprazole and amoxicillin." | 3.70 | Effect of genetic differences in omeprazole metabolism on cure rates for Helicobacter pylori infection and peptic ulcer. ( Furuta, T; Hanai, H; Ishizaki, T; Kamata, T; Kaneko, E; Kawasaki, T; Kosuge, K; Kubota, T; Ohashi, K; Takashima, M, 1998) |
| "We studied the recurrence of upper gastrointestinal bleeding (UGIB) in a cohort of patients who had an episode of peptic ulcer bleed, and we investigated the effect of maintenance treatment with cimetidine, omeprazole, and ranitidine." | 3.70 | Secondary prevention of upper gastrointestinal bleeding associated with maintenance acid-suppressing treatment in patients with peptic ulcer bleed. ( García Rodríguez, LA; Ruigómez, A, 1999) |
| "A prospective trial was designed to study the effectiveness of the 1-week combination of lansoprazole, clarithromycin and amoxycillin in 102 consecutive patients with active peptic ulcer." | 3.70 | Impact of clarithromycin resistance on the effectiveness of a regimen for Helicobacter pylori: a prospective study of 1-week lansoprazole, amoxycillin and clarithromycin in active peptic ulcer. ( Ducóns, JA; Ferrero, M; Gomollón, F; Guirao, R; Montoro, M; Santolaria, S, 1999) |
| "One hundred eight patients with cultured H pylori-positive gastritis or peptic ulcer were treated with three regimens: quadruple treatment without proton pump inhibitors (n = 25), dual treatment with omeprazole and amoxicillin (INN, amoxicilline) (n = 26), and triple treatment with omeprazole, amoxicillin, and clarithromycin (n = 57)." | 3.70 | CYP2C19 genotype-related efficacy of omeprazole for the treatment of infection caused by Helicobacter pylori. ( Aoyama, N; Kasuga, M; Kita, T; Komada, F; Okumura, K; Shirakawa, K; Tanigawara, Y, 1999) |
| "To evaluate endogenous and exogenous factors affecting the quality of ulcer healing produced by proton pump inhibitors, gastric acid pH, serum gastrin, and serum pepsinogen (PG) I and II were measured in peptic ulcer patients before and after treatment with lansoprazole 30 mg once daily." | 3.69 | Factors affecting quality of ulcer healing after lansoprazole treatment. ( Hanai, H; Ito, G; Kaneko, E; Nakagawara, M; Nawano, M; Ooi, S; Watanabe, F, 1995) |
| "These findings indicate that (1) peptic esophagitis was a common cause of chronic abdominal pain in pediatric patients and (2) omeprazole was effective in the treatment of esophagitis in children and adolescents that was resistant to high-dose histamine2-receptor antagonists." | 3.69 | Omeprazole treatment of children with peptic esophagitis refractory to ranitidine therapy. ( Kane, R; Karjoo, M, 1995) |
| "The efficacy of omeprazole, 20 mg once daily, in suppressing Helicobacter pylori colonization was studied in 33 patients with peptic ulcers." | 3.69 | Suppression of Helicobacter pylori colonization with omeprazole. ( Fukuda, Y, 1996) |
| " pylori infection and peptic ulcer disease or functional dyspepsia were treated with either omeprazole 20 mg b." | 3.69 | One-week triple therapy with omeprazole, amoxycillin and either clarithromycin or metronidazole for cure of Helicobacter pylori infection. ( Becker, T; Börsch, G; Labenz, J; Peitz, U; Stolte, M; Tillenburg, B, 1996) |
| "Fifty-two patients with peptic ulcer disease and antral biopsies containing Helicobacter pylori sensitive to metronidazole were given a 7-day course of treatment: omeprazole 20 mg b." | 3.69 | A one-week quadruple eradication regimen for Helicobacter pylori in routine clinical practice. ( Scott, BB; Vautier, G, 1997) |
| " Thirty-two consecutive patients (suffering from either peptic ulcer or nonulcer dyspepsia) with Helicobacter pylori infection received omeprazole (40 mg) + bismuth subcitrate (240 mg x 4) + amoxicillin suspension (2000 mg x 4) + metronidazole (500 mg x 4), for only one day." | 3.68 | One-day therapy for treatment of Helicobacter pylori infection. ( Barbara, L; Biasco, G; Corinaldesi, R; Gasperoni, S; Paparo, GF; Ricci-Maccarini, M; Stanghellini, V; Tucci, A; Varoli, O, 1993) |
| "Long-term omeprazole therapy in humans results in moderate hypergastrinemia and a significant argyrophil cell hyperplasia, which are correlated to the grade of corpus gastritis." | 3.68 | Long-term omeprazole therapy in peptic ulcer disease: gastrin, endocrine cell growth, and gastritis. ( Brunner, G; Creutzfeldt, W; Lamberts, R; Solcia, E; Strüber, HG, 1993) |
| " Serum gastrin levels, non-antral gastric endocrine (argyrophil) cell growth, and the severity and type of concomitant gastritis were monitored in 66 unoperated and 8 antrectomized patients with poorly responsive peptic ulcer or reflux oesophagitis during up to 5 years' treatment with high-dose omeprazole, 40 mg daily." | 3.68 | Inter-relationship between serum gastrin levels, gastric mucosal histology and gastric endocrine cell growth. ( Creutzfeldt, W; Lamberts, R, 1992) |
| "pylori positive peptic ulcer disease were treated with a two weeks regimen consisting of 20 mg omeprazole twice daily and 500 mg amoxicillin six times daily." | 3.68 | [Modified combined omeprazole/amoxicillin therapy for Helicobacter pylori eradication: a pilot study]. ( Adamek, RJ; Birkholz, S; Opferkuch, W; Ricken, D; Rühl, GH; Wegener, M, 1992) |
| "Thirty patients with peptic ulcers resistant to at least 8 weeks of continuous therapy with full-dose H2-receptor antagonists alone or followed by other anti-ulcer drugs, were treated with the gastric proton pump inhibitor omeprazole (40 mg), administered orally once daily for up to 8 weeks." | 3.68 | Omeprazole in the treatment of peptic ulcers resistant to H2-receptor antagonists. ( Guerreiro, AS; Neves, BC; Quina, MG, 1990) |
| "A total of 143 patients with peptic ulceration of the duodenum, stomach and oesophagus who did not respond to 3 or more months of high-dose treatment with ranitidine, 450 mg or more daily, were treated with oral omeprazole, 40 mg daily." | 3.68 | Efficacy and safety of omeprazole in the long-term treatment of peptic ulcer and reflux oesophagitis resistant to ranitidine. ( Brunner, GH; Creutzfeldt, W; Lamberts, R, 1990) |
| "36 patients with chronic gastric or oesophageal peptic ulceration (including 6 with antrectomy), resistant to high-dose ranitidine treatment for at least 3 months, were successfully treated with 40-60 mg of omeprazole daily for periods between 1 and 2 years." | 3.67 | Long-term omeprazole treatment in man: effects on gastric endocrine cell populations. ( Brunner, G; Creutzfeldt, W; Jacubaschke, U; Lamberts, R; Maas, S; Stöckmann, F, 1988) |
| " Adverse events were recorded by patients in specially developed diaries." | 2.87 | Efficacy and safety of the use of rebamipide in the scheme of triple eradication therapy of Helicobacter pylori infection: a prospective randomized comparative study. ( Andreev, DN; Dicheva, DT; Maev, IV; Partzvania-Vinogradova, EV; Samsonov, AA, 2018) |
| " Adverse events were recorded by patients in specially developed diaries." | 2.87 | Evaluation of the efficacy and safety of the hybrid scheme for eradication therapy of Helicobacter pylori infection. ( Andreev, DN; Dicheva, DT; Maiev, IV; Partzvania-Vinogradova, EV; Yurenev, GL, 2018) |
| " Adverse events (AEs) caused study withdrawal in 13." | 2.82 | Long-Term Safety of a Coordinated Delivery Tablet of Enteric-Coated Aspirin 325 mg and Immediate-Release Omeprazole 40 mg for Secondary Cardiovascular Disease Prevention in Patients at GI Risk. ( Cryer, BL; Eisen, GM; Fort, JG; Goldstein, JL; Lanas, A; Scheiman, JM; Whellan, DJ, 2016) |
| "Randomized patients with available aspirin dosing information in COGENT (N = 3,752) were divided into "low-dose" (≤ 100 mg) and "high-dose" (>100 mg) aspirin groups." | 2.82 | Proton-Pump Inhibitors Reduce Gastrointestinal Events Regardless of Aspirin Dose in Patients Requiring Dual Antiplatelet Therapy. ( Bhatt, DL; Cannon, CP; Cohen, M; Cryer, BL; Doros, G; Goldsmith, MA; Hsieh, WH; Laine, L; Lanas, A; Lapuerta, P; Liu, Y; Schnitzer, TJ; Shook, TL; Vaduganathan, M, 2016) |
| "Omeprazole is a proton pump inhibitor with proven efficacy in the prevention and treatment of PUD." | 2.76 | Prophylactic use of omeprazole associated with a reduced risk of peptic ulcer disease among maintenance hemodialysis patients. ( Chang, CT; Hsu, WM; Huang, CC; Kuo, HL; Liang, CC; Lin, HH; Liu, JH; Wang, IK; Yeh, HC, 2011) |
| "Incidence of gastric cancer in the two groups was determined based on the results of annual endoscopy and questionnaire surveys, as well as Yamagata Prefectural Cancer Registry data, and was compared between the two groups and by results of H pylori therapy." | 2.74 | Does Helicobacter pylori eradication therapy for peptic ulcer prevent gastric cancer? ( Fukase, K; Kawata, S; Mabe, K; Matsuda, T; Oizumi, H; Shibata, A; Takahashi, M; Takeda, H; Tsukuma, H, 2009) |
| "At endoscopy, gastroduodenal ulcers were diagnosed in 6 (4%) and 8 (5%) patients in the eradication and placebo group, respectively (p = ." | 2.73 | Eradication of Helicobacter pylori does not reduce the incidence of gastroduodenal ulcers in patients on long-term NSAID treatment: double-blind, randomized, placebo-controlled trial. ( Bijlsma, JW; Boers, M; de Leest, HT; Dijkmans, BA; Houben, HH; Huisman, AM; Kadir, SW; Kostense, PJ; Kuipers, EJ; Lems, WF; Steen, KS; van de Laar, MA; van Tulder, MW; Vonkeman, HE, 2007) |
| "Levodopa was prescribed for groups 1 and 3." | 2.72 | Does delayed gastric emptying shorten the H pylori eradication period? A double blind clinical trial. ( Alizadeh, M; Arj, A; Bagheri-Lankarani, K; Bahri-Najafi, R; Dehbashi, N; Emami, MH; Esmaeili, A; Fattahi, MR; Geramizadeh, B; Kaviani, MJ; Saberfiroozi, MM; Taghavi, AR, 2006) |
| "Rabeprazole is a new proton pump inhibitor, which has been reported to induce a faster acid suppression than other drugs of the same category." | 2.71 | Comparable Helicobacter pylori eradication rates obtained with 4- and 7-day rabeprazole-based triple therapy: a preliminary study. ( Bilardi, C; Dulbecco, P; Gambaro, C; Iiritano, E; Mansia, C; Savarino, V; Usai, P; Vigneri, S; Zentilin, P, 2003) |
| "Peptic ulcer was found in 6." | 2.71 | Does the 'test-and-treat' strategy work in primary health care for management of uninvestigated dyspepsia? A prospective two-year follow-up study of 1552 patients. ( Färkkilä, M; Sarna, S; Sipponen, P; Valtonen, V, 2004) |
| " We determined the therapeutic effects of sofalcone and polaprezinc when combined with rabeprazole, amoxicillin and clarithromycin for Helicobacter pylori infection." | 2.71 | Sofalcone, a mucoprotective agent, increases the cure rate of Helicobacter pylori infection when combined with rabeprazole, amoxicillin and clarithromycin. ( Furusu, H; Inoue, K; Isomoto, H; Kohno, S; Ohnita, K; Wen, CY, 2005) |
| " Sequential blood samples were collected over 24 h to characterize SOS absorption and pharmacokinetic parameters." | 2.70 | A randomized, pharmacokinetic and pharmacodynamic, cross-over study of duodenal or jejunal administration compared to nasogastric administration of omeprazole suspension in patients at risk for stress ulcers. ( Metzler, MH; Miedema, BW; Olsen, KM; Phillips, JO; Rangnekar, NJ; Rebuck, JA, 2001) |
| " We performed serial endoscopy, checked for adverse events, and laboratory values." | 2.70 | Pantoprazole therapy in the long-term management of severe acid peptic disease: clinical efficacy, safety, serum gastrin, gastric histology, and endocrine cell studies. ( Bardhan, KD; Bishop, AE; Cherian, P; Fischer, R; Lühmann, R; McCaldin, B; Morris, P; Ng, W; Perry, MJ; Polak, JM; Romanska, H; Rowland, A; Schneider, A; Thompson, M, 2001) |
| " Sixty patients received 40 mg of omeprazole twice a day, 1500 mg of amoxicillin three times a day, and 300 mg of rebamipide three times a day (group OAR); the other 60 patients received the same dosage of omeprazole and amoxicillin but no rebamipide for two weeks (group OA)." | 2.69 | Effect of rebamipide on Helicobacter pylori infection in patients with peptic ulcer. ( Ando, K; Arakawa, T; Harihara, S; Higuchi, K; Ito, H; Kobayashi, K; Kuroki, T; Nebiki, H; Uchida, T, 1998) |
| "Pretreatment with omeprazole did not reduce the cure rate for this new quadruple therapy." | 2.69 | A new quadruple therapy for the eradication of Helicobacter pylori. Effect of pretreatment with omeprazole on the cure rate. ( Maeda, K; Nishimura, H; Oda, K; Ohkuma, K; Okabe, N; Okada, M; Oki, K; Seo, M; Shirotani, T, 1998) |
| "Omeprazole pretreatment did not influence eradication rates." | 2.69 | Dual versus triple therapy: comparison of five antibiotic regimens for eradication of Helicobacter pylori in a prospective, randomized study. ( Bojarski, C; Epple, HJ; Fromm, M; Kirstein, FW; Riecken, EO; Schulzke, JD; Victor, L, 1998) |
| "All peptic ulcers were healed." | 2.69 | Triple regimens using lansoprazole or ranitidine bismuth citrate for Helicobacter pylori eradication. ( De Fanis, C; Di Virgilio, M; Pantaleone, U; Pizzicanella, G; Russo, L; Sciampa, G; Silla, M; Spadaccini, A, 1998) |
| "pylori recurrence rate." | 2.69 | [Recurrence rate of H. pylori after successful eradication and second eradication therapy after initial failure of treatment]. ( Iijima, K; Kato, K; Ohara, S; Sekine, H, 1999) |
| "pylori eradication for the treatment of peptic ulcer disease, a randomized controlled trial to compare the efficacy of proton pump inhibitor-based dual and triple regimens was conducted." | 2.69 | [Evaluation of the efficacy and the cost-effectiveness of proton pump inhibitor-based dual and triple therapy regimens for H. pylori eradication in peptic ulcer disease]. ( Habu, Y; Inokuchi, H; Kiyota, K; Ko, K; Sugano, Y; Waki, S, 1999) |
| "Chronic urticaria is one of the most frequent skin diseases." | 2.69 | Helicobacter pylori as a possible bacterial focus of chronic urticaria. ( Brehler, R; Domschke, W; Foerster, E; Luger, TA; Pohle, T; Wustlich, S, 1999) |
| " Pre-treatment with a proton pump inhibitor, higher doses or more frequent dosing may be necessary to increase the cure rate of short duration regimens." | 2.69 | Comparison of two 3-day Helicobacter pylori eradication regimens with a standard 1-week regimen. ( Cross, R; Grimley, CE; Illing, RC; Lismore, JR; Loft, DE; Nwokolo, CU; O'sullivan, M; Penny, A; Shebani, M, 1999) |
| " The aim of this study was to determine the optimal dose and duration of lansoprazole (LA) administration in combination with amoxicillin (AMPC) and metronidazole (MNZ)." | 2.69 | Eradication of Helicobacter pylori using 30 mg or 60 mg lansoprazole combined with amoxicillin and metronidazole: one and two weeks of a new triple therapy. ( Asaka, M; Ishizuka, J; Kagaya, H; Katagiri, M; Kato, M; Komatsu, Y; Kudo, M; Kudo, T; Nishikawa, K; Sugiyama, T; Sukegawa, M; Takeda, H; Toyota, J, 1999) |
| "Functional dyspepsia is a heterogeneous condition and a uniform response to drug treatment is not likely." | 2.69 | Identifying responders to acid suppression in dyspepsia using a random starting day trial. ( Bonnevie, O; Breinstrup, H; Bytzer, P; Funch-Jensen, P; Hansen, JM; Matzen, P; Meineche-Schmidt, V; Rune, S; Schaffalitzky De Muckadell, OB, 2000) |
| "Omeprazole (OM) has been shown to be superior to H2-Blockers in terms of complete healing rates of gastric (GU) and duodenal ulcers (DU)." | 2.68 | [Treatment of acute peptic gastroduodenal ulcer: omeprazole is superior to ranitidine especially in the early phase of ulcer healing. A prospective controlled randomized serial endoscopy study]. ( Guthke, A; Hotz, J; Kark, W; Otten, O; Plein, K; Wiedbrauck, F, 1995) |
| "Lansoprazole was found to be effective in patients who exhibited peak 13CO2 values that were at least two-thirds less than the pretreatment values." | 2.68 | 13C-UBT using an infrared spectrometer for detection of Helicobacter pylori and for monitoring the effects of lansoprazole. ( Kajiwara, M; Kokubun, N; Murai, S; Nakagawa, T; Ohara, H; Saito, N; Suzuki, T; Tsujino, D; Yamamoto, M; Yoneshima, M, 1995) |
| "Lansoprazole 30 mg/day was administered to 124 gastric ulcer (GU) patients and 57 duodenal ulcer (DU) patients." | 2.68 | Peptic ulcer therapy with lansoprazole and Helicobacter pylori eradication. ( Kato, T; Ogoshi, K; Sakagawa, T, 1995) |
| "Lansoprazole is a potent antisecretory drug also possessing anti-Helicobacter pylori activity in vitro." | 2.68 | Lansoprazole capsules and amoxicillin oral suspension in the treatment of peptic ulcer disease. ( Bang, CJ; Berstad, A; Hatlebakk, JG; Hausken, T; Nesje, LB, 1995) |
| "Pirenzepine has been reported to inhibit gastrin secretion." | 2.68 | Effects of pirenzepine on omeprazole-induced hypergastrinemia and acid suppression in peptic ulcer patients. ( Fukino, Y; Hamada, M; Haruma, K; Inoue, M; Kajiyama, G; Kamiyasu, T; Sumii, K; Sumii, M; Tari, A, 1996) |
| "Omeprazole was significantly more effective than placebo and misoprostol in reducing the frequency and degree of the endoscopic worsening, either after CMF or after 5-FU (P < 0." | 2.68 | Misoprostol and omeprazole in the prevention of chemotherapy-induced acute gastroduodenal mucosal injury. A randomized, placebo-controlled pilot study. ( Abbasciano, V; Nielsen, I; Sartori, S; Tassinari, D; Trevisani, L, 1996) |
| "Pretreatment clarithromycin resistance averaged 5% and had not been acquired by any strains post-therapy." | 2.68 | One-week triple therapy with omeprazole, amoxycillin and clarithromycin for treatment of Helicobacter pylori infection. ( el-Zimaity, HM; Genta, RM; Graham, DY; Yousfi, MM, 1996) |
| "Some recent studies have reported high recurrence rates after apparent cure." | 2.68 | Long-term follow-up after cure of Helicobacter pylori infection with 4 days of quadruple therapy. ( De Boer, WA; Driessen, WM; Geuskens, LM; Lai, JY, 1996) |
| "Cumulative recurrence rates at six months did not statistically differ among the three different groups (27% in H pylori negative, 46% in H pylori positive, and 31% in those where H pylori was eradicated during the healing phase), although a numerical trend in favour of a higher recurrence rate in infected patients was evident." | 2.68 | Role of Helicobacter pylori in ulcer healing and recurrence of gastric and duodenal ulcers in longterm NSAID users. Response to omeprazole dual therapy. ( Bianchi Porro, G; Caruso, I; Imbesi, V; Montrone, F; Parente, F, 1996) |
| " In conclusion, H pylori eradication rates using high dose ranitidine plus amoxycillin and metronidazole may be similar to that of low dose omeprazole in combination with the same antibiotics for omeprazole with clarithromycin." | 2.68 | Randomised controlled trial of ranitidine versus omeprazole in combination with antibiotics for eradication of Helicobacter pylori. ( Bamford, KB; Collins, JS; Molloy, C; Sloan, JM; Tham, TC; Watson, RG, 1996) |
| "Metronidazole resistance was induced in 8 out of 16 with a sensitive strain." | 2.68 | One-day intensified lansoprazole-quadruple therapy for cure of Helicobacter pylori infection. ( de Boer, WA; Ouwehand, ME; Schade, RW; Schneeberger, PM; Tytgat, GN; van Etten, RJ; van Unnik, AJ, 1997) |
| "Lansoprazole has superior anti-Helicobacter activity in vitro and possibly also in vivo; therefore we investigated quadruple therapy with lansoprazole." | 2.68 | Effectiveness of quadruple therapy using lansoprazole, instead of omeprazole, in curing Helicobacter pylori infection. ( de Boer, WA; Driessen, WM; Lai, JY; Schneeberger, PM; van de Wouw, BA; van Etten, RJ, 1996) |
| "On a randomly selected day the clinical charts of 3685 inpatients were reviewed by a gastroenterologist and data were collected concerning the drug used, its dosage and indications for the prescription." | 2.68 | Are we correctly using the inhibitors of gastric acid secretion and cytoprotective drugs? Results of a multicentre study. ( Comin, U; Cortelezzi, C; Curzio, M; Ferrara, A; Ferraris, L; Gullotta, R; Minoli, G; Prada, A; Rocca, F, 1997) |
| "Treatment with misoprostol combined with an H2RA resulted in 60% success for ulcer healing within the next 2 months in nonresponders, without affecting the intraluminal pH measured during treatment with an H2RA alone." | 2.67 | H2-receptor antagonist-refractory ulcer: its pathophysiology and treatment. ( Arakawa, T; Fukuda, T; Higuchi, K; Kobayashi, K; Nakamura, H, 1991) |
| "The magnitude and duration of changes in nocturnal intragastric acidity caused by 25 days of dosing with the antisecretory drugs ranitidine and omeprazole were investigated in a double-blind study of 22 healthy subjects." | 2.67 | Nocturnal intragastric acidity during and after a period of dosing with either ranitidine or omeprazole. ( Hudson, M; Nwokolo, CU; Pounder, RE; Prewett, EJ; Sawyerr, AM, 1991) |
| " The incidence of serious adverse events reported in comparative short-term studies with H2-receptor antagonists and placebo were similar." | 2.66 | The clinical safety of omeprazole. ( Sölvell, L, 1989) |
| "Omeprazole is a substituted benzimidazole which inhibits profoundly and long-lasting human acid secretion." | 2.66 | [Omeprazole in the therapy of acid-induced diseases]. ( Dammann, HG; Müller, P; Simon, B, 1987) |
| " The results of studies comparing the clinical efficacy of different PPI dosage forms and routes of administration, safety considerations, and cost-effectiveness analyses are among the factors to consider when making formulary decisions for this class of drugs." | 2.43 | Proton pump inhibitor formulary considerations in the acutely ill. Part 2: Clinical efficacy, safety, and economics. ( Devlin, JW; Olsen, KM; Welage, LS, 2005) |
| " Administration of immediate-release omeprazole at bedtime results in a rapid and sustained elevation of gastric pH, and seems to provide better night time control of gastric acidity than that observed with conventional morning dosing of delayed-release proton pump inhibitors." | 2.43 | Review of immediate-release omeprazole for the treatment of gastric acid-related disorders. ( Castell, D, 2005) |
| "Pantoprazole (Protonix) is an irreversible proton pump inhibitor (PPI) that reduces gastric acid secretion." | 2.42 | Pantoprazole: an update of its pharmacological properties and therapeutic use in the management of acid-related disorders. ( Cheer, SM; Faulds, D; Lamb, HM; Prakash, A, 2003) |
| "Lansoprazole is a proton pump inhibitor (PPI) which is an effective and well-tolerated treatment option in the management of acid-related disorders." | 2.42 | Lansoprazole fast disintegrating tablet: a new formulation for an established proton pump inhibitor. ( Baldi, F; Malfertheiner, P, 2003) |
| " Therefore, a clear understanding of alternative dosing formulations and related efficacies is key in order for the clinician to select the most appropriate agent and strategy to optimize outcomes and cost-effectiveness for each patient." | 2.42 | Alternative dosing for PPI therapy: rationale and options. ( Johnson, DA, 2003) |
| "Rabeprazole is a newer generation proton pump inhibitor that suppresses the gastric proton pump and acid secretion more rapidly than does omeprazole, lansoprazole or pantoprazole." | 2.42 | Review article: relief of symptoms in gastric acid-related diseases--correlation with acid suppression in rabeprazole treatment. ( Miner, P, 2004) |
| "Proton pump inhibitors are used to treat gastroesophageal reflux, a symptom common in pregnancy." | 2.41 | Use of proton pump inhibitors during pregnancy and rates of major malformations: a meta-analysis. ( Abdollahi, M; Koren, G; Magee, LA; Moretti, ME; Nikfar, S, 2002) |
| "Studies that appeared to show that GERD could be provoked by antimicrobial therapy of duodenal ulcers also have methodological weaknesses." | 2.41 | Motion--Helicobacter pylori worsens GERD: arguments for the motion. ( O'Morain, CA; Qasim, A, 2002) |
| "Lansoprazole is an inhibitor of gastric acid secretion and also exhibits antibacterial activity against Helicobacter pylori in vitro." | 2.41 | Lansoprazole: an update of its place in the management of acid-related disorders. ( Jarvis, B; Matheson, AJ, 2001) |
| " The superior acid control achieved by esomeprazole is mainly due to an advantageous metabolism compared with racemate omeprazole, leading to improved bioavailability and to enhanced delivery of the drug to the gastric proton pump." | 2.41 | Clinical pharmacology and safety profile of esomeprazole, the first enantiomerically pure proton pump inhibitor. ( Savarino, V; Scarpignato, C; Tonini, M; Vigneri, S, 2001) |
| "Lansoprazole is a proton pump inhibitor that reduces gastric acid secretion." | 2.40 | Lansoprazole. An update of its pharmacological properties and clinical efficacy in the management of acid-related disorders. ( Langtry, HD; Wilde, MI, 1997) |
| "Rabeprazole is a proton pump inhibitor with antisecretory properties." | 2.40 | Rabeprazole. ( Faulds, D; Prakash, A, 1998) |
| "Misoprostol has also been shown to decrease NSAID-associated gastrointestinal (GI) complications by 40% compared with placebo." | 2.40 | Agents used in the prevention and treatment of nonsteroidal anti-inflammatory drug-associated symptoms and ulcers. ( Isenberg, J; Scheiman, J, 1998) |
| "Eradication rate of Helicobacter pylori in dual therapy (omeprazole/amoxicillin) are reported in the range of 28-91%, side effect such as loose stool and skin reaction are reported 3." | 2.40 | [Eradication rate and side effect from a point of view of Helicobacter pylori eradication of peptic ulcer disease in dual therapy or new triple therapy]. ( Iwasaki, A, 1999) |
| "Lansoprazole has undergone extensive clinical evaluation for the treatment of acid-peptic diseases." | 2.40 | Safety profile of Lansoprazole: the US clinical trial experience. ( Freston, JW; Haber, M; Heller, CA; Jennings, D; Rose, PA, 1999) |
| " While the short-term risk of complications appears to be minimal, the tolerance of these drugs in chronic use requires careful monitoring because of the potential consequences of prolonged inhibition of acid secretion." | 2.40 | [Proton pump inhibitors in pediatrics]. ( Faure, C; Languepin, J; Pelatan, C, 1999) |
| "Rabeprazole is an inhibitor of the gastric proton pump." | 2.40 | Rabeprazole: a review of its use in acid-related gastrointestinal disorders. ( Langtry, HD; Markham, A, 1999) |
| "Pantoprazole is a proton pump inhibitor which has recently had its clinical license extended to include maintenance therapy for the treatment of reflux oesophagitis, Helicobacter pylori eradication and short-term intravenous administration." | 2.40 | Pantoprazole, Prout and the proton pump. ( Modlin, I; Playford, RJ; Podas, T, 1999) |
| " Considerably more work, however, is required to identify the ideal dosage and combination that will give the best eradication rates with the simplest regimen and fewest side effects." | 2.39 | The potential value of lansoprazole in Helicobacter pylori eradication. ( Axon, AT, 1995) |
| "Treatment with omeprazole plus two different antibiotics has also been used in a number of studies." | 2.39 | The role of omeprazole and antibiotic combinations in the eradication of Helicobacter pylori--an update. ( Axon, AT, 1994) |
| "Although ulcer recurrence and complications can be prevented, many patients with peptic ulcer disease fail to receive the benefits of modern therapeutic regimens." | 2.39 | Review article: Helicobacter pylori eradication--understandable caution but no excuse for inertia. ( Penston, JG, 1994) |
| " Minor adverse events include headache, diarrhoea, dizziness, pruritus and rash." | 2.39 | Safety of proton pump inhibitors--an overview. ( Arnold, R, 1994) |
| " Pantoprazole formulated in an enteric-coated tablet displays high bioavailability and linear pharmacokinetics whether on single or multiple dose regimens." | 2.39 | Review article: the continuing development of proton pump inhibitors with particular reference to pantoprazole. ( Huber, R; Kohl, B; Sachs, G; Senn-Bilfinger, J; Simon, WA; Sturm, E, 1995) |
| " The bioavailability of lansoprazole is 85%; that of omeprazole is 54%." | 2.39 | Lansoprazole and omeprazole in the treatment of acid peptic disorders. ( Blum, RA, 1996) |
| " It has a high and constant bioavailability (approximately 77%) which does not change on multiple dosing, so that maximum blood levels are achieved after the first dose." | 2.39 | Pantoprazole, a new proton-pump inhibitor, has a precise and predictable profile of activity. ( Parsons, ME, 1996) |
| "Clarithromycin is useful for treatment of H." | 2.39 | Efficacy of clarithromycin in eradicating Helicobacter pylori. ( Kihira, K; Kimura, K; Saifuku, K; Satoh, K; Takimoto, T; Taniguchi, Y, 1996) |
| "Treatment with omeprazole and amoxycillin could provide both rapid healing of ulcers and eradication of H." | 2.38 | Compliance, adverse events and antibiotic resistance in Helicobacter pylori treatment. ( Malfertheiner, P, 1993) |
| "ECL-cell hyperplasia and carcinoids which occur during application of very high doses of omeprazole in rats are not caused by a direct effect of omeprazole." | 2.38 | [Risk for developing tumors in therapy with the proton pump inhibitor omeprazole]. ( Arnold, R; Eissele, R, 1993) |
| "Omeprazole is a weak base that reaches the parietal cell through the bloodstream, diffuses through the cytoplasm, and becomes activated and trapped as a sulfenamide in the acidic canaliculus of the parietal cell." | 2.38 | Control of gastric acid secretion. Histamine H2-receptor antagonists and H+K(+)-ATPase inhibitors. ( Schubert, ML; Shamburek, RD, 1992) |
| "Omeprazole has been used successfully in the treatment of reflux esophagitis and the Zollinger-Ellison syndrome in the United States over the past year and has received approval recently as first-line therapy for duodenal ulcer disease." | 2.38 | Proton-pump inhibition for acid-related disease. ( Holt, S, 1991) |
| "Omeprazole is a potent and effective antisecretory drug." | 2.38 | Omeprazole. ( Langman, MJ, 1991) |
| "Omeprazole has a simple treatment regimen: 20 mg once daily is recommended in the routine treatment of DU, GU and RO." | 2.38 | Treatment of acid-related disorders with gastric acid inhibitors: the state of the art. ( Blum, AL, 1990) |
| "Omeprazole has been shown to provide more rapid symptom relief and to heal ulcers more quickly and reliably than H2-receptor antagonists in duodenal ulcer, gastric ulcer and reflux oesophagitis." | 2.38 | Clinical development programme for omeprazole. ( Walan, A, 1990) |
| "Omeprazole has been approved by the Food and Drug Administration for short-term therapy of severe erosive esophagitis, poorly responsive symptomatic gastroesophageal reflux disease, and long-term management of Zollinger-Ellison syndrome." | 2.38 | Omeprazole: a novel antisecretory agent for the treatment of acid-peptic disorders. ( Dukes, GE; Hak, LJ; Lampkin, TA; Ouellet, D, 1990) |
| "Omeprazole has been shown to give significantly higher healing rates than ranitidine or cimetidine in patients with duodenal ulcer and gastric ulcer." | 2.38 | Clinical utility and safety of omeprazole. ( Walan, A, 1989) |
| "Treatment with omeprazole, 20 mg, increased 24-hour plasma gastrin to the same extent as after highly selective vagotomy." | 2.38 | Effect of omeprazole on gastric acid secretion and plasma gastrin in man. ( Cederberg, C; Lind, T; Olausson, M; Olbe, L, 1989) |
| "Famotidine is an even more potent H2 receptor antagonist, and initial clinical studies are promising." | 2.37 | Pharmacological management of patients with peptic ulcer disease: prospects for the late 1980's. ( Mahachai, V; Thomson, AB, 1987) |
| "Although medical treatment of peptic ulcer has been used for centuries, surgery was still the main treatment of recurrent peptic ulcer in the nineteen seventies." | 2.37 | Medical treatment of peptic ulcer disease. ( Andersen, BN, 1988) |
| "Omeprazole is a substituted benzimidazole derivative which markedly inhibits basal and stimulated gastric acid secretion." | 2.37 | Omeprazole. A preliminary review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in peptic ulcer disease and Zollinger-Ellison syndrome. ( Campoli-Richards, DM; Clissold, SP, 1986) |
| "Omeprazole was healthcare professional (HCP)-preferred first-line treatment (60." | 1.72 | Patient journey in erosive oesophagitis: real-world perspectives from US physicians and patients. ( Atkinson, C; Brunton, S; Howden, CW; Jacob, R; Mark Fendrick, A; Pelletier, C; Spechler, SJ; Vaezi, MF, 2022) |
| "Omeprazole was superior to famotidine with less gastrointestinal symptoms and recurrent ulcers/erosions in patients using 24-week low-dose aspirin." | 1.40 | Comparison of proton pump inhibitor and histamine-2 receptor antagonist in the prevention of recurrent peptic ulcers/erosions in long-term low-dose aspirin users: a retrospective cohort study. ( Chan, HH; Chen, WC; Cheng, JS; Chiang, PH; Lai, KH; Li, YD; Tsai, TJ; Tsai, WL; Tsay, FW; Wang, EM, 2014) |
| "Omeprazole treatment did not result in mucosal injury or inflammation; however, there were marked shifts in numbers and types of enteric bacteria, including a significant reduction (∼80%) of jejunal Actinobacteria and Bifidobacteria spp." | 1.37 | Proton pump inhibitors exacerbate NSAID-induced small intestinal injury by inducing dysbiosis. ( Bercik, P; Bolla, M; Collins, SM; de Palma, G; Denou, E; Jury, J; McKnight, W; Ongini, E; Syer, S; Verdu, E; Vong, L; Wallace, JL, 2011) |
| "Omeprazole (100 mg/kg) was given p." | 1.36 | Protective effect of lafutidine, a histamine H2 receptor antagonist, against loxoprofen-induced small intestinal lesions in rats. ( Amagase, K; Kato, S; Ochi, A; Sugihara, T; Takeuchi, K, 2010) |
| "Chronic urticaria is a persistent urticaria lasting longer than 6 weeks, affecting 20% of the general population." | 1.35 | Helicobacter pylori infection in patients with chronic urticaria: correlation with pathologic findings in gastric biopsies. ( Abdou, AG; Elnaidany, NF; Elshayeb, EI; Farag, AG, 2009) |
| " Application of a combined preparation, consisting of 20 mg of omeprazol, 500 mg of clarithromycin, 1000 mg amoxicillin, in a standard dosage of 3 tablets twice a day during 7 days have permitted to achieve the H." | 1.35 | [Antihelicobacteric therapy for the patients with recurrent complicated postoperative gastroduodenal ulcer: indications, principles of conduction, efficacy]. ( Buka, GIu; Veligotskiĭ, NN, 2009) |
| " The ulcers scarred after the long-term administration of a proton pump inhibitor (PPI), but recurred after the suspension." | 1.35 | Recurrent peptic ulcer disease in a pediatric patient with type 1 neurofibromatosis and primary ciliary dyskinesia. ( Di Stefano, V; Francavilla, R; Lionetti, E; Pavone, L; Principi, MB; Ruggieri, M, 2009) |
| "Gastroesophageal reflux disease is a common and chronic disorder but long term, prospective studies of the fate of patients seeking medical advice are scarce." | 1.34 | Prospective Acid Reflux Study of Iran (PARSI): methodology and study design. ( Abedi, B; Alimohamadi, SM; Ghotbi, MH; Malekzadeh, R; Mamarabadi, M; Mofid, A; Mostajabi, P; Nasseri-Moghaddam, S; Nouraie, M; Razjouyan, H; Sohrabpour, AA; Sotoudeh, M; Tofangchiha, S, 2007) |
| "Proton pump inhibitors play an important role in increasing the bioavailability of antibiotics in the gastric mucus by altering gastric volumes and increasing the stability of some antibiotics, e." | 1.33 | Helicobacter pylori: factors affecting eradication and recurrence. ( Vakil, N, 2005) |
| "pylori induces de novo GERD symptoms in ulcer patients." | 1.31 | Symptomatic benefit 1-3 years after H. pylori eradication in ulcer patients: impact of gastroesophageal reflux disease. ( Dickson, A; El-Nujumi, A; El-Omar, E; Kelman, A; McColl, KE, 2000) |
| "To report two cases of anaphylactic reactions to proton-pump inhibitors (PPIs)." | 1.31 | Anaphylactic reactions to proton-pump inhibitors. ( Mees, EB; Meyboom, RH; Natsch, S; Vinks, MH; Voogt, AK, 2000) |
| "Melatonin was also highly effective in scavenging *OH generated in vitro by a Cu2+-ascorbate system." | 1.31 | Melatonin protects against stress-induced gastric lesions by scavenging the hydroxyl radical. ( Bandyopadhyay, D; Bandyopadhyay, U; Banerjee, RK; Biswas, K; Reiter, RJ, 2000) |
| "It was found that patients with gastroduodenal ulcer have metabolic, less frequently hypercapnic acidosis with suppressed gastric secretion of HCO3-." | 1.31 | [Relations of acid-base balance and gastric secretion of hydrogen carbonate ions in patients with peptic ulcer]. ( Ivashkina, TG; Kulikov, AN; Malov, IuS, 2001) |
| "1 year after drug therapy the recurrence of CDU is revealed in 16." | 1.31 | [Current principles of the use of laparoscopic surgery in gastroduodenal ulcer]. ( Fedorov, AV; Sazhin, VP, 2001) |
| "We determined late recrudescence rates, true reinfection, and ulcer recurrence." | 1.31 | Recrudescence and reinfection with Helicobacter pylori after eradication therapy in Bangladeshi adults. ( Ahmad, MM; Arefin, MS; Bardhan, P; Bauerfeind, P; Beglinger, C; Glatz-Krieger, K; Gyr, N; Hasan, M; Hildebrand, P; Khan, AK; Parvin, S; Rahman, A; Rossi, L; Terracciano, L, 2001) |
| "The influence of synthetic drugs prescribed for peptic ulcer on the pharmacokinetic fate of glycyrrhizin (GL) from Shaoyao-Gancao-tang (SGT, a traditional Chinese formulation, Shakuyaku-Kanzo-to in Japanese) was investigated in rats." | 1.31 | The influence of commonly prescribed synthetic drugs for peptic ulcer on the pharmacokinetic fate of glycyrrhizin from Shaoyao-Gancao-tang. ( Akao, T; He, JX; Nishino, T; Tani, T, 2001) |
| "Omeprazole was also not statistically different from misoprostol for gastric ulcer prevention in those whose NSAID use was complicated by an active H." | 1.31 | Critical effect of Helicobacter pylori infection on the effectiveness of omeprazole for prevention of gastric or duodenal ulcers among chronic NSAID users. ( Graham, DY, 2002) |
| "Presence of a gastroduodenal ulcer, age, gender and smoking habit did not differ significantly between the eradicated and noneradicated groups." | 1.31 | Failure of Helicobacter pylori eradication: is poor compliance the main cause? ( Baumann, R; Buri, P; Cunningham, M; Dederding, JP; Gallaz, L; Girard, L; Godin, N; Merki, H; Metry, JM; Sitavanc, R; Wermeille, J; Zelger, G, 2002) |
| "To evaluate management of dyspepsia, gastroduodenal ulcer and Helicobacter pylori infection in the setting of family practice." | 1.31 | [Management of dyspepsia, gastroduodenal ulcer and Helicobacter pylori infection in primary care]. ( Azagra, R; Calvet, X; Cubells, MJ; Gené, E; López, T, 2002) |
| " Dosage and treatment duration were evaluated, along with the way in which morbidity, self-evaluated health, the demographic pattern and life-style characteristics influence drug prescription." | 1.30 | Antacid (A02A) and antiulcer (A02B) drug prescription patterns: predicting factors, dosage and treatment duration. ( Girbes Pelechano, VJ; Llopis-González, A; Morales Suárez-Varela, MM; Pérez-Benajas, MA, 1998) |
| " Discouraging the use of over-the-counter H2 antagonists, ruling out long-term use of nonsteroidal anti-inflammatory drugs before selecting the treatment regimen, and considering expected treatment compliance are important aspects of PUD management that emerged from this case." | 1.30 | Understanding peptic ulcer disease pharmacotherapeutics. ( Navuluri, R; Yue, S, 1999) |
| "Treatment with omeprazole once daily has been shown to be superior to that with ranitidine and misoprostol in this respect." | 1.30 | Quality of life in arthritis patients using nonsteroidal anti-inflammatory drugs. ( Wiklund, I, 1999) |
| "Hyperemesis gravidarum is the most severe spectrum of gastrointestinal complaints in pregnant women." | 1.30 | Helicobacter pylori infection and persistent hyperemesis gravidarum. ( Jacoby, EB; Porter, KB, 1999) |
| "She had been suffering from gastroduodenal ulcer for about ten years." | 1.29 | [A case report of prosthetic valve replacement for malfunction of the Hancock valve in mitral position associated with recurrent peptic ulcer and renal dysfunction]. ( Aomi, S; Fujino, S; Hashimoto, A; Hirai, M; Koyanagi, H; Koyanagi, T; Sakahashi, H; Tokunaga, H, 1995) |
| "Therefore, we diagnosed bronchial asthma associated with reflux esophagitis and gastroduodenal ulcer." | 1.29 | [A case of bronchial asthma associated with reflux esophagitis, whose peak expiratory flow rate improved with omeprazole and cisapride]. ( Arakawa, M; Fujimori, K; Suzuki, E, 1994) |
| "The H." | 1.29 | Highly significant change of the clinical course of relapsing and complicated peptic ulcer disease after cure of Helicobacter pylori infection. ( Börsch, G; Labenz, J, 1994) |
| "With omeprazole, the costs were lower and the effectiveness better than with the H2-receptor antagonist." | 1.29 | Economic evaluation of new medical technology. ( Jönsson, B, 1994) |
| " H2-receptors blocking drugs or gastric acidity buffers were withdrawn for 2 weeks, then omeprazole was administered for 4 weeks at a daily dosage of 20 mg." | 1.29 | Effects of omeprazole therapy on peptic disease and serum gastrin levels in hemodialysis patients. A preliminary study. ( Di Maggio, A; Franceschi, M; Loperfido, A; Montemurro, NE; Scatizzi, A, 1993) |
| " The omeprazole metabolic ratio may serve the double purpose of phenotyping for CYP2C19 and to individualize dosing in omeprazole-treated patients." | 1.29 | Phenocopies of poor metabolizers of omeprazole caused by liver disease and drug treatment. ( Brockmöller, J; Esdorn, F; Roots, I; Rost, KL, 1995) |
| "Pre-treatment metronidazole susceptible H pylori were significantly more likely to respond to the triple therapy used than those with the metronidazole resistant ones (14 of 15 v five of 10) (p = 0." | 1.29 | Prevalence of metronidazole resistant Helicobacter pylori strains among Chinese peptic ulcer disease patients and normal controls in Hong Kong. ( Ching, CK; Lai, CL; Lai, KC; Lam, SK; Leung, KP; Wong, BC; Yung, RW, 1996) |
| "To verify the effectiveness and side-effect profile of an eradicating regimen consisting of omeprazole 20 mg daily for 4 weeks and, during the first week, combination antimicrobial treatment with tinidazole 500 mg b." | 1.29 | High effectiveness and safety of one-week antibiotic regimen in Helicobacter pylori eradication. ( Carli, G; Dalla Libera, M; Gamberini, S; Gullini, S; Merighi, A; Pazzi, P; Scagliarini, R, 1996) |
| "Treatment of peptic ulcers has become easier with the advent of H2 blockers." | 1.28 | [Movement of gastric acid secretion and influence of proton pump inhibitors on histamine H2 receptor antagonist resistant ulcer]. ( Asaki, S; Hongo, M; Kimpara, T; Ohara, S, 1992) |
| "Chronic atrophic gastritis was found in 45 (10." | 1.28 | Gastric endocrine cells and gastritis in patients receiving long-term omeprazole treatment. ( Carlsson, R; Dalväg, A; Fiocca, R; Havu, N; Solcia, E, 1992) |
| "The omeprazole plasma levels were 611 +/- 323 and 881 +/- 533 ng/ml after 2 and 4 h." | 1.28 | Effect of omeprazole on nocturnal intragastric pH in cirrhotics with inadequate antisecretory response to ranitidine. ( Bode, JC; Klotz, U; Sarem-Aslani, A; Treiber, G; Walker, S, 1991) |
| "Omeprazole is a potent and long-acting inhibitor of pentagastrin stimulated gastric acid secretion in normal subjects, and this prompted a study of the effect of omeprazole on gastric acid hypersecretion and acid peptic disease resulting from endogenous hypergastrinaemia in Zollinger-Ellison patients." | 1.27 | Present experiences with omeprazole in the Zollinger-Ellison syndrome. ( Lamers, CB, 1986) |
| "Omeprazole has been given to more than 2500 subjects, mostly in short-term studies for 2-4 weeks, but also to some patients for more than 2 years." | 1.27 | Safety aspects of omeprazole. ( Sölvell, L, 1986) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 49 (6.60) | 18.7374 |
| 1990's | 386 (52.02) | 18.2507 |
| 2000's | 258 (34.77) | 29.6817 |
| 2010's | 43 (5.80) | 24.3611 |
| 2020's | 6 (0.81) | 2.80 |
| Authors | Studies |
|---|---|
| Jain, KS | 1 |
| Shah, AK | 1 |
| Bariwal, J | 1 |
| Shelke, SM | 1 |
| Kale, AP | 1 |
| Jagtap, JR | 1 |
| Bhosale, AV | 1 |
| Abu El-Ella, SS | 1 |
| El-Mekkawy, MS | 1 |
| Mohamed Selim, A | 1 |
| Vaezi, MF | 1 |
| Brunton, S | 1 |
| Mark Fendrick, A | 1 |
| Howden, CW | 5 |
| Atkinson, C | 1 |
| Pelletier, C | 1 |
| Jacob, R | 1 |
| Spechler, SJ | 1 |
| Bai, G | 1 |
| Yi, J | 1 |
| Yu, Y | 1 |
| Du, H | 1 |
| Corazziari, ES | 1 |
| Gasbarrini, A | 1 |
| D'Alba, L | 1 |
| D'Ovidio, V | 1 |
| Riggio, O | 1 |
| Passaretti, S | 1 |
| Annibale, B | 3 |
| Cicala, M | 1 |
| Repici, A | 1 |
| Bassotti, G | 1 |
| Ciacci, C | 1 |
| Di Sabatino, A | 1 |
| Neri, M | 1 |
| Bragazzi, MC | 1 |
| Ribichini, E | 1 |
| Radocchia, G | 1 |
| Iovino, P | 1 |
| Marazzato, M | 1 |
| Schippa, S | 1 |
| Badiali, D | 1 |
| Ghasemkhani, N | 1 |
| Tabrizi, AS | 1 |
| Namazi, F | 1 |
| Nazifi, S | 1 |
| Zhang, J | 1 |
| Diao, P | 1 |
| Zhang, L | 2 |
| Collares-Pelizaro, RVA | 1 |
| Santos, JS | 1 |
| Nonino, CB | 1 |
| dos Reis Dias, LA | 1 |
| Gaitani, CM | 1 |
| Salgado, W | 1 |
| Andreev, DN | 2 |
| Maev, IV | 2 |
| Dicheva, DT | 2 |
| Samsonov, AA | 1 |
| Partzvania-Vinogradova, EV | 2 |
| Yurenev, GL | 1 |
| Maiev, IV | 1 |
| Sharma, P | 1 |
| Seyedmajidi, S | 1 |
| Mirsattari, D | 1 |
| Zojaji, H | 1 |
| Zanganeh, E | 1 |
| Seyyedmajidi, M | 2 |
| Almasi, S | 1 |
| Zali, M | 1 |
| McNicholl, AG | 1 |
| Marin, AC | 1 |
| Molina-Infante, J | 1 |
| Castro, M | 1 |
| Barrio, J | 1 |
| Ducons, J | 3 |
| Calvet, X | 8 |
| de la Coba, C | 1 |
| Montoro, M | 4 |
| Bory, F | 3 |
| Perez-Aisa, A | 1 |
| Forné, M | 1 |
| Gisbert, JP | 4 |
| Kuramoto, T | 1 |
| Umegaki, E | 1 |
| Nouda, S | 1 |
| Narabayashi, K | 1 |
| Kojima, Y | 1 |
| Yoda, Y | 2 |
| Ishida, K | 1 |
| Kawakami, K | 2 |
| Abe, Y | 1 |
| Takeuchi, T | 1 |
| Inoue, T | 1 |
| Murano, M | 1 |
| Tokioka, S | 1 |
| Higuchi, K | 4 |
| Ma, B | 1 |
| Hang, L | 1 |
| Chen, G | 1 |
| Du, Y | 1 |
| Sachs, G | 6 |
| Shin, JM | 1 |
| Munson, K | 1 |
| Scott, DR | 1 |
| Chen, WC | 1 |
| Li, YD | 1 |
| Chiang, PH | 1 |
| Tsay, FW | 1 |
| Chan, HH | 2 |
| Tsai, WL | 1 |
| Tsai, TJ | 1 |
| Wang, EM | 1 |
| Cheng, JS | 2 |
| Lai, KH | 2 |
| Elokhina, EV | 1 |
| Kostenko, MB | 1 |
| Livzan, MA | 1 |
| Scalskiy, SV | 1 |
| Alimadadi, M | 1 |
| Amirkhanlou, S | 1 |
| Hafezi, AA | 1 |
| Homapour, S | 1 |
| Vafaeimanesh, J | 1 |
| Vakili, MA | 1 |
| Goldstein, JL | 3 |
| Whellan, DJ | 1 |
| Scheiman, JM | 4 |
| Cryer, BL | 2 |
| Eisen, GM | 1 |
| Lanas, A | 8 |
| Fort, JG | 1 |
| Dai, GZ | 1 |
| Fan, XJ | 1 |
| Tian, QS | 1 |
| Zhu, SK | 1 |
| Zhao, KX | 1 |
| Shen, DL | 1 |
| Vaduganathan, M | 1 |
| Bhatt, DL | 1 |
| Liu, Y | 1 |
| Hsieh, WH | 1 |
| Doros, G | 1 |
| Cohen, M | 1 |
| Schnitzer, TJ | 1 |
| Shook, TL | 1 |
| Lapuerta, P | 1 |
| Goldsmith, MA | 1 |
| Laine, L | 3 |
| Cannon, CP | 1 |
| Kruszelnicka, O | 1 |
| Świerszcz, J | 1 |
| Bednarek, J | 1 |
| Chyrchel, B | 1 |
| Surdacki, A | 1 |
| Nessler, J | 1 |
| Chang, YC | 1 |
| Hsiao, PJ | 1 |
| Wu, KL | 1 |
| Hsiao, CJ | 1 |
| Lane, MB | 1 |
| Larson, JC | 1 |
| Stokes, JE | 1 |
| Tolbert, MK | 1 |
| Silva, FM | 3 |
| Eisig, JN | 3 |
| Teixeira, AC | 1 |
| Barbuti, RC | 3 |
| Navarro-Rodriguez, T | 3 |
| Mattar, R | 1 |
| Bulych, PV | 1 |
| Kosiakov, AN | 1 |
| Babich, NV | 1 |
| Felga, GE | 1 |
| Zaterka, S | 2 |
| Hong, EJ | 1 |
| Park, DI | 2 |
| Oh, SJ | 1 |
| Song, MJ | 1 |
| Choi, WH | 1 |
| Hong, CH | 1 |
| Park, JH | 1 |
| Kim, HJ | 3 |
| Cho, YK | 2 |
| Shon, CI | 1 |
| Jeon, WK | 2 |
| Kim, BI | 2 |
| Qi, Z | 1 |
| Jie, L | 1 |
| Haixia, C | 1 |
| Xiaoying, Z | 1 |
| Chan, FK | 8 |
| Maity, P | 1 |
| Biswas, K | 2 |
| Chattopadhyay, I | 1 |
| Banerjee, RK | 2 |
| Bandyopadhyay, U | 2 |
| Oganesian, TS | 1 |
| Dutra, RC | 1 |
| Fava, MB | 1 |
| Alves, CC | 1 |
| Ferreira, AP | 1 |
| Barbosa, NR | 1 |
| Ntaios, G | 1 |
| Chatzinikolaou, A | 1 |
| Kaiafa, G | 1 |
| Savopoulos, C | 1 |
| Hatzitolios, A | 1 |
| Karamitsos, D | 1 |
| Abdou, AG | 1 |
| Elshayeb, EI | 1 |
| Farag, AG | 1 |
| Elnaidany, NF | 1 |
| Tseng, GY | 3 |
| Fang, CT | 1 |
| Lin, HJ | 4 |
| Yang, HB | 2 |
| Tseng, GC | 1 |
| Wang, PC | 1 |
| Liao, PC | 1 |
| Cheng, YT | 1 |
| Huang, CH | 1 |
| Veligotskiĭ, NN | 1 |
| Buka, GIu | 1 |
| Mabe, K | 1 |
| Takahashi, M | 3 |
| Oizumi, H | 1 |
| Tsukuma, H | 1 |
| Shibata, A | 1 |
| Fukase, K | 1 |
| Matsuda, T | 1 |
| Takeda, H | 3 |
| Kawata, S | 1 |
| Lionetti, E | 1 |
| Francavilla, R | 1 |
| Ruggieri, M | 1 |
| Di Stefano, V | 1 |
| Principi, MB | 1 |
| Pavone, L | 1 |
| Kucheriavyĭ, IuA | 1 |
| Lakshmi, V | 1 |
| Singh, N | 1 |
| Shrivastva, S | 1 |
| Mishra, SK | 1 |
| Dharmani, P | 2 |
| Mishra, V | 1 |
| Palit, G | 2 |
| Kim, PK | 1 |
| Dorshimer, GW | 1 |
| Garrido, A | 2 |
| Iborra, MI | 1 |
| Saperas, E | 1 |
| de Sousa, M | 1 |
| Zhang, WP | 1 |
| Ge, HN | 1 |
| Guo, JW | 1 |
| Amagase, K | 2 |
| Ochi, A | 1 |
| Sugihara, T | 1 |
| Kato, S | 3 |
| Takeuchi, K | 1 |
| Scheiman, J | 2 |
| Berger, MF | 1 |
| Nguyen, H | 1 |
| Koizumi, W | 2 |
| Tanabe, S | 2 |
| Nakatani, K | 1 |
| Ishido, K | 1 |
| Nishimura, K | 1 |
| Azuma, M | 1 |
| Ae, T | 1 |
| Sasaki, T | 1 |
| Katada, C | 1 |
| Nakayama, N | 1 |
| Saigenji, K | 2 |
| Mei, Q | 1 |
| Li, QS | 1 |
| Hu, YM | 1 |
| Xu, JM | 1 |
| Ni, N | 1 |
| Moeckel, GW | 1 |
| Kumar, C | 1 |
| Felga, G | 1 |
| Celinski, K | 1 |
| Konturek, SJ | 1 |
| Konturek, PC | 1 |
| Brzozowski, T | 1 |
| Cichoz-Lach, H | 1 |
| Slomka, M | 1 |
| Malgorzata, P | 1 |
| Bielanski, W | 1 |
| Reiter, RJ | 3 |
| Hiraishi, H | 2 |
| Maeda, M | 1 |
| Sasai, T | 1 |
| Kanke, K | 2 |
| Shimada, T | 2 |
| Liang, CC | 1 |
| Wang, IK | 1 |
| Lin, HH | 1 |
| Yeh, HC | 1 |
| Liu, JH | 1 |
| Kuo, HL | 1 |
| Hsu, WM | 1 |
| Huang, CC | 1 |
| Chang, CT | 1 |
| Ghadir, MR | 1 |
| Shafaghi, A | 1 |
| Iranikhah, A | 1 |
| Pakdin, A | 1 |
| Joukar, F | 1 |
| Mansour-Ghanaei, F | 1 |
| Choi, KH | 1 |
| Chung, WC | 1 |
| Lee, KM | 1 |
| Paik, CN | 1 |
| Kim, EJ | 1 |
| Kang, BK | 1 |
| Oak, JH | 1 |
| Jung, SH | 2 |
| Wallace, JL | 1 |
| Syer, S | 1 |
| Denou, E | 1 |
| de Palma, G | 1 |
| Vong, L | 1 |
| McKnight, W | 1 |
| Jury, J | 1 |
| Bolla, M | 1 |
| Bercik, P | 1 |
| Collins, SM | 1 |
| Verdu, E | 1 |
| Ongini, E | 1 |
| Urgesi, R | 1 |
| Pelecca, G | 1 |
| Cianci, R | 1 |
| Masini, A | 1 |
| Zampaletta, C | 1 |
| Riccioni, ME | 1 |
| Faggiani, R | 1 |
| Yeomans, ND | 2 |
| Kim, JY | 1 |
| Kim, N | 2 |
| Park, HK | 1 |
| Jo, HJ | 1 |
| Shin, CM | 1 |
| Lee, SH | 2 |
| Park, YS | 2 |
| Hwang, JH | 2 |
| Kim, JW | 4 |
| Jeong, SH | 1 |
| Lee, DH | 2 |
| Nam, RH | 1 |
| Kim, JM | 2 |
| Lee, JH | 1 |
| Jung, HC | 2 |
| Song, IS | 2 |
| Ermis, F | 1 |
| Akyuz, F | 1 |
| Uyanikoglu, A | 1 |
| Kurt, R | 1 |
| Pinarbasi, B | 1 |
| Nazik, H | 1 |
| Kaymakoglu, S | 1 |
| Mungan, Z | 1 |
| Messinger-Rapport, BJ | 1 |
| Morley, JE | 1 |
| Thomas, DR | 1 |
| Gammack, JK | 1 |
| Figura, N | 1 |
| Moretti, E | 1 |
| Vaglio, L | 1 |
| Langone, F | 1 |
| Vernillo, R | 1 |
| Vindigni, C | 1 |
| Giordano, N | 1 |
| Szabó, IL | 1 |
| Czimmer, J | 1 |
| Szolcsányi, J | 1 |
| Mózsik, G | 1 |
| Tsimmerman, IaS | 1 |
| Bandyopadhyay, D | 2 |
| Bandyopadhyay, A | 1 |
| Das, PK | 1 |
| Inaba, T | 1 |
| Mizuno, M | 3 |
| Kawai, K | 3 |
| Yokota, K | 2 |
| Oguma, K | 2 |
| Miyoshi, M | 2 |
| Take, S | 1 |
| Okada, H | 2 |
| Tsuji, T | 2 |
| Jung, HK | 1 |
| Son, HY | 1 |
| Jung, SA | 2 |
| Yi, SY | 1 |
| Yoo, K | 2 |
| Kim, DY | 1 |
| Moon, IH | 1 |
| Lee, HC | 1 |
| Nikfar, S | 1 |
| Abdollahi, M | 1 |
| Moretti, ME | 1 |
| Magee, LA | 1 |
| Koren, G | 1 |
| Guardiola, J | 1 |
| Tito, L | 1 |
| Andreu, V | 1 |
| Guirao, R | 3 |
| Vanderhoff, BT | 1 |
| Tahboub, RM | 1 |
| Labenz, J | 18 |
| Blum, AL | 5 |
| Bolten, WW | 1 |
| Dragosics, B | 1 |
| Rösch, W | 1 |
| Stolte, M | 6 |
| Koelz, HR | 1 |
| Boixeda, D | 3 |
| Bermejo, F | 2 |
| Martín-De-Argila, C | 1 |
| López-Sanromán, A | 1 |
| Defarges, V | 1 |
| Hernández-Ranz, F | 1 |
| Milicua, JM | 1 |
| García-Plaza, A | 1 |
| Imaeda, H | 1 |
| Ishii, H | 2 |
| Goto, M | 2 |
| Kinoshita, Y | 2 |
| Fujishiro, H | 2 |
| Amano, Y | 1 |
| Adachi, K | 2 |
| Mak, SK | 2 |
| Loo, CK | 2 |
| Wong, AM | 1 |
| Wong, PN | 2 |
| Lo, KY | 2 |
| Tong, GM | 2 |
| Lam, EK | 2 |
| Wong, AK | 2 |
| Johnson, M | 1 |
| Guilford, S | 1 |
| Libretto, SE | 1 |
| Campbell, DR | 1 |
| Haber, MM | 1 |
| Sheldon, E | 1 |
| Collis, C | 1 |
| Lukasik, N | 1 |
| Huang, B | 1 |
| O'Morain, CA | 1 |
| Qasim, A | 1 |
| De Francesco, V | 4 |
| Faleo, D | 1 |
| Panella, C | 3 |
| Ierardi, E | 4 |
| Margiotta, M | 2 |
| Kawai, T | 1 |
| Kudo, T | 2 |
| Ogiahara, S | 1 |
| Handa, Y | 1 |
| Moriyasu, F | 1 |
| Gorshkov, VA | 1 |
| Maiden, LP | 1 |
| Harris, AW | 1 |
| Nemytin, IuV | 1 |
| Makarov, IuS | 1 |
| Pavlov, AI | 1 |
| Kashchenko, OI | 1 |
| Lezhenina, NP | 1 |
| Golochalova, TV | 1 |
| Kim, JI | 1 |
| Park, SH | 2 |
| Kim, JK | 1 |
| Chung, IS | 1 |
| Chung, KW | 1 |
| Sun, HS | 1 |
| Cheer, SM | 1 |
| Prakash, A | 2 |
| Faulds, D | 3 |
| Lamb, HM | 1 |
| Graham, DY | 8 |
| Leitner, A | 1 |
| Zöllner, P | 1 |
| Patel, AS | 1 |
| Pohl, JF | 1 |
| Easley, DJ | 1 |
| Kawabata, H | 1 |
| Habu, Y | 3 |
| Tomioka, H | 1 |
| Kutsumi, H | 1 |
| Kobayashi, M | 1 |
| Oyasu, K | 1 |
| Hayakumo, T | 1 |
| Mizuno, S | 2 |
| Kiyota, K | 3 |
| Nakajima, M | 1 |
| Kimoto, K | 2 |
| Inokuchi, H | 3 |
| Miki, I | 1 |
| Aoyama, N | 3 |
| Sakai, T | 2 |
| Shirasaka, D | 2 |
| Wambura, CM | 1 |
| Maekawa, S | 1 |
| Kuroda, K | 1 |
| Tamura, T | 1 |
| Kita, T | 3 |
| Sakaeda, T | 1 |
| Okumura, K | 3 |
| Kasuga, M | 2 |
| Hawkey, CJ | 6 |
| Atherton, JC | 2 |
| Treichel, HC | 1 |
| Thjodleifsson, B | 2 |
| Ravic, M | 1 |
| Asaka, M | 7 |
| Baldi, F | 1 |
| Malfertheiner, P | 4 |
| Kato, M | 5 |
| Sugiyama, T | 4 |
| Satoh, K | 5 |
| Kuwayama, H | 5 |
| Fukuda, Y | 7 |
| Fujioka, T | 5 |
| Takemoto, T | 3 |
| Kimura, K | 6 |
| Shimoyama, T | 6 |
| Shimizu, K | 2 |
| Kobayashi, S | 2 |
| van Hout, BA | 1 |
| Klok, RM | 1 |
| Brouwers, JR | 1 |
| Postma, MJ | 1 |
| Martín De Argila, C | 3 |
| López Sanromán, A | 1 |
| Hernández Ranz, F | 1 |
| García Plaza, A | 2 |
| Zullo, A | 5 |
| Hassan, C | 3 |
| Morini, S | 4 |
| Unge, P | 3 |
| Sipponen, P | 2 |
| Ekström, P | 2 |
| Hellblom, M | 1 |
| Ohlin, B | 1 |
| Stubberöd, A | 1 |
| Kihira, K | 4 |
| Yube, T | 1 |
| Yoshida, Y | 4 |
| Sapone, A | 1 |
| Vaira, D | 2 |
| Trespidi, S | 1 |
| Perna, F | 1 |
| Gatta, L | 2 |
| Tampieri, A | 1 |
| Ricci, C | 2 |
| Cantelli-Forti, G | 1 |
| Miglioli, M | 2 |
| Biagi, GL | 1 |
| Paolini, M | 1 |
| Udd, M | 1 |
| Miettinen, P | 1 |
| Palmu, A | 1 |
| Julkunen, R | 1 |
| Wheeldon, TU | 2 |
| Hoang, TT | 2 |
| Phung, DC | 1 |
| Björkman, A | 1 |
| Granström, M | 2 |
| Sörberg, M | 3 |
| Rodrigo, L | 1 |
| Márquez, JL | 1 |
| Bajador, E | 2 |
| Pérez-Roldan, F | 1 |
| Cabrol, J | 1 |
| Quintero, E | 1 |
| Gomollón, F | 6 |
| Santolaria, S | 2 |
| Lorente, S | 1 |
| Cucala, M | 1 |
| Nuevo, J | 1 |
| Ferrández, A | 1 |
| Karateev, AE | 1 |
| Murav'ev, IuV | 1 |
| Radenska-Lopovok, SG | 1 |
| Nasonova, VA | 1 |
| Suzuki, H | 1 |
| Masaoka, T | 1 |
| Nomura, S | 1 |
| Hoshino, Y | 1 |
| Kurabayashi, K | 1 |
| Minegishi, Y | 1 |
| Suzuki, M | 2 |
| Choi, BK | 1 |
| Yang, SY | 1 |
| Park, ET | 1 |
| Jang, YS | 1 |
| Lee, YJ | 1 |
| Seol, SY | 1 |
| Chung, JM | 1 |
| Lai, KC | 4 |
| Lam, SK | 4 |
| Chu, KM | 3 |
| Hui, WM | 3 |
| Kwok, KF | 1 |
| Wong, BC | 5 |
| Hu, HC | 1 |
| Wong, WM | 3 |
| Chan, OO | 1 |
| Chan, CK | 1 |
| Luo, JY | 1 |
| Niu, CY | 1 |
| Wang, XQ | 1 |
| Zhu, YL | 1 |
| Gong, J | 1 |
| Bochenek, WJ | 1 |
| Peters, S | 1 |
| Fraga, PD | 1 |
| Wang, W | 1 |
| Mack, ME | 1 |
| Osato, MS | 2 |
| El-Zimaity, HM | 3 |
| Davis, KD | 1 |
| Takahashi, S | 2 |
| Johnson, DA | 1 |
| Gambaro, C | 1 |
| Bilardi, C | 1 |
| Dulbecco, P | 1 |
| Iiritano, E | 1 |
| Zentilin, P | 1 |
| Mansia, C | 1 |
| Usai, P | 1 |
| Vigneri, S | 3 |
| Savarino, V | 4 |
| van Rensburg, CJ | 3 |
| Hartmann, M | 1 |
| Thorpe, A | 1 |
| Venter, L | 1 |
| Theron, I | 1 |
| Lühmann, R | 2 |
| Wurst, W | 1 |
| Maltz, C | 1 |
| Marangi, S | 1 |
| Burattini, O | 1 |
| Berloco, P | 1 |
| Russo, F | 1 |
| Barone, M | 1 |
| Di Leo, A | 1 |
| Minenna, MF | 2 |
| Stoppino, V | 2 |
| Francavilla, A | 1 |
| Saltanova, SD | 1 |
| Tkach, OS | 1 |
| Yang, KC | 1 |
| Wang, GM | 1 |
| Chen, JH | 1 |
| Chen, TJ | 1 |
| Lee, SC | 2 |
| Ng, FH | 1 |
| Wong, SY | 1 |
| Chen, WH | 1 |
| Chang, CM | 1 |
| Berkowitz, BA | 1 |
| Furuta, T | 3 |
| Shirai, N | 1 |
| Xiao, F | 1 |
| El-Omar, EM | 2 |
| Rabkin, CS | 1 |
| Sugimura, H | 1 |
| Ishizaki, T | 2 |
| Ohashi, K | 2 |
| Bustamante Baléna, M | 1 |
| Ponce García, J | 1 |
| Peitz, U | 4 |
| Raps, S | 1 |
| Plein, K | 2 |
| Leodolter, A | 1 |
| Hotz Dagger, J | 1 |
| Färkkilä, M | 1 |
| Sarna, S | 1 |
| Valtonen, V | 1 |
| Gribajcević, M | 1 |
| Vanis, N | 1 |
| Mesihović, R | 1 |
| Bhatia, V | 1 |
| Ahuja, V | 1 |
| Das, B | 1 |
| Bal, C | 1 |
| Sharma, MP | 1 |
| Sharara, AI | 1 |
| Chaar, HF | 1 |
| Racoubian, E | 1 |
| Moukhachen, O | 1 |
| Barada, KA | 1 |
| Mourad, FH | 1 |
| Araj, GF | 1 |
| Della Valle, N | 1 |
| Pietrini, L | 1 |
| Winn, S | 1 |
| Monno, R | 1 |
| Phuncarg, DC | 1 |
| Nilsson, LE | 1 |
| Giral, A | 1 |
| Ozdogan, O | 1 |
| Celikel, CA | 1 |
| Tozun, N | 1 |
| Ulusoy, NB | 1 |
| Kalayci, C | 1 |
| de Korwin, JD | 1 |
| Ducrotté, P | 1 |
| Vallot, T | 1 |
| Kondo, Y | 2 |
| Joh, T | 2 |
| Sasaki, M | 2 |
| Oshima, T | 2 |
| Itoh, K | 2 |
| Tanida, S | 2 |
| Kataoka, H | 2 |
| Ohara, H | 3 |
| Nomura, T | 1 |
| Itoh, M | 2 |
| Janssen, MJ | 1 |
| Laheij, RJ | 1 |
| Jansen, JB | 1 |
| de Boer, WA | 9 |
| Hung, LC | 1 |
| Suen, BY | 1 |
| Wong, VW | 1 |
| Hui, AJ | 1 |
| Wu, JC | 3 |
| Leung, WK | 2 |
| Lee, YT | 1 |
| To, KF | 2 |
| Chung, SC | 2 |
| Sung, JJ | 4 |
| Cryer, B | 1 |
| Horn, J | 1 |
| Miner, P | 1 |
| Pilotto, A | 3 |
| Franceschi, M | 4 |
| Longoa, MG | 1 |
| Scarcelli, C | 1 |
| Orsitto, G | 1 |
| Perri, FC | 1 |
| D'Ambrosio, LP | 1 |
| Leandro, G | 3 |
| Asfeldt, AM | 1 |
| Løchen, ML | 1 |
| Straume, B | 1 |
| Steigen, SE | 1 |
| Florholmen, J | 1 |
| Goll, R | 1 |
| Nestegard, O | 1 |
| Paulssen, EJ | 1 |
| Isakov, VA | 2 |
| Bak-Romaniszyn, L | 1 |
| Wojtuń, S | 1 |
| Gil, J | 1 |
| Płaneta-Małecka, I | 1 |
| Diav-Citrin, O | 1 |
| Arnon, J | 1 |
| Shechtman, S | 1 |
| Schaefer, C | 1 |
| van Tonningen, MR | 1 |
| Clementi, M | 1 |
| De Santis, M | 1 |
| Robert-Gnansia, E | 1 |
| Valti, E | 1 |
| Malm, H | 1 |
| Ornoy, A | 1 |
| Bardhan, KD | 5 |
| Bishop, AE | 2 |
| Polak, JM | 2 |
| Romanska, HM | 1 |
| Rowland, A | 2 |
| Thompson, M | 3 |
| Morris, P | 3 |
| Schaefer-Preuss, S | 1 |
| Luehmann, R | 1 |
| McCaldin, B | 2 |
| Feng, LY | 1 |
| Yao, XX | 1 |
| Jiang, SL | 1 |
| Isomoto, H | 1 |
| Furusu, H | 1 |
| Ohnita, K | 1 |
| Wen, CY | 1 |
| Inoue, K | 2 |
| Kohno, S | 1 |
| Terano, A | 3 |
| Coursol, CJ | 1 |
| Sanzari, SE | 1 |
| Sun, WH | 1 |
| Ou, XL | 1 |
| Cao, DZ | 1 |
| Yu, Q | 1 |
| Yu, T | 1 |
| Hu, JM | 1 |
| Zhu, F | 1 |
| Sun, YL | 1 |
| Fu, XL | 1 |
| Su, H | 1 |
| Kim, SH | 1 |
| Sung, IK | 1 |
| Sohn, CI | 1 |
| Keum, DK | 1 |
| Lin, SR | 1 |
| Miyake, K | 2 |
| Ueki, N | 1 |
| Suzuki, K | 2 |
| Shinji, Y | 1 |
| Kusunoki, M | 1 |
| Hiratsuka, T | 1 |
| Nishigaki, H | 1 |
| Tatsuguchi, A | 1 |
| Futagami, S | 1 |
| Wada, K | 1 |
| Tsukui, T | 1 |
| Nakajima, A | 1 |
| Yoshino, S | 1 |
| Sakamoto, C | 2 |
| Vergara, M | 1 |
| Catalán, M | 1 |
| Bernabucci, V | 1 |
| Cavina, M | 1 |
| Mishra, PK | 1 |
| Maurya, R | 1 |
| Chauhan, VS | 1 |
| Ahmed, W | 2 |
| Arif, A | 1 |
| Alam, SE | 1 |
| Biswal, N | 1 |
| Ananathakrishnan, N | 1 |
| Kate, V | 1 |
| Srinivasan, S | 1 |
| Nalini, P | 1 |
| Mathai, B | 1 |
| Choi, SM | 1 |
| Kim, DH | 1 |
| Oh, TY | 1 |
| Ahn, BO | 1 |
| Kwon, JW | 1 |
| Kim, WB | 1 |
| Bujanda, L | 1 |
| Montserrat, A | 1 |
| Gostishchev, VK | 1 |
| Evseev, MA | 1 |
| Ogasawara, N | 1 |
| Okada, N | 1 |
| Sano, H | 1 |
| Nakao, H | 1 |
| Sobue, S | 1 |
| Singh, G | 1 |
| Triadafilopoulos, G | 1 |
| Ando, T | 1 |
| Minami, M | 1 |
| Mizuno, T | 1 |
| Watanabe, O | 1 |
| Ishiguro, K | 1 |
| Ina, K | 1 |
| Kusugami, K | 1 |
| Nobata, K | 1 |
| Nishiwaki, T | 1 |
| Tsuzuki, T | 1 |
| Shimada, M | 1 |
| El-Omar, E | 2 |
| Goto, H | 3 |
| Magalhães, AF | 1 |
| Carvalhaes, A | 1 |
| Natan-Eisig, J | 1 |
| Paraíso-Ferraz, JG | 1 |
| Trevisan, M | 1 |
| Zaterkaad, S | 1 |
| Devlin, JW | 1 |
| Welage, LS | 1 |
| Olsen, KM | 2 |
| Castell, D | 1 |
| Hu, WH | 2 |
| Chan, AO | 2 |
| Wong, J | 2 |
| Vakil, N | 1 |
| Armstrong, D | 2 |
| Schaeverbeke, T | 1 |
| Broutet, N | 1 |
| Zerbib, F | 1 |
| Combe, B | 1 |
| Bertin, P | 1 |
| Lamouliatte, H | 1 |
| Perié, F | 1 |
| Joubert-Collin, M | 1 |
| Mégraud, F | 1 |
| Murakami, K | 3 |
| Sato, R | 2 |
| Okimoto, T | 3 |
| Watanabe, K | 2 |
| Nasu, M | 1 |
| Kodama, M | 3 |
| Abe, T | 2 |
| Sato, S | 1 |
| Arita, T | 1 |
| Butorov, IV | 2 |
| Osoianu, IuP | 2 |
| Butorov, SI | 2 |
| Maksimov, VV | 2 |
| Go, MF | 1 |
| Pregun, I | 1 |
| Herszényi, L | 1 |
| Juhász, M | 1 |
| Miheller, P | 1 |
| Tulassay, Z | 2 |
| Lule, GN | 1 |
| You, JH | 2 |
| Lau, W | 1 |
| Lee, IY | 1 |
| Yung, M | 1 |
| Ching, JY | 1 |
| Lee, KK | 2 |
| Díte, P | 3 |
| Kunovská, M | 2 |
| Pulgretová, D | 1 |
| Woznica, V | 1 |
| Petrtýl, J | 1 |
| Hůlek, P | 1 |
| Pásková, J | 1 |
| Dostalík, Z | 1 |
| Novotný, I | 2 |
| Procházka, V | 1 |
| Hegyi, P | 1 |
| Zelenková, J | 1 |
| Samek, M | 1 |
| Králová, Z | 1 |
| Vyhnálek, P | 1 |
| Matejovic, F | 1 |
| Weinberg, J | 1 |
| Kyzeková, J | 1 |
| Ji, KY | 1 |
| Hu, FL | 1 |
| Ji, S | 1 |
| Kim, HS | 2 |
| Jee, MK | 1 |
| Park, KW | 1 |
| Uh, Y | 1 |
| Lee, DK | 2 |
| Song, JS | 1 |
| Baik, SK | 2 |
| Kwon, SO | 2 |
| Emami, MH | 1 |
| Saberfiroozi, MM | 1 |
| Arj, A | 1 |
| Taghavi, AR | 1 |
| Bagheri-Lankarani, K | 1 |
| Dehbashi, N | 1 |
| Fattahi, MR | 1 |
| Alizadeh, M | 1 |
| Kaviani, MJ | 1 |
| Bahri-Najafi, R | 1 |
| Geramizadeh, B | 1 |
| Esmaeili, A | 1 |
| Namiot, DB | 1 |
| Namiot, Z | 1 |
| Kemona, A | 1 |
| Bucki, R | 1 |
| Gotebiewska, M | 1 |
| Duggan, AE | 1 |
| Lassen, AT | 1 |
| Belousov, IuB | 1 |
| Karpov, OI | 1 |
| Belousov, DIu | 1 |
| Beketov, AS | 1 |
| Alkim, H | 1 |
| Unal, S | 1 |
| Okur, H | 1 |
| Imir, T | 1 |
| Czerwionka-Szaflarska, M | 1 |
| Brazowski, J | 1 |
| Chung, SJ | 1 |
| Lee, KH | 1 |
| de Leest, HT | 1 |
| Steen, KS | 1 |
| Lems, WF | 1 |
| Bijlsma, JW | 1 |
| van de Laar, MA | 1 |
| Huisman, AM | 1 |
| Vonkeman, HE | 1 |
| Houben, HH | 1 |
| Kadir, SW | 1 |
| Kostense, PJ | 1 |
| van Tulder, MW | 1 |
| Kuipers, EJ | 1 |
| Boers, M | 1 |
| Dijkmans, BA | 1 |
| Ford, AC | 1 |
| Forman, D | 2 |
| Nathan, J | 2 |
| Crocombe, WD | 1 |
| Axon, AT | 8 |
| Moayyedi, P | 6 |
| Nasseri-Moghaddam, S | 1 |
| Razjouyan, H | 1 |
| Alimohamadi, SM | 1 |
| Mamarabadi, M | 1 |
| Ghotbi, MH | 1 |
| Mostajabi, P | 1 |
| Sohrabpour, AA | 1 |
| Sotoudeh, M | 1 |
| Abedi, B | 1 |
| Mofid, A | 1 |
| Nouraie, M | 1 |
| Tofangchiha, S | 1 |
| Malekzadeh, R | 1 |
| Münzová, H | 1 |
| Peura, D | 1 |
| Wilcox, CM | 1 |
| Niculescu, L | 1 |
| Berger, M | 1 |
| Tzathas, C | 1 |
| Triantafyllou, K | 1 |
| Mallas, E | 1 |
| Triantafyllou, G | 1 |
| Ladas, SD | 1 |
| Jung, JM | 1 |
| Shim, KN | 1 |
| Oh, HJ | 1 |
| Na, YJ | 1 |
| Jung, HS | 1 |
| Burkov, SG | 1 |
| Arutiunov, AT | 1 |
| Nikiforov, PA | 1 |
| Hansen, JM | 2 |
| Wildner-Christensen, M | 1 |
| Hallas, J | 1 |
| Schaffalitzky de Muckadell, OB | 2 |
| Baker, DE | 1 |
| Levine, JB | 1 |
| Fimmel, CJ | 1 |
| Ashley, SW | 1 |
| Cheung, LY | 1 |
| Dammann, HG | 5 |
| Walter, TA | 1 |
| Müller, P | 7 |
| Simon, B | 7 |
| Hirai, M | 1 |
| Hashimoto, A | 1 |
| Aomi, S | 1 |
| Tokunaga, H | 1 |
| Koyanagi, T | 1 |
| Sakahashi, H | 1 |
| Fujino, S | 1 |
| Koyanagi, H | 1 |
| Prásek, J | 1 |
| Domschke, W | 3 |
| Dettmer, A | 1 |
| Fenner, T | 1 |
| Gregor, M | 1 |
| Hesse, P | 1 |
| Holtmann, G | 2 |
| van Husen, N | 1 |
| Miederer, SE | 2 |
| Schentke, KU | 1 |
| Schütz, E | 1 |
| Jensen, RT | 3 |
| Fraker, DL | 1 |
| Lessell, S | 1 |
| Classen, M | 2 |
| Creutzfeldt, W | 8 |
| Petersen, KH | 1 |
| Heintze, K | 1 |
| Hotz, J | 1 |
| Kark, W | 1 |
| Wiedbrauck, F | 1 |
| Guthke, A | 1 |
| Otten, O | 1 |
| Ogura, K | 1 |
| Ota, S | 1 |
| Katoh, M | 1 |
| Kudoh, M | 1 |
| Kagaya, H | 2 |
| Katagiri, M | 2 |
| Suzuki, T | 1 |
| Nakagawa, T | 1 |
| Yoneshima, M | 1 |
| Yamamoto, M | 1 |
| Tsujino, D | 1 |
| Murai, S | 1 |
| Saito, N | 2 |
| Kokubun, N | 1 |
| Kajiwara, M | 1 |
| Futami, H | 1 |
| Arai, H | 1 |
| Hanai, H | 3 |
| Kaneko, E | 3 |
| Fujino, MA | 1 |
| Morozumi, A | 1 |
| Kobayashi, K | 4 |
| Ueda, F | 1 |
| Suzuki, Y | 1 |
| Uchida, N | 1 |
| Tachikawa, H | 1 |
| Sano, S | 1 |
| Ohtsuka, H | 1 |
| Yamamoto, Y | 2 |
| Asaki, S | 2 |
| Sato, A | 1 |
| Sakurada, H | 1 |
| Takeda, T | 1 |
| Hongo, M | 2 |
| Toyota, T | 1 |
| Ashida, K | 1 |
| Sakaguchi, M | 1 |
| Tanaka, M | 1 |
| Takiuchi, H | 1 |
| Egashira, Y | 1 |
| Katsu, K | 1 |
| Ito, G | 1 |
| Nakagawara, M | 1 |
| Watanabe, F | 1 |
| Ooi, S | 1 |
| Nawano, M | 1 |
| Hoshino, E | 1 |
| Umeda, N | 1 |
| Sano, J | 1 |
| Miki, K | 1 |
| Yahagi, N | 1 |
| Oka, M | 1 |
| Kimura, M | 2 |
| Miyashita, H | 1 |
| Mine, T | 1 |
| Yasuda, H | 1 |
| Akimoto, K | 1 |
| Katoaka, A | 1 |
| Mashima, H | 1 |
| Tajima, A | 1 |
| Fukujin, H | 1 |
| Tsuchida, T | 1 |
| Takano, T | 1 |
| Nagasawa, J | 1 |
| Ohashi, T | 1 |
| Sakata, J | 1 |
| Haraguchi, Y | 1 |
| Eto, T | 1 |
| Murakami, M | 3 |
| Saita, H | 2 |
| Takahashi, Y | 2 |
| Kusaka, S | 1 |
| Asagoe, K | 1 |
| Dekigai, H | 1 |
| Matsumoto, M | 1 |
| Seki, M | 1 |
| Maeda, S | 1 |
| Ogoshi, K | 1 |
| Kato, T | 2 |
| Sakagawa, T | 1 |
| Dajani, EZ | 2 |
| Agrawal, NM | 1 |
| Sezai, S | 1 |
| Sakurabayashi, S | 1 |
| Hirano, M | 1 |
| Oka, H | 1 |
| Yabana, T | 1 |
| Kobayashi, T | 1 |
| Nakamura, T | 3 |
| Tytgat, GN | 10 |
| al-Assi, MT | 2 |
| Cole, RA | 1 |
| Karttunen, TJ | 1 |
| el-Zimaity, H | 1 |
| Genta, RM | 3 |
| Bayerdörffer, E | 1 |
| Yamamoto, I | 2 |
| Okui, M | 1 |
| Tamura, K | 2 |
| Della Beffa, V | 1 |
| Carelli-Basile, A | 1 |
| Leli, R | 1 |
| Fontana, D | 1 |
| Scheen, AJ | 1 |
| Börsch, G | 12 |
| Park, KN | 1 |
| Hahm, JS | 1 |
| Harada, T | 1 |
| Jaup, BH | 1 |
| Norrby, A | 1 |
| Dowling, PM | 1 |
| Burette, A | 2 |
| Glupczynski, Y | 1 |
| Mela, GS | 1 |
| Celle, G | 1 |
| Treiber, G | 5 |
| Klotz, O | 1 |
| Fujimori, K | 1 |
| Suzuki, E | 1 |
| Arakawa, M | 1 |
| Kaneko, H | 1 |
| Mitsuma, T | 1 |
| Nagai, H | 1 |
| Harada, M | 1 |
| Kotera, H | 1 |
| Furusawa, A | 1 |
| Morise, K | 1 |
| Singer, S | 1 |
| Parry, RG | 1 |
| Deodhar, HA | 1 |
| Barnes, JN | 1 |
| Karjoo, M | 1 |
| Kane, R | 1 |
| Goddard, A | 1 |
| Logan, R | 1 |
| Rühl, GH | 8 |
| Becker, T | 2 |
| Tillenburg, B | 2 |
| Sollböhmer, M | 2 |
| Degtiareva, II | 1 |
| Semeunovich, S | 1 |
| Kharchenko, NV | 1 |
| Petrovich, S | 1 |
| Gaĭsenko, AV | 1 |
| Egorova, IT | 1 |
| Harris, A | 1 |
| Misiewicz, JJ | 1 |
| de Boer, W | 1 |
| Driessen, W | 1 |
| Jansz, A | 1 |
| Tytgat, G | 1 |
| Berndt, H | 1 |
| Thros, H | 1 |
| Sigurdsson, H | 1 |
| Oddsson, E | 1 |
| Bjodleifsson, B | 1 |
| Bertrams, J | 1 |
| Ohtaki, T | 1 |
| Kudo, M | 2 |
| Kimura, T | 1 |
| Meguro, T | 1 |
| Horita, S | 1 |
| Gad, A | 1 |
| Goh, KL | 1 |
| Peh, SC | 1 |
| Parasakthi, N | 1 |
| Wong, NW | 1 |
| Tan, KK | 1 |
| Lo, YL | 1 |
| Capodicasa, E | 1 |
| Ciaccio, V | 1 |
| Corazzi, F | 1 |
| De Bellis, F | 1 |
| Bucaneve, G | 1 |
| Ficola, F | 1 |
| Pelli, MA | 1 |
| Iwasaki, A | 2 |
| Miyazawa, K | 1 |
| Kawamura, Y | 1 |
| Sakai, Y | 1 |
| Tashiro, Y | 1 |
| Ito, K | 1 |
| Arakawa, Y | 2 |
| Matsuo, Y | 1 |
| Jorias, I | 1 |
| Penston, JG | 1 |
| Padrós i Bou, J | 1 |
| Hirschowitz, BI | 2 |
| Kerr, GD | 1 |
| O'Connor, HJ | 3 |
| Freston, JW | 2 |
| Jönsson, B | 2 |
| Floch, MH | 1 |
| Adamek, RJ | 8 |
| Opferkuch, W | 6 |
| Wegener, M | 6 |
| Zala, G | 1 |
| Giezendanner, S | 1 |
| Flury, R | 1 |
| Wüst, J | 1 |
| Meyenberger, C | 1 |
| Ammann, R | 1 |
| Wirth, HP | 1 |
| Nousbaum, JB | 1 |
| Berthou, F | 1 |
| Carlhant, D | 1 |
| Riche, C | 1 |
| Robaszkiewicz, M | 1 |
| Gouerou, H | 1 |
| Arnold, R | 7 |
| Brunner, G | 5 |
| Harke, U | 1 |
| Lööf, L | 1 |
| Engstrand, L | 1 |
| Wormsley, KG | 2 |
| Freitag, M | 1 |
| Montemurro, NE | 1 |
| Di Maggio, A | 1 |
| Loperfido, A | 1 |
| Scatizzi, A | 1 |
| Behler, EM | 1 |
| Loeffler, KM | 1 |
| Elta, GH | 2 |
| Fried, M | 3 |
| Siegrist, H | 1 |
| Frei, R | 1 |
| Froehlich, F | 2 |
| Duroux, P | 2 |
| Thorens, J | 2 |
| Blum, A | 1 |
| Bille, J | 2 |
| Gonvers, JJ | 2 |
| Gyr, K | 2 |
| Hunt, RH | 4 |
| Bell, GD | 2 |
| Powell, KU | 2 |
| Tucci, A | 1 |
| Corinaldesi, R | 1 |
| Stanghellini, V | 1 |
| Paparo, GF | 1 |
| Gasperoni, S | 1 |
| Biasco, G | 2 |
| Varoli, O | 1 |
| Ricci-Maccarini, M | 1 |
| Barbara, L | 1 |
| Eissele, R | 1 |
| Petersen, KU | 1 |
| Petrin, P | 1 |
| Costantino, V | 1 |
| Canton, A | 1 |
| McCloy, R | 1 |
| Nair, R | 1 |
| Lamberts, R | 4 |
| Strüber, HG | 1 |
| Solcia, E | 4 |
| Sastry, MS | 1 |
| Diwan, PV | 1 |
| Krishna, DR | 1 |
| Hennig, U | 1 |
| Fuchs, W | 3 |
| Huber, R | 1 |
| Kohl, B | 1 |
| Senn-Bilfinger, J | 1 |
| Simon, WA | 1 |
| Sturm, E | 1 |
| Lipchik, RJ | 1 |
| Rost, KL | 1 |
| Brockmöller, J | 1 |
| Esdorn, F | 1 |
| Roots, I | 1 |
| Pfaffenbach, B | 3 |
| Sahay, P | 1 |
| Tompkins, DS | 1 |
| Deltenre, M | 2 |
| Jonas, C | 2 |
| van Gossum, M | 1 |
| Buset, M | 1 |
| Otero, J | 2 |
| De Koster, E | 2 |
| Takimoto, T | 2 |
| Taniguchi, Y | 2 |
| Saifuku, K | 2 |
| Ido, K | 1 |
| Uemura, N | 2 |
| Okamoto, S | 2 |
| Mukai, T | 1 |
| Yamaguchi, S | 2 |
| Kaji, M | 1 |
| Hrruma, K | 1 |
| Sumii, K | 3 |
| Kajiyama, G | 3 |
| Hatlebakk, JG | 1 |
| Nesje, LB | 1 |
| Hausken, T | 1 |
| Bang, CJ | 1 |
| Berstad, A | 1 |
| Layer, P | 1 |
| Goebell, H | 1 |
| Mordenti, P | 1 |
| Brandi, G | 1 |
| Paganelli, GM | 1 |
| Santucci, R | 1 |
| Wilson, BV | 1 |
| Knudsen, T | 1 |
| Tari, A | 2 |
| Hamada, M | 2 |
| Kamiyasu, T | 2 |
| Fukino, Y | 1 |
| Sumii, M | 1 |
| Haruma, K | 3 |
| Inoue, M | 2 |
| Ching, CK | 1 |
| Leung, KP | 1 |
| Yung, RW | 1 |
| Lai, CL | 2 |
| Yamamoto, H | 1 |
| Okabe, S | 4 |
| van der Hulst, RW | 2 |
| Weel, JF | 2 |
| Verheul, SB | 1 |
| Keller, JJ | 1 |
| ten Kate, FJ | 2 |
| van der Ende, A | 2 |
| Rauws, EA | 2 |
| Dankert, J | 2 |
| Dalla Libera, M | 1 |
| Pazzi, P | 1 |
| Carli, G | 1 |
| Gamberini, S | 1 |
| Scagliarini, R | 1 |
| Merighi, A | 1 |
| Gullini, S | 1 |
| Markham, A | 2 |
| McTavish, D | 2 |
| Cozzoli, A | 1 |
| Denis, P | 1 |
| Roesch, W | 1 |
| Blum, RA | 2 |
| Driessen, WM | 4 |
| Jansz, AR | 1 |
| Markitziu, A | 1 |
| Aframian, D | 1 |
| Bulgakov, SA | 1 |
| Sartori, S | 1 |
| Trevisani, L | 1 |
| Nielsen, I | 1 |
| Tassinari, D | 1 |
| Abbasciano, V | 1 |
| Yousfi, MM | 1 |
| Lai, JY | 3 |
| Geuskens, LM | 1 |
| Carling, L | 1 |
| Wetterhus, S | 1 |
| Wingren, PE | 1 |
| Anker-Hansen, O | 1 |
| Lundegårdh, G | 1 |
| Thorhallsson, E | 1 |
| Hackelsberger, A | 1 |
| Bianchi Porro, G | 3 |
| Parente, F | 1 |
| Imbesi, V | 1 |
| Montrone, F | 2 |
| Caruso, I | 2 |
| Schwizer, W | 1 |
| Saraga, E | 1 |
| Nicolet, M | 1 |
| Pignatelli, B | 1 |
| Bonagura, AF | 1 |
| Dabezies, MA | 1 |
| Bertschinger, P | 1 |
| Lamers, CB | 5 |
| Parsons, ME | 1 |
| Meyer, UA | 1 |
| Wang, K | 1 |
| Chua, RT | 1 |
| Perng, CL | 4 |
| Tsay, SH | 1 |
| Lee, SD | 2 |
| Hopefl, A | 1 |
| Tonokatsu, Y | 1 |
| Tsujiai, T | 1 |
| Leonhardt, U | 1 |
| Ritzel, U | 1 |
| Ramadori, G | 1 |
| Garnett, WR | 1 |
| Gimeno, L | 1 |
| Valdepérez, J | 1 |
| Yus, C | 1 |
| Marzo, J | 1 |
| Pérez-Caballero, MC | 1 |
| Lux, G | 1 |
| Tham, TC | 1 |
| Collins, JS | 1 |
| Molloy, C | 1 |
| Sloan, JM | 1 |
| Bamford, KB | 1 |
| Watson, RG | 1 |
| Tamura, H | 1 |
| Tokushima, H | 1 |
| Murakawa, M | 1 |
| Matsumura, O | 1 |
| Itoyama, S | 1 |
| Sekine, S | 1 |
| Hirose, H | 1 |
| Mitarai, T | 1 |
| Isoda, K | 1 |
| Walker, S | 3 |
| Klotz, U | 3 |
| Vautier, G | 1 |
| Scott, BB | 2 |
| van Etten, RJ | 2 |
| Schade, RW | 1 |
| Ouwehand, ME | 1 |
| Schneeberger, PM | 3 |
| van Unnik, AJ | 1 |
| Meise, KS | 1 |
| Greenson, JK | 1 |
| Coffey, RJ | 1 |
| Chalmers, DM | 1 |
| Kinoshita, M | 1 |
| Tamaki, H | 1 |
| Wyncoll, DL | 1 |
| Roberts, PC | 1 |
| Beale, RJ | 1 |
| McLuckie, A | 1 |
| Ström, M | 1 |
| Jönsson, KA | 1 |
| Spinzi, G | 1 |
| Bortoli, A | 1 |
| Colombo, E | 1 |
| Lesinigo, E | 1 |
| Venturelli, R | 1 |
| Terruzzi, V | 1 |
| Imperiali, G | 1 |
| Minoli, G | 2 |
| D'Ambra, G | 1 |
| Luzzi, I | 1 |
| Marcheggiano, A | 1 |
| Iannoni, C | 1 |
| Paoletti, M | 1 |
| Anania, MC | 1 |
| Marignani, M | 1 |
| Delle Fave, G | 1 |
| Veldhuyzen van Zanten, SJ | 1 |
| Sherman, PM | 1 |
| Bateman, DN | 1 |
| Damianos, AJ | 1 |
| McGarrity, TJ | 1 |
| Ebell, MH | 1 |
| Warbasse, L | 1 |
| Brenner, C | 1 |
| Takeyama, J | 1 |
| Ebina, K | 1 |
| Naganuma, H | 1 |
| Schweigart, U | 1 |
| Franck, H | 1 |
| Schepp, W | 1 |
| Lehn, N | 1 |
| Becker, K | 1 |
| Aly, A | 1 |
| Pohle, T | 2 |
| Hilker, E | 1 |
| Langtry, HD | 2 |
| Wilde, MI | 1 |
| Matsukura, N | 1 |
| Kishimoto, S | 1 |
| Walsh, JH | 1 |
| Chey, WD | 1 |
| Fisher, L | 1 |
| Barnett, JL | 1 |
| Nostrant, T | 1 |
| DelValle, J | 1 |
| Hasler, WL | 1 |
| Vreeburg, EM | 1 |
| De Vlaam-Schluter, GM | 1 |
| Trienekens, PH | 1 |
| Snel, P | 1 |
| Zuberi, BF | 1 |
| Lal, S | 1 |
| Sheikh, RM | 1 |
| Rinaldi, V | 1 |
| Pugliano, F | 1 |
| Diana, F | 1 |
| Attili, AF | 1 |
| Szymanski, C | 2 |
| van de Wouw, BA | 1 |
| Pipkin, GA | 1 |
| Dixon, JS | 1 |
| Williamson, R | 1 |
| Wood, JR | 1 |
| Loane, J | 1 |
| Bindel, H | 1 |
| Bhutta, AS | 1 |
| Cunnane, K | 2 |
| Lo, WC | 2 |
| Lee, FY | 2 |
| Franko, TG | 1 |
| Richter, JE | 1 |
| Gullotta, R | 1 |
| Ferraris, L | 1 |
| Cortelezzi, C | 1 |
| Prada, A | 1 |
| Comin, U | 1 |
| Rocca, F | 1 |
| Ferrara, A | 1 |
| Curzio, M | 1 |
| Seelis, RE | 1 |
| Dohmen, W | 1 |
| Boixeda de Miquel, D | 2 |
| Tanimura, H | 2 |
| Kawano, S | 3 |
| Kubo, M | 1 |
| Tanabe, J | 1 |
| Asai, A | 1 |
| Ito, T | 1 |
| Hahm, KB | 1 |
| Lee, KJ | 1 |
| Kim, YS | 1 |
| Kim, JH | 1 |
| Cho, SW | 1 |
| Yim, H | 1 |
| Joo, HJ | 1 |
| Haga, Y | 1 |
| Nakatsura, T | 1 |
| Shibata, Y | 1 |
| Sameshima, H | 1 |
| Nakamura, Y | 1 |
| Tanimura, M | 1 |
| Ogawa, M | 1 |
| Matsukawa, Y | 1 |
| Nishinarita, S | 1 |
| Kaneko, M | 1 |
| Takei, M | 1 |
| Horie, T | 1 |
| Kawamura, F | 1 |
| Kurosaka, H | 1 |
| el-Nujumi, A | 3 |
| Williams, C | 1 |
| Ardill, JE | 1 |
| Oien, K | 1 |
| McColl, KE | 3 |
| Kim, JG | 1 |
| Lindsetmo, RO | 1 |
| Johnsen, R | 1 |
| Revhaug, A | 1 |
| Lanas Arbeloa, A | 1 |
| Serrano Aulló, MT | 1 |
| Walters, JK | 2 |
| Zimmermann, AE | 2 |
| Souney, PF | 1 |
| Katona, BG | 2 |
| Chang, FY | 1 |
| McLoughlin, R | 1 |
| Kelly, S | 1 |
| Laundon, J | 1 |
| Talley, NJ | 1 |
| Lanza, FL | 1 |
| Wahlqvist, P | 1 |
| Malizia, T | 1 |
| Tejada, M | 1 |
| Marchetti, F | 1 |
| Favini, P | 1 |
| Pizzarelli, G | 1 |
| Campa, M | 1 |
| Senesi, S | 1 |
| Sheu, BS | 1 |
| Wu, JJ | 1 |
| Huang, AH | 1 |
| Lin, XZ | 1 |
| Di Mario, F | 2 |
| Bozzola, L | 2 |
| Valerio, G | 2 |
| Thamer, M | 1 |
| Ray, NF | 1 |
| Henderson, SC | 1 |
| Rinehart, CS | 1 |
| Sherman, CR | 1 |
| Ferguson, JH | 1 |
| Lazzaroni, M | 2 |
| Petrillo, M | 3 |
| Manzionna, G | 1 |
| Kader, SA | 1 |
| Mansour, AM | 1 |
| Mohran, Z | 1 |
| el-Taoil, A | 1 |
| Abdalla, KF | 1 |
| Tsuneoka, H | 1 |
| Takaba, M | 1 |
| Nagatomi, Y | 1 |
| Mori, K | 1 |
| Matsumoto, T | 2 |
| Honda, T | 1 |
| García, N | 2 |
| Campo, R | 2 |
| Brullet, E | 2 |
| Comet, R | 1 |
| Navarro, M | 1 |
| Murray, LS | 1 |
| Dickson, A | 2 |
| Kelman, AW | 1 |
| Hilditch, TE | 1 |
| Massimo Claar, G | 1 |
| Monaco, S | 1 |
| Del Veccho Blanco, C | 1 |
| Capurso, L | 2 |
| Fusillo, M | 1 |
| de Boer, SY | 1 |
| Siem, TH | 1 |
| Lambert, JR | 1 |
| Kidd, SL | 1 |
| Shi, H | 1 |
| Jennings, DE | 1 |
| Greski-Rose, PA | 1 |
| Morales Suárez-Varela, MM | 1 |
| Pérez-Benajas, MA | 1 |
| Girbes Pelechano, VJ | 1 |
| Llopis-González, A | 1 |
| Hashimoto, Y | 1 |
| Weilert, F | 1 |
| Smith, AC | 1 |
| Stokes, PL | 1 |
| Guslandi, M | 2 |
| DeMarco, PJ | 1 |
| Schulman, S | 1 |
| Shikhman, AR | 1 |
| Sou, Y | 1 |
| Kaitani, K | 1 |
| Nishio, K | 1 |
| Gautam, M | 1 |
| Por, CP | 1 |
| Evans, MF | 1 |
| Korman, MG | 1 |
| Bolin, TD | 1 |
| Nicholson, FB | 1 |
| Engelman, JL | 1 |
| Bazzoli, F | 1 |
| Pozzato, P | 1 |
| Zagari, M | 1 |
| Fossi, S | 1 |
| Ricciardiello, L | 1 |
| Nicolini, G | 1 |
| Berretti, D | 1 |
| De Luca, L | 1 |
| Pedersen, PJ | 1 |
| Bjorkman, DJ | 1 |
| Peterson, WL | 2 |
| Cook, DJ | 1 |
| Nebiki, H | 1 |
| Arakawa, T | 4 |
| Ando, K | 1 |
| Uchida, T | 1 |
| Ito, H | 1 |
| Harihara, S | 1 |
| Kuroki, T | 1 |
| Szczepanski, L | 1 |
| Filipowicz-Sosnowska, A | 1 |
| Wason, CM | 1 |
| Peacock, RA | 1 |
| Gillon, KR | 1 |
| Louw, JA | 1 |
| Moola, S | 1 |
| Kotze, D | 1 |
| Marks, IN | 1 |
| Baczek, J | 1 |
| Laskowiec, G | 1 |
| Stack, WA | 1 |
| Knifton, A | 1 |
| Thirlwell, D | 1 |
| Cockayne, A | 1 |
| Jenkins, D | 1 |
| Okada, M | 1 |
| Oki, K | 1 |
| Shirotani, T | 1 |
| Seo, M | 1 |
| Okabe, N | 1 |
| Maeda, K | 1 |
| Nishimura, H | 1 |
| Ohkuma, K | 1 |
| Oda, K | 1 |
| Kirstein, FW | 1 |
| Epple, HJ | 1 |
| Bojarski, C | 1 |
| Victor, L | 1 |
| Fromm, M | 1 |
| Riecken, EO | 1 |
| Schulzke, JD | 1 |
| Spadaccini, A | 1 |
| De Fanis, C | 1 |
| Sciampa, G | 1 |
| Russo, L | 1 |
| Silla, M | 1 |
| Pantaleone, U | 1 |
| Di Virgilio, M | 1 |
| Pizzicanella, G | 1 |
| Israel, DM | 1 |
| Hassall, E | 1 |
| Sagar, M | 3 |
| Seensalu, R | 3 |
| Tybring, G | 1 |
| Dahl, ML | 1 |
| Bertilsson, L | 3 |
| Bell, AD | 1 |
| Isenberg, J | 1 |
| Kobayashi, H | 1 |
| Watanabe, T | 2 |
| Nakahara, A | 2 |
| Mutoh, H | 1 |
| Tanaka, N | 1 |
| Uchiyama, Y | 1 |
| Kamata, T | 1 |
| Takashima, M | 1 |
| Kosuge, K | 1 |
| Kawasaki, T | 1 |
| Kubota, T | 1 |
| Lee, CL | 1 |
| Tu, TC | 1 |
| Wu, CH | 1 |
| Chen, TK | 1 |
| Chan, CC | 1 |
| Huang, SH | 1 |
| Sakaki, N | 2 |
| Kozawa, H | 1 |
| Yamada, Y | 1 |
| Kato, H | 1 |
| Kamisawa, T | 1 |
| Momma, K | 1 |
| Sohn, SK | 2 |
| Chang, MS | 2 |
| Chung, YK | 2 |
| Kim, KB | 2 |
| Wook, TW | 1 |
| Kim, SG | 1 |
| Choi, WS | 2 |
| Dekkers, CP | 1 |
| Beker, JA | 1 |
| Gabryelewicz, A | 1 |
| Bell, NE | 1 |
| Humphries, TJ | 1 |
| Lepe, JA | 1 |
| Guerrero, FJ | 1 |
| Palomo, S | 1 |
| Sikirić, P | 1 |
| Seiwerth, S | 1 |
| Desković, S | 1 |
| Grabarević, Z | 1 |
| Marović, A | 1 |
| Rucman, R | 1 |
| Petek, M | 1 |
| Konjevoda, P | 1 |
| Jadrijević, S | 1 |
| Sosa, T | 1 |
| Perović, D | 1 |
| Aralica, G | 1 |
| Turković, B | 1 |
| Freedman, MD | 1 |
| Sekine, H | 1 |
| Ohara, S | 2 |
| Iijima, K | 1 |
| Kato, K | 1 |
| Sugano, Y | 2 |
| Ko, K | 1 |
| Waki, S | 1 |
| Shirai, T | 1 |
| Kurumada, T | 1 |
| Kouda, K | 1 |
| Watanabe, S | 2 |
| Tada, U | 1 |
| Wada, T | 1 |
| Takagi, A | 1 |
| Harasawa, S | 1 |
| Miwa, T | 1 |
| Nakagawa, M | 1 |
| Ooishi, M | 1 |
| Kawamura, N | 1 |
| Ooizumi, H | 1 |
| Saitou, M | 1 |
| Nakagawa, S | 1 |
| Sato, K | 3 |
| Kumakura, Y | 1 |
| Sugano, K | 1 |
| Harase, I | 1 |
| Okuda, J | 1 |
| Ida, K | 1 |
| Imaizumi, H | 1 |
| Nakai, H | 1 |
| Ohida, M | 1 |
| Ieiri, I | 1 |
| Wada, Y | 1 |
| Mamiya, K | 1 |
| Urae, A | 1 |
| Iimori, E | 1 |
| Otsubo, K | 1 |
| Higuchi, S | 2 |
| Rose, PA | 1 |
| Heller, CA | 1 |
| Haber, M | 1 |
| Jennings, D | 1 |
| Navuluri, R | 1 |
| Yue, S | 1 |
| Wiklund, I | 1 |
| Lad, R | 1 |
| Miwa, H | 3 |
| Nagahara, A | 3 |
| Ohkura, R | 2 |
| Murai, T | 1 |
| Shimizu, H | 1 |
| Sato, N | 4 |
| Janczewska, I | 1 |
| Ljungdahl, A | 1 |
| García Rodríguez, LA | 1 |
| Ruigómez, A | 1 |
| Wustlich, S | 1 |
| Brehler, R | 1 |
| Luger, TA | 1 |
| Foerster, E | 1 |
| Uchiyama, K | 1 |
| Wakatsuki, D | 1 |
| Kakinoki, B | 1 |
| Takeuchi, Y | 1 |
| Araki, T | 1 |
| Morinaka, Y | 1 |
| Fortunato, A | 1 |
| Rassu, M | 1 |
| Meli, S | 1 |
| Soffiati, G | 1 |
| Scagnelli, M | 1 |
| Jacoby, EB | 1 |
| Porter, KB | 1 |
| Ducóns, JA | 2 |
| Ferrero, M | 2 |
| Sieg, A | 1 |
| Sellinger, M | 1 |
| Schlauch, D | 1 |
| Hörner, M | 1 |
| Grimley, CE | 1 |
| Penny, A | 1 |
| O'sullivan, M | 1 |
| Shebani, M | 1 |
| Lismore, JR | 1 |
| Cross, R | 1 |
| Illing, RC | 1 |
| Loft, DE | 1 |
| Nwokolo, CU | 2 |
| Houben, MH | 1 |
| Hensen, EF | 1 |
| Hulst, RW | 1 |
| Hoff, BW | 1 |
| Ende, AV | 1 |
| Kate, FJ | 1 |
| Faure, C | 1 |
| Pelatan, C | 1 |
| Languepin, J | 1 |
| Ellenrieder, V | 1 |
| Boeck, W | 1 |
| Richter, C | 1 |
| Marre, R | 1 |
| Adler, G | 1 |
| Glasbrenner, B | 1 |
| de Grauw, WJ | 1 |
| Tanigawara, Y | 1 |
| Shirakawa, K | 1 |
| Komada, F | 1 |
| García Cabezudo, J | 1 |
| Simón, MA | 1 |
| Playford, RJ | 2 |
| Podas, T | 1 |
| Modlin, I | 1 |
| Nishikawa, K | 1 |
| Ishizuka, J | 1 |
| Komatsu, Y | 1 |
| Sukegawa, M | 1 |
| Toyota, J | 1 |
| Moreira Vicente, V | 1 |
| Kelman, A | 1 |
| Taskin, V | 1 |
| Gurer, I | 1 |
| Ozyilkan, E | 1 |
| Sare, M | 1 |
| Hilmioglu, F | 1 |
| van Doorn, LJ | 2 |
| Nouhan, N | 1 |
| Plaisier, AP | 1 |
| Quint, WG | 1 |
| Woo, TW | 1 |
| Lee, SB | 1 |
| Park, CJ | 1 |
| Pillans, PI | 1 |
| Kubler, PA | 1 |
| Radford, JM | 1 |
| Overland, V | 1 |
| Remacha, B | 1 |
| Sáinz, R | 1 |
| Lehmann, FS | 1 |
| Drewe, J | 1 |
| Terracciano, L | 2 |
| Beglinger, C | 2 |
| Adamsson, I | 1 |
| Edlund, C | 1 |
| Nord, CE | 1 |
| Natsch, S | 1 |
| Vinks, MH | 1 |
| Voogt, AK | 1 |
| Mees, EB | 1 |
| Meyboom, RH | 1 |
| Dobrilla, G | 1 |
| Azuma, T | 2 |
| Ito, S | 2 |
| Suto, H | 1 |
| Ito, Y | 1 |
| Miyaji, H | 1 |
| Yamazaki, Y | 2 |
| Kuriyama, M | 1 |
| Kullavanijaya, P | 1 |
| Gonlachanvit, S | 1 |
| Mahachai, V | 2 |
| Kladchareon, N | 1 |
| Baños, F | 1 |
| Madridejos, R | 1 |
| Cabezas, C | 1 |
| Burrull, M | 1 |
| Lafuente, C | 1 |
| Morera, R | 1 |
| Feltbower, R | 2 |
| Brown, J | 2 |
| Mason, S | 2 |
| Mason, J | 2 |
| Richards, ID | 1 |
| Dowell, AC | 1 |
| Arroyo, MT | 1 |
| Leditschke, IA | 1 |
| Coombes, JA | 1 |
| Lau, JY | 1 |
| Yung, MY | 2 |
| Wong, SK | 1 |
| Ng, EK | 1 |
| Lee, CW | 1 |
| Chan, AC | 1 |
| Libby, ED | 1 |
| Einecke, D | 1 |
| Piqué, JM | 2 |
| Amidon, PB | 1 |
| Jankovich, R | 1 |
| Stoukides, CA | 1 |
| Kaul, AF | 1 |
| Romero Gómez, M | 1 |
| Martínez Delgado, C | 1 |
| Grande, L | 1 |
| Otero Fernández, MA | 1 |
| Vargas, J | 1 |
| Castro Fernández, M | 1 |
| Flores, S | 1 |
| Opazo, H | 1 |
| Valderrama, D | 1 |
| Aguilera, R | 1 |
| Marchese, A | 1 |
| Valderrama, S | 1 |
| Yamamoto, S | 1 |
| Matsumura, N | 1 |
| Mashiba, H | 1 |
| Sasaki, N | 1 |
| Taniyama, K | 1 |
| Rapoport, SI | 1 |
| Lapteva, ON | 1 |
| Raĭkhlin, NT | 1 |
| Smirnova, EA | 1 |
| Khutsishvili, MB | 1 |
| Rasulov, MI | 1 |
| Giannini, E | 1 |
| Romagnoli, P | 1 |
| Fasoli, A | 1 |
| Chiarbonello, B | 1 |
| Malfatti, F | 1 |
| Botta, F | 1 |
| Risso, D | 1 |
| Lantieri, PB | 1 |
| Testa, R | 1 |
| Bezborodnyĭ, SD | 2 |
| Bytzer, P | 1 |
| Rune, S | 2 |
| Bonnevie, O | 1 |
| Breinstrup, H | 1 |
| Funch-Jensen, P | 1 |
| Matzen, P | 1 |
| Meineche-Schmidt, V | 1 |
| Stridsberg, M | 1 |
| Kjellin, A | 1 |
| Mârdh, S | 1 |
| Hizawa, K | 1 |
| Nakahara, T | 1 |
| Yano, Y | 1 |
| Inuzuka, S | 1 |
| Akagi, K | 1 |
| Hsu, PI | 1 |
| Tseng, HH | 1 |
| Lo, GH | 1 |
| Lo, CC | 1 |
| Lin, CK | 1 |
| Ku, MK | 1 |
| Peng, NJ | 1 |
| Chien, EJ | 1 |
| Chen, W | 1 |
| Hsu, PN | 1 |
| Lanas, AI | 1 |
| Satoh, R | 1 |
| Kagawa, J | 1 |
| Kim, KH | 1 |
| Jeong, YS | 1 |
| Seo, JI | 1 |
| Cho, MY | 1 |
| Phillips, JO | 1 |
| Rebuck, JA | 1 |
| Rangnekar, NJ | 1 |
| Miedema, BW | 1 |
| Metzler, MH | 1 |
| Lutgen, N | 1 |
| Delforge, M | 1 |
| Bastens, B | 1 |
| Demoulin, JC | 1 |
| Fontaine, F | 1 |
| Gillard, V | 1 |
| Gerard, A | 1 |
| Endo, H | 1 |
| Yoshida, H | 1 |
| Ohmi, N | 1 |
| Rathi, P | 1 |
| Sawant, P | 1 |
| Gopanpallikar, A | 1 |
| Singh, A | 1 |
| Newton, W | 1 |
| Avidan, B | 1 |
| Melzer, E | 1 |
| Keller, N | 1 |
| Bar-Meir, S | 1 |
| Hiruma-Lima, CA | 1 |
| Gracioso, JS | 1 |
| Toma, W | 1 |
| Almeida, AB | 1 |
| Paula, AC | 1 |
| Brasil, DS | 1 |
| Muller, AH | 1 |
| Souza Brito, AR | 1 |
| Malov, IuS | 1 |
| Kulikov, AN | 1 |
| Ivashkina, TG | 1 |
| Athmann, C | 1 |
| Boldt, JH | 1 |
| Lüth, S | 1 |
| Teyssen, S | 1 |
| Kölbel, CB | 1 |
| Singer, MV | 1 |
| Souney, PE | 1 |
| Levine, D | 1 |
| Erstad, BL | 1 |
| Cherian, P | 1 |
| Romanska, H | 1 |
| Perry, MJ | 1 |
| Schneider, A | 1 |
| Fischer, R | 1 |
| Ng, W | 1 |
| Gené, E | 2 |
| Sanfeliu, I | 1 |
| Yamada, T | 2 |
| Hojo, M | 1 |
| Ishiki, K | 1 |
| Nagahara, Y | 1 |
| Maga, T | 1 |
| Torigoe, T | 1 |
| Nasu, J | 1 |
| Savides, TJ | 1 |
| Pratha, V | 1 |
| van der Steen, WJ | 1 |
| Ho, VK | 1 |
| Hsu, CC | 1 |
| Chen, JJ | 1 |
| Hu, TH | 1 |
| Lu, SN | 1 |
| Changchien, CS | 1 |
| Sazhin, VP | 1 |
| Fedorov, AV | 1 |
| Grigor'ev, PIa | 2 |
| Iakovenko, EP | 1 |
| Talanova, EV | 1 |
| Ishihara, S | 1 |
| Okuyama, T | 1 |
| Ishimura, N | 1 |
| Ono, M | 1 |
| Hashimoto, T | 1 |
| Kazumori, H | 1 |
| Kaji, T | 1 |
| Sato, H | 1 |
| Fukuda, R | 1 |
| Laterre, PF | 1 |
| Horsmans, Y | 1 |
| Palmer, KR | 1 |
| Hildebrand, P | 1 |
| Bardhan, P | 1 |
| Rossi, L | 1 |
| Parvin, S | 1 |
| Rahman, A | 1 |
| Arefin, MS | 1 |
| Hasan, M | 1 |
| Ahmad, MM | 1 |
| Glatz-Krieger, K | 1 |
| Bauerfeind, P | 1 |
| Gyr, N | 1 |
| Khan, AK | 1 |
| Tankovic, J | 1 |
| Lamarque, D | 1 |
| Lascols, C | 1 |
| Soussy, CJ | 1 |
| Delchier, JC | 1 |
| Matheson, AJ | 1 |
| Jarvis, B | 1 |
| Misawa, H | 1 |
| Ohtaka, K | 1 |
| Naesdal, J | 2 |
| Wilson, I | 1 |
| He, JX | 1 |
| Akao, T | 1 |
| Nishino, T | 1 |
| Tani, T | 1 |
| Wittig, J | 1 |
| Ammon, S | 1 |
| Kwok, T | 1 |
| Hui, Y | 1 |
| Chan, HL | 1 |
| Chan, CS | 1 |
| Hui, E | 1 |
| Woo, J | 1 |
| Tonini, M | 1 |
| Scarpignato, C | 1 |
| Gremse, DA | 1 |
| Khan, Z | 1 |
| Nair, P | 1 |
| O'Shea, C | 1 |
| Spiers, N | 1 |
| Wicks, AC | 1 |
| Barth, J | 1 |
| Hahne, W | 1 |
| Duffett, S | 1 |
| Drummond, M | 1 |
| Crocombe, W | 1 |
| Baena, JM | 1 |
| López, C | 1 |
| Hidalgo, A | 1 |
| Rams, F | 1 |
| Jiménez, S | 1 |
| García, M | 1 |
| Hernández, MR | 1 |
| Fu, HY | 1 |
| Kamada, T | 2 |
| Kusunoki, H | 1 |
| Miyatani, H | 1 |
| Tokuyama, T | 1 |
| Hirakawa, R | 1 |
| Sawada, A | 1 |
| Chiba, T | 1 |
| Tanaka, A | 1 |
| Suga, M | 1 |
| Takata, H | 1 |
| Ohara, T | 1 |
| Koizumi, K | 1 |
| Kiriyama, Y | 1 |
| Wermeille, J | 1 |
| Cunningham, M | 1 |
| Dederding, JP | 1 |
| Girard, L | 1 |
| Baumann, R | 1 |
| Zelger, G | 1 |
| Buri, P | 1 |
| Metry, JM | 1 |
| Sitavanc, R | 1 |
| Gallaz, L | 1 |
| Merki, H | 1 |
| Godin, N | 1 |
| Noble, DW | 1 |
| Azagra, R | 1 |
| López, T | 1 |
| Cubells, MJ | 1 |
| Lau, GK | 1 |
| Yuen, MF | 1 |
| Sugiyama, M | 1 |
| Katamura, H | 1 |
| Yanai, H | 1 |
| Tada, M | 1 |
| Okita, K | 1 |
| Sato, Y | 1 |
| Miyazaki, T | 1 |
| Kimpara, T | 1 |
| Yukawa, K | 1 |
| Yukawa, E | 1 |
| Inamoto, Y | 1 |
| Miyahara, T | 1 |
| Kawaguchi, A | 1 |
| Nogao, S | 1 |
| Niwa, H | 1 |
| Perroni, GB | 1 |
| De Matteis, G | 1 |
| Pellizzeri, F | 1 |
| Cassone, A | 1 |
| Malara, F | 1 |
| Shamburek, RD | 1 |
| Schubert, ML | 1 |
| Møller, H | 1 |
| Nissen, A | 1 |
| Mosbech, J | 1 |
| Pikkarainen, P | 1 |
| Tarpila, S | 1 |
| Tsukamoto, Y | 2 |
| Niwa, Y | 1 |
| Arisawa, T | 2 |
| Barradell, LB | 1 |
| Brunner, GH | 2 |
| Thiesemann, C | 1 |
| Fiocca, R | 2 |
| Havu, N | 2 |
| Dalväg, A | 1 |
| Carlsson, R | 1 |
| Joelson, S | 1 |
| Joelson, IB | 1 |
| Lundborg, P | 1 |
| Walan, A | 4 |
| Wallander, MA | 1 |
| Ebert, R | 1 |
| Lee, M | 1 |
| Aldred, K | 1 |
| Lee, E | 1 |
| Prince, MD | 1 |
| Feldman, M | 1 |
| Cappell, MS | 1 |
| Gyenes, E | 3 |
| Birkholz, S | 1 |
| Ricken, D | 1 |
| Pace, V | 1 |
| Fidanza, F | 1 |
| Zechini, F | 1 |
| Holt, S | 2 |
| Hinchliffe, RF | 1 |
| Daly, MJ | 1 |
| Carroll, NJ | 1 |
| Harford, WV | 1 |
| Koop, H | 3 |
| Rubin, W | 1 |
| Langman, MJ | 2 |
| Fukuda, T | 1 |
| Nakamura, H | 1 |
| Maton, PN | 1 |
| Lack, EE | 1 |
| Collen, MJ | 1 |
| Cornelius, MJ | 1 |
| David, E | 1 |
| Gardner, JD | 2 |
| Camara, DS | 2 |
| Corasanti, JG | 1 |
| Cataldi, R | 1 |
| Meeroff, M | 1 |
| Kashimura, H | 1 |
| Fukutomi, H | 1 |
| Moriya, S | 1 |
| Omura, N | 1 |
| Kashiwagi, H | 1 |
| Inagaki, Y | 1 |
| Aoki, T | 1 |
| Inatomi, N | 2 |
| Nagaya, H | 2 |
| Takami, K | 1 |
| Shino, A | 1 |
| Satoh, H | 2 |
| Sarem-Aslani, A | 1 |
| Bode, JC | 1 |
| Helander, HF | 1 |
| Simonsson, M | 1 |
| Sundler, F | 1 |
| Rutgersson, K | 1 |
| Helander, KG | 1 |
| Eriksson, S | 1 |
| Naumann-Koch, C | 1 |
| Guerreiro, AS | 1 |
| Neves, BC | 1 |
| Quina, MG | 1 |
| Marks, DR | 1 |
| Joy, JV | 1 |
| Bonheim, NA | 1 |
| Bianchi Poro, G | 1 |
| Ardizzone, S | 1 |
| Desideri, S | 1 |
| Prewett, EJ | 1 |
| Hudson, M | 1 |
| Sawyerr, AM | 1 |
| Pounder, RE | 1 |
| Chosidow, O | 1 |
| Joly, P | 1 |
| Laurent-Puig, P | 1 |
| Prost, C | 1 |
| Espagne, E | 1 |
| Wechsler, J | 1 |
| Roujeau, JC | 1 |
| Revuz, J | 1 |
| Sölvell, L | 3 |
| Klein, M | 1 |
| Uhl, D | 1 |
| Davis, RH | 1 |
| Stott, NC | 1 |
| Barber, JH | 1 |
| Freeling, P | 1 |
| Peers, EM | 1 |
| Richardson, PD | 1 |
| Lampkin, TA | 1 |
| Ouellet, D | 1 |
| Hak, LJ | 1 |
| Dukes, GE | 1 |
| Hajela, R | 1 |
| Cunningham, GM | 1 |
| Kapur, BM | 1 |
| Peachey, JE | 1 |
| Devenyi, P | 1 |
| De Giacomo, C | 1 |
| Villani, L | 1 |
| Licardi, G | 1 |
| Scotta, MS | 1 |
| Rindi, G | 1 |
| Elm, G | 1 |
| Inada, I | 1 |
| Nohara, A | 1 |
| Nakamura, N | 1 |
| Maki, Y | 1 |
| Wallmark, B | 1 |
| de Bruijne, JW | 1 |
| De Natale, G | 1 |
| De Natale, F | 1 |
| Marino, A | 1 |
| Mazure, PA | 1 |
| Pigliacampo, J | 1 |
| Chelvam, P | 1 |
| Wong, EC | 1 |
| Debas, HT | 2 |
| Mulholland, MW | 1 |
| Olbe, L | 1 |
| Cederberg, C | 1 |
| Lind, T | 1 |
| Olausson, M | 1 |
| Farup, PG | 1 |
| Lauritsen, K | 1 |
| Laursen, LS | 1 |
| Madsen, JR | 1 |
| Akimoto, Y | 1 |
| Pappas, TN | 1 |
| Mulvihill, SJ | 1 |
| Goto, Y | 1 |
| Thomson, AB | 1 |
| Andersen, BN | 1 |
| Vasil'eva, ZI | 1 |
| Hameeteman, W | 1 |
| Jansen, JM | 1 |
| Wilson, JA | 1 |
| Higaki, E | 1 |
| Higuchi, T | 1 |
| Sato, M | 1 |
| Hara, K | 1 |
| McArthur, KE | 1 |
| Gugler, R | 2 |
| Kommerell, B | 1 |
| Fukui, A | 2 |
| Nakazawa, S | 2 |
| Sugiyama, S | 1 |
| Ozawa, T | 1 |
| Ohno, T | 1 |
| Segawa, K | 1 |
| Takano, K | 1 |
| Hase, S | 1 |
| Osada, T | 1 |
| Kawabe, Y | 1 |
| Isal, JP | 1 |
| Stöckmann, F | 1 |
| Jacubaschke, U | 1 |
| Maas, S | 1 |
| Clissold, SP | 1 |
| Campoli-Richards, DM | 1 |
| Stasiewicz, J | 1 |
| Deveney, CW | 1 |
| Deveney, KE | 1 |
| Spenney, JG | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Phase 4, Prospective, Randomized and Comparative Study Comparing Sequential and Concomitant Therapy for Helicobacter Pylori Eradication in Routine Clinical Practice[NCT01273441] | Phase 4 | 338 participants (Actual) | Interventional | 2010-12-31 | Completed | ||
| A 12-Month, Phase 3, Open-Label, Multi-Center Study to Evaluate the Long-Term Safety of PA32540 in Subjects Who Are at Risk for Developing Aspirin-Associated Gastric Ulcers[NCT00995410] | Phase 3 | 380 participants (Actual) | Interventional | 2009-10-31 | Completed | ||
| A Randomized, Double-Blind, Double-Dummy, Parallel Group, Phase 3 Efficacy and Safety Study of CGT-2168 Compared With Clopidogrel to Reduce Upper Gastrointestinal Events Including Bleeding and Symptomatic Ulcer Disease[NCT00557921] | Phase 3 | 5,000 participants (Anticipated) | Interventional | 2007-12-31 | Terminated (stopped due to Terminated by Sponsor) | ||
| Double-Blind, Triple Dummy, Parallel-Group, Randomized, Six-Month Study To Compare Celecoxib (200 Mg BID) With Diclofenac Sr (75 Mg BID) Plus Omeprazole (20 Mg QD) For Gastrointestinal Events In Subjects With Osteoarthritis And Rheumatoid Arthritis At Hig[NCT00141102] | Phase 4 | 4,484 participants (Actual) | Interventional | 2005-10-31 | Completed | ||
| Comparison of High Dose Infusion and Low Dose Bolus Intravenous Omeprazole for Treatment of Bleeding Ulcer With Adherent Clot[NCT02536989] | Phase 4 | 40 participants (Actual) | Interventional | 2009-03-31 | Completed | ||
| Comparative Recurrence Rate Investigation of Esomeprazole Versus Lansoprazole in Triple-Combination Therapy to Eradicate Helicobacter Pylori Infection Among Pediatrics: Multicentre, Randomized, and Controlled Trials[NCT05861687] | Phase 2/Phase 3 | 51 participants (Actual) | Interventional | 2021-08-01 | Completed | ||
| Rifaximin Associated With Classic Triple Therapy (Inhibitor of Proton Pump, Amoxicillin and Clarithromycin) for the Eradication of Helicobacter Pylori Infection[NCT03124199] | Phase 3 | 40 participants (Actual) | Interventional | 2014-02-28 | Completed | ||
| Effect of the CYP2C19 Polymorphism in Helicobacter Pylori Eradication[NCT03650543] | Phase 4 | 133 participants (Actual) | Interventional | 2012-09-10 | Completed | ||
| the Effect of Daily Use of Proton Pump Inhibitors for One Month on Renal Function[NCT03910647] | Phase 2 | 200 participants (Anticipated) | Interventional | 2019-12-31 | Not yet recruiting | ||
| Double-blind, Placebo-controlled Study of the Safety and Efficacy of Eszopiclone in the Treatment of Insomnia in Patients With Chronic Low Back Pain[NCT00365976] | Phase 4 | 58 participants (Actual) | Interventional | 2006-08-31 | Completed | ||
| Sequential Therapy Versus Triple Therapy for Helicobacter Pylori Eradication: a Placebo-controlled Trial[NCT00403364] | Phase 2/Phase 3 | 300 participants | Interventional | 2003-07-31 | Completed | ||
| Proton Pump Inhibitors in the Prevention of Iron Reaccumulation in Patient With Hereditary Hemochromatosis[NCT01524757] | 48 participants (Anticipated) | Interventional | 2012-03-31 | Not yet recruiting | |||
| Pharmacogenomics-Based Tailor-Made Strategy for Eradication of Helicobacter Pylori[NCT00149084] | Phase 3 | 296 participants | Interventional | 2003-04-30 | Recruiting | ||
| Comparison of Hybrid and Bismuth Containing Quadruple Therapies for Helicobacter Pylori Eradication: a Randomized Controlled Trial[NCT02541864] | 330 participants (Actual) | Interventional | 2013-07-31 | Completed | |||
| Comparison of Two Rescue Therapies for Helicobacter Pylori Infection - A Multicenter Randomized Controlled Trial[NCT02547012] | 51 participants (Actual) | Interventional | 2013-11-30 | Completed | |||
| Comparison of 12-day Reverse Hybrid Therapy and 12-day Standard Triple Therapy for Helicobacter Pylori Infection - a Randomized Controlled Trial (REHYTRI Study)[NCT02359435] | 440 participants (Actual) | Interventional | 2012-10-31 | Completed | |||
| Personalized Treatment for Refractory H Pylori Infection[NCT02547025] | 126 participants (Actual) | Interventional | 2012-08-01 | Completed | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Incidence of adverse events and monitoring vital signs and clinical laboratory values. All AEs were coded into preferred terms according to MedDRA (Medical Dictionary for Regulatory Activities) and classified by system organ class (SOC). (NCT00995410)
Timeframe: 12 months
| Intervention | participants (Number) |
|---|---|
| PA32540 Tablet | 379 |
Most Frequent (≥ 1%) Treatment Emergent Adverse Events by System Organ Class leading to Discontinuation (NCT00995410)
Timeframe: 12 months
| Intervention | participants (Number) | ||||
|---|---|---|---|---|---|
| Subjects with any AE Leading to Discontinuation | Gastrointestinal disorders | Neoplasms benign, malignant and unspecified | Cardiac Disorders | Investigations | |
| PA32540 Tablet | 51 | 15 | 7 | 6 | 6 |
(NCT00141102)
Timeframe: Month 6/ET
| Intervention | mg/dL (Least Squares Mean) |
|---|---|
| Celecoxib | 0.058 |
| Oral Diclofenac Plus Omeprazole | 0.073 |
(NCT00141102)
Timeframe: Month 6/ET
| Intervention | ug/dL (Least Squares Mean) |
|---|---|
| Celecoxib | -3.396 |
| Oral Diclofenac Plus Omeprazole | -1.990 |
(NCT00141102)
Timeframe: Month 6/ET
| Intervention | percent (Least Squares Mean) |
|---|---|
| Celecoxib | -0.306 |
| Oral Diclofenac Plus Omeprazole | -1.425 |
(NCT00141102)
Timeframe: Month 6/ET
| Intervention | grams (g)/deciliter (dL) (Least Squares Mean) |
|---|---|
| Celecoxib | -0.017 |
| Oral Diclofenac Plus Omeprazole | -0.423 |
(NCT00141102)
Timeframe: Month 6/ET
| Intervention | microgram (ug)/dL (Least Squares Mean) |
|---|---|
| Celecoxib | 2.517 |
| Oral Diclofenac Plus Omeprazole | 1.952 |
"Subjects rated response to question: Considering all the ways the osteoarthritis or rheumatoid arthritis affects you, how are you doing today? using a 1 to 5 grading scale where 1=very good and 5=very poor." (NCT00141102)
Timeframe: Month 6/Early Termination (ET)
| Intervention | scores on a scale (Least Squares Mean) |
|---|---|
| Celecoxib | 0.754 |
| Oral Diclofenac Plus Omeprazole | 0.773 |
Interview occurred via telephone to obtain follow-up mortality and hospitalization information. (NCT00141102)
Timeframe: 6 months following last dose
| Intervention | participants (Number) |
|---|---|
| Celecoxib | 2018 |
| Oral Diclofenac Plus Omeprazole | 2023 |
Interview occurred via telephone to obtain follow-up mortality and hospitalization information. (NCT00141102)
Timeframe: 6 months following last dose
| Intervention | participants (Number) |
|---|---|
| Celecoxib | 82 |
| Oral Diclofenac Plus Omeprazole | 79 |
A clinically significant decrease from baseline was defined as a fall in hematocrit > = 10 percentage points and/or hemoglobin > = 2 g/dL. (NCT00141102)
Timeframe: 6 month treatment duration
| Intervention | participants (Number) |
|---|---|
| Celecoxib | 45 |
| Oral Diclofenac Plus Omeprazole | 123 |
CSULGIE=any of the following: gastroduodenal (GD) hemorrhage; gastric outlet obstruction; GD, small or large bowel perforation; small or large bowel hemorrhage; clinically significant anemia of defined GI origin; acute GI hemorrhage of unknown origin, including presumed small bowel hemorrhage; clinically significant anemia of presumed occult GI origin including possible small bowel blood loss. Subjects were assessed by an independent GI Events Adjudication Committee, who were blinded to study treatment assignments. (NCT00141102)
Timeframe: 6 month treatment duration
| Intervention | participants (Number) |
|---|---|
| Celecoxib | 20 |
| Oral Diclofenac Plus Omeprazole | 81 |
CSULGIE=any of the following: GD hemorrhage; gastric outlet obstruction; GD, small or large bowel perforation; small or large bowel hemorrhage; clinically significant anemia of defined GI origin; acute GI hemorrhage of unknown origin, including presumed small bowel hemorrhage; clinically significant anemia of presumed occult GI origin including possible small bowel blood loss. Subjects with evaluation at an event visit and found to have an ulcer on endoscopy, but did not meet any criteria considered for the primary endpoint by the GI committee were designated as having an SU. (NCT00141102)
Timeframe: 6 month treatment duration
| Intervention | participants (Number) |
|---|---|
| Celecoxib | 25 |
| Oral Diclofenac Plus Omeprazole | 92 |
"Abdominal symptoms were defined by the Medical Dictionary for Regulatory Activities MedDRA System Organ Class (SOC) 'Gastrointestinal Disorders' and keeping high level group term (HLGT) equal to Gastrointestinal Signs and Symptoms." (NCT00141102)
Timeframe: 6 month treatment duration
| Intervention | participants (Number) |
|---|---|
| Celecoxib | 132 |
| Oral Diclofenac Plus Omeprazole | 162 |
Subjects with evaluation at an event visit and found to have an ulcer on endoscopy, but did not meet any criteria considered for the primary endpoint by the GI committee were designated as having an SU. (NCT00141102)
Timeframe: 6 month treatment duration
| Intervention | participants (Number) |
|---|---|
| Celecoxib | 5 |
| Oral Diclofenac Plus Omeprazole | 11 |
"GI AEs were defined using MedDRA SOC Gastrointestinal Disorders but excluding the following HLGTs: Benign Neoplasms Gastrointestinal; Dental and Gingival Conditions; Oral Soft Tissue Conditions; Salivary Gland Conditions; and Tongue Conditions." (NCT00141102)
Timeframe: 6 month treatment duration
| Intervention | participants (Number) |
|---|---|
| Celecoxib | 114 |
| Oral Diclofenac Plus Omeprazole | 167 |
(NCT00141102)
Timeframe: Month 6/ET
| Intervention | IU/L (Least Squares Mean) | ||
|---|---|---|---|
| GGT | AST | ALT | |
| Celecoxib | -2.689 | -0.901 | -1.151 |
| Oral Diclofenac Plus Omeprazole | 7.455 | 1.490 | 5.213 |
CSULGIE=any of the following: gastroduodenal (GD) hemorrhage; gastric outlet obstruction; GD, small or large bowel perforation; small or large bowel hemorrhage; clinically significant anemia of defined GI origin; acute GI hemorrhage of unknown origin, including presumed small bowel hemorrhage; clinically significant anemia of presumed occult GI origin including possible small bowel blood loss. Subjects were assessed by an independent GI Events Adjudication Committee, who were blinded to study treatment assignments. (NCT00141102)
Timeframe: 6 month treatment duration
| Intervention | participants (Number) | |
|---|---|---|
| History of GD Ulceration (n=395, 400) | No History of GD Ulceration (n=1843, 1846) | |
| Celecoxib | 7 | 13 |
| Oral Diclofenac Plus Omeprazole | 13 | 68 |
GGT ULN was 49 international units (IU)/liter (L) for females and 61 IU/L for males, AST ULN was 37 IU/L for females and 39 IU/L for males, and ALT ULN was 43 IU/L for females and 45 IU/L for males. (NCT00141102)
Timeframe: 6 month treatment duration
| Intervention | participants (Number) | ||
|---|---|---|---|
| GGT | AST | ALT | |
| Celecoxib | 26 | 8 | 13 |
| Oral Diclofenac Plus Omeprazole | 86 | 12 | 27 |
Percentage of patients that has comply with treatment, considered as intake of more than 90% of study drugs in patients who attended the post-treatment visit. (NCT03124199)
Timeframe: 1 month
| Intervention | percentage of participants (Number) |
|---|---|
| Rifaximin | 100 |
Percentage of Participants with H.Pylori Infection Eradication confirmed with urea breath test at least 4 weeks after the end of treatment (NCT03124199)
Timeframe: 1 month
| Intervention | percentage of participants (Number) |
|---|---|
| Rifaximin | 61 |
Patients with side effects present during treatment and in the 4 weeks after end of treatment (NCT03124199)
Timeframe: 1 month
| Intervention | participants (Number) | ||||
|---|---|---|---|---|---|
| with diarrhea | with metallic taste | headache | nausea | abdominal pain | |
| Rifaximin | 13 | 9 | 5 | 5 | 1 |
The Hamilton Depression Scale - 24 Items (HAM-D-24) measures depression severity. Items are rated on a scale from 0 (symptoms not present) to a maximum of 2 to 4 (symptom extremely severe) for a total score range of 0 to 76. The higher the score, the more severe. (NCT00365976)
Timeframe: prenaprosyn baseline, postnaprosyn Baseline, Week 1, Week 2, week 4
| Intervention | units on a scale (Mean) | ||||
|---|---|---|---|---|---|
| prenaprosyn Baseline | postnaprosyn Baseline | Week 1 | Week 2 | Week 4 | |
| Eszopiclone | 6.45 | 6.38 | 4.54 | 4.14 | 2.62 |
| Placebo | 7.10 | 6.57 | 5.53 | 5.07 | 6.21 |
The ISI is a seven-item self-report questionnaire that provides a global measure of insomnia severity based on difficulty falling or staying asleep, satisfaction with sleep, or degree of impairment with daytime functioning. The total score ranges from 0-28: 0-7 (no clinical insomnia), 8-14 (subthreshold insomnia), 15-21 (insomnia of moderate severity), and 22-28 (severe insomnia). (NCT00365976)
Timeframe: Prenaprosyn Baseline, Postnaprosyn Baseline, Week 1, Week 2 week 4
| Intervention | units on a scale (Mean) | ||||
|---|---|---|---|---|---|
| Prenaprosyn Baseline | Postnaprosyn baseline | Week 1 | Week 2 | Week 4 | |
| Eszopiclone | 18.85 | 18.00 | 11.28 | 10.61 | 8.38 |
| Placebo | 20.26 | 16.78 | 12.85 | 12.74 | 13.75 |
(NCT00365976)
Timeframe: Postnaprosyn Baseline, Week 1, Week 2 week 4
| Intervention | minutes (Mean) | |||
|---|---|---|---|---|
| Postnaprosyn Baseline | Week 1 | Week 2 | Week 4 | |
| Eszopiclone | 38.28 | 22.36 | 17.50 | 15.28 |
| Placebo | 34.11 | 27.00 | 23.10 | 19.91 |
Nightly total sleep time was averaged from diary entries. (NCT00365976)
Timeframe: Postnaprosyn baseline, Week 1, week 2, week 4
| Intervention | Minutes (Mean) | |||
|---|---|---|---|---|
| postnaprosyn baseline | week 1 | week 2 | Week 4 | |
| Eszopiclone | 316.96 | 403.47 | 421.97 | 411.97 |
| Placebo | 380.45 | 375.56 | 382.11 | 388.96 |
(NCT00365976)
Timeframe: Postnaprosyn Baseline, Week 1, Week 2 week 4
| Intervention | awakenings (Mean) | |||
|---|---|---|---|---|
| Postnaprosyn Baseline | Week 1 | Week 2 | Week 4 | |
| Eszopiclone | 2.29 | 1.31 | 1.35 | 1.33 |
| Placebo | 2.08 | 1.98 | 2.13 | 2.34 |
Pain ratings included a global impression of pain rating (PGI) (1-5 rating with 1 being little pain and 5 is worst pain) (NCT00365976)
Timeframe: postnaprosyn Baseline, Week 1, Week 2 week 4
| Intervention | units on a scale (Mean) | |||
|---|---|---|---|---|
| postnaprosyn Baseline | Week 1 | Week 2 | Week 4 | |
| Eszopiclone | 4.02 | 3.54 | 3.30 | 3.08 |
| Placebo | 3.90 | 3.82 | 4.01 | 3.80 |
"The Roland-Morris Low Back Pain Disability Questionnaire (RMLBPDQ) is a 24-item instrument that assesses the extent to which activities of daily living are affected by LBP. It is composed of 24 yes-no items assessing potential disabilities.~Scores range from 0 (no disability) to 24 (severe disability)." (NCT00365976)
Timeframe: prenaprosyn baseline, postnaprosyn Baseline, Week 1, Week 2, week 4
| Intervention | units on a scale (Mean) | ||||
|---|---|---|---|---|---|
| prenaprosyn Baseline | postnaprosyn Baseline | Week 1 | Week 2 | Week 4 | |
| Eszopiclone | 12.27 | 9.97 | 9.10 | 7.63 | 6.59 |
| Placebo | 11.33 | 10.30 | 9.05 | 9.32 | 7.94 |
Sleep quality ratings are based on a 1-10 Likert scale. Low scores represent poorer sleep quality and higher scores represent better quality sleep (NCT00365976)
Timeframe: Postnaprosyn Baseline, Week 1, Week 2 week 4
| Intervention | units on a scale (Mean) | |||
|---|---|---|---|---|
| Postnaprosyn Baseline | Week 1 | Week 2 | Week 4 | |
| Eszopiclone | 4.52 | 5.99 | 6.18 | 6.38 |
| Placebo | 4.44 | 4.90 | 5.33 | 5.29 |
Scores are measured on a 100 mm Visual Analog Scale (VAS). The VAS scale ranges from 0 to 100 mm with the lower score indicating less pain and the higher score indicating greater pain (NCT00365976)
Timeframe: Postnaprosyn baseline, Week 1, Week 2, Week 4
| Intervention | units on a scale (Mean) | |||
|---|---|---|---|---|
| Postnaprosyn Baseline | Week 1 | Week 2 | Week 4 | |
| Eszopiclone | 48.51 | 40.72 | 34.70 | 31.69 |
| Placebo | 53.79 | 51.99 | 51.25 | 51.60 |
(NCT00365976)
Timeframe: Postnaprosyn Baseline, Week 1, Week 2 week 4
| Intervention | minutes (Mean) | |||
|---|---|---|---|---|
| Postnaprosyn Baseline | Week 1 | Week 2 | Week 4 | |
| Eszopiclone | 91.51 | 49.34 | 37.07 | 36.74 |
| Placebo | 81.43 | 76.71 | 81.32 | 76.18 |
Repeated endoscopy with rapid urease test, histological examination and culture or urea breath tests are conducted to assess H. pylori status. (NCT02541864)
Timeframe: at the 6th week after the end of anti- H. pylori therapy
| Intervention | participants (Number) |
|---|---|
| Pantoprazole+Bismuth+Tetra+Metro | 154 |
| Hybrid Therapy | 154 |
Evaluate eradication outcome by endoscopy urease test and histology or urea breath test (NCT02547012)
Timeframe: six weeks after the end of anti-H pylori therapy.
| Intervention | participants (Number) |
|---|---|
| Esomeprazole+Amox+Levo+Tetra | 13 |
| Esomeprazole+Amox+Levo | 21 |
Evaluate eradication outcome by endoscopy urease test and histology or urea breath test (NCT02359435)
Timeframe: at the 6th week after the end of anti- H. pylori therapy
| Intervention | participants (Number) |
|---|---|
| Reverse Hybrid Therapy | 206 |
| Standard Triple Therapy | 191 |
190 reviews available for omeprazole and Gastroduodenal Ulcer
| Article | Year |
|---|---|
Recent advances in proton pump inhibitors and management of acid-peptic disorders.
Topics: Animals; Anti-Ulcer Agents; Gastric Acid; Gastroesophageal Reflux; Helicobacter Infections; Humans; | 2007 |
The use of neem for controlling gastric hyperacidity and ulcer.
Topics: Animals; Anti-Ulcer Agents; Azadirachta; Gastric Acid; Omeprazole; Peptic Ulcer; Phytotherapy; Plant | 2009 |
[Strategy to manage low dose aspirin-induced gastrointestinal injury].
Topics: Anti-Ulcer Agents; Aspirin; Cardiovascular Diseases; Cerebrovascular Disorders; Clopidogrel; Famotid | 2011 |
Reducing the risk of gastroduodenal ulcers with a fixed combination of esomeprazole and low-dose acetyl salicylic acid.
Topics: Anti-Ulcer Agents; Aspirin; Cardiovascular Diseases; Cerebrovascular Disorders; Drug Therapy, Combin | 2011 |
Molecular pharmacological approaches to effects of capsaicinoids and of classical antisecretory drugs on gastric basal acid secretion and on indomethacin-induced gastric mucosal damage in human healthy subjects (mini review).
Topics: Adult; Afferent Pathways; Animals; Anti-Inflammatory Agents, Non-Steroidal; Anti-Ulcer Agents; Atrop | 2013 |
[Ulcer disease: challenging problems of etiology, pathogenesis, differential treatment].
Topics: Anti-Bacterial Agents; Anti-Ulcer Agents; Antioxidants; Disease Management; Drug Resistance, Multipl | 2012 |
Use of proton pump inhibitors during pregnancy and rates of major malformations: a meta-analysis.
Topics: Abnormalities, Drug-Induced; Female; Fetus; Gastroesophageal Reflux; Humans; Maternal-Fetal Exchange | 2002 |
[Treatment of peptic ulcer related to rheumatic diseases].
Topics: Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Rheumatoid; Histamine H2 Antagonists; Humans; Lu | 2002 |
[Several points that should be noticed during PPI treatment for peptic ulcers in elderly patients].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Aged; Anti-Ulcer Agents; Drug Interactions; Helicobacter In | 2002 |
Motion--Helicobacter pylori worsens GERD: arguments for the motion.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Bacterial Agents; Anti-Ulcer Agents; Clinical Trials a | 2002 |
Tenatoprazole. Benatoprazole, TU 199.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Animals; Clinical Trials as Topic; Humans; Imidazoles; Omep | 2002 |
Pantoprazole: an update of its pharmacological properties and therapeutic use in the management of acid-related disorders.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Inflammatory Agents, Non-Steroidal; Anti-Ulcer Agents; | 2003 |
What's new: proton pump inhibitors and pediatrics.
Topics: Child; Dyspepsia; Gastroesophageal Reflux; Helicobacter Infections; Helicobacter pylori; Humans; Ome | 2003 |
[Guidelines in the management of Helicobacter pylori infection in Japan].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Amoxicillin; Clarithromycin; Drug Therapy, Combination; Gas | 2003 |
Lansoprazole fast disintegrating tablet: a new formulation for an established proton pump inhibitor.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Administration, Oral; Anti-Ulcer Agents; Biological Availab | 2003 |
A pharmacoeconomic comparison of the efficacy and costs of pantoprazole and omeprazole for the treatment of peptic ulcer or gastroesophageal reflux disease in The Netherlands.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Ulcer Agents; Benzimidazoles; Cost-Benefit Analysis; E | 2003 |
Helicobacter pylori infection in patients with liver cirrhosis: facts and fictions.
Topics: Ammonia; Anti-Ulcer Agents; Drug Therapy, Combination; Helicobacter Infections; Helicobacter pylori; | 2003 |
Treatment and prevention of aspirin-induced gastroduodenal ulcers and gastrointestinal bleeding.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Anti-Ulcer Agents; Aspirin; Dose-Response Relationship, Dru | 2002 |
Current consensus on the diagnosis and treatment of H. pylori-associated gastroduodenal disease.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Amoxicillin; Animals; Apoptosis; Chemistry, Clinical; Clari | 2003 |
[The treatment of Helicobacter pylori infection in upper gastrointestinal disorders].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Clinical Trials as Topic; Dyspepsia; Gastritis; Gastrointes | 2003 |
Alternative dosing for PPI therapy: rationale and options.
Topics: Antacids; Capsules; Cost-Benefit Analysis; Dose-Response Relationship, Drug; Gastroesophageal Reflux | 2003 |
The role of proton pump inhibitors in NSAID-associated gastropathy and upper gastrointestinal symptoms.
Topics: Antacids; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Dyspepsia; Humans; Omeprazole; Peptic Ul | 2003 |
[Place and significance of proton pump inhibitors in current treatment of peptic ulcers].
Topics: Cost-Benefit Analysis; Humans; Hydrogen-Ion Concentration; Omeprazole; Peptic Ulcer; Proton Pump Inh | 2003 |
[Antisecretor treatment of digestive hemorrhage associated to peptic ulcer: an approximation to the available evidence].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Ulcer Agents; Benzimidazoles; Clinical Trials as Topic | 2004 |
Omeprazole/antacid-powder suspension--Santarus: Acitrel, Rapinex Powder for oral suspension, SAN 05.
Topics: Administration, Oral; Anti-Ulcer Agents; Clinical Trials, Phase III as Topic; Drug Combinations; Hum | 2004 |
[New-generation proton pump inhibitors: progress in the treatment of peptic acid diseases?].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adenosine Triphosphatases; Anti-Ulcer Agents; Benzimidazole | 2004 |
Review article: relationship between the metabolism and efficacy of proton pump inhibitors--focus on rabeprazole.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Ulcer Agents; Aryl Hydrocarbon Hydroxylases; Benzimida | 2004 |
Review article: relief of symptoms in gastric acid-related diseases--correlation with acid suppression in rabeprazole treatment.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Ulcer Agents; Benzimidazoles; Esophagitis; Gastric Aci | 2004 |
[Proton pump inhibitors as the basis of anti-helicobacter therapeutic schemes].
Topics: Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Clarithromycin; Drug Therapy, Combination; Fe | 2004 |
Omeprazole/Antacid-powder suspension-Santarus: omeprazole/sodium bicarbonate powder-Santarus, SAN 05.
Topics: Antacids; Anti-Ulcer Agents; Chemistry, Pharmaceutical; Clinical Trials, Phase III as Topic; Drug Co | 2004 |
[Peptic ulcer disease etiology, diagnosis and treatment].
Topics: Adult; Anti-Inflammatory Agents, Non-Steroidal; Anti-Ulcer Agents; Child; Gastroscopy; Helicobacter | 2004 |
[Diagnosis of and therapy for peptic ulcer].
Topics: Amoxicillin; Anti-Inflammatory Agents, Non-Steroidal; Anti-Ulcer Agents; Clarithromycin; Drug Therap | 2005 |
Meta-analysis: role of Helicobacter pylori eradication in the prevention of peptic ulcer in NSAID users.
Topics: Amoxicillin; Anti-Bacterial Agents; Anti-Inflammatory Agents, Non-Steroidal; Anti-Ulcer Agents; Clin | 2005 |
Appropriate choice of proton pump inhibitor therapy in the prevention and management of NSAID-related gastrointestinal damage.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Inflammatory Agents, Non-Steroidal; Anti-Ulcer Agents; | 2005 |
Proton pump inhibitor formulary considerations in the acutely ill. Part 2: Clinical efficacy, safety, and economics.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Acute Disease; Anti-Ulcer Agents; Capsules; Humans; Lansopr | 2005 |
Review of immediate-release omeprazole for the treatment of gastric acid-related disorders.
Topics: Administration, Oral; Anti-Ulcer Agents; Circadian Rhythm; Dosage Forms; Drug Administration Schedul | 2005 |
What is potent acid inhibition, and how can it be achieved?
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Ulcer Agents; Benzimidazoles; Clinical Trials as Topic | 2005 |
Intravenous proton pump inhibitor therapy: a rationale for use.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Ulcer Agents; Benzimidazoles; Gastroesophageal Reflux; | 2005 |
[Is the successful eradication of Helicobacter pylori sufficient for the healing of peptic ulcer?].
Topics: Antacids; Anti-Ulcer Agents; Drug Administration Schedule; Helicobacter Infections; Helicobacter pyl | 2006 |
Interaction or relationship between Helicobacter pylori and non-steroidal anti-inflammatory drugs in upper gastrointestinal diseases.
Topics: Anti-Bacterial Agents; Anti-Inflammatory Agents, Non-Steroidal; Anti-Ulcer Agents; Aspirin; Cardiova | 2006 |
Acid-related disorders and use of antisecretory medication.
Topics: Anti-Ulcer Agents; Denmark; Drug Utilization; Enzyme Inhibitors; Esophagitis; Esophagoscopy; Female; | 2007 |
[Proton pump inhibitors in developmental period medicine].
Topics: Adult; Age Factors; Anti-Ulcer Agents; Child; Drug Interactions; Duodenitis; Enzyme Inhibitors; Esom | 2007 |
Pylera plus omeprazole: quadruple treatment for Helicobacter pylori.
Topics: Antacids; Anti-Infective Agents; Anti-Ulcer Agents; Bismuth; Capsules; Drug Therapy, Combination; He | 2008 |
Pharmacologic options for the control of peptic ulcer disease.
Topics: Antacids; Anti-Ulcer Agents; Benzimidazoles; Bismuth; Carbenoxolone; Cimetidine; Duodenal Ulcer; His | 1984 |
[Proton pump blockers and their significance in gastroenterology].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Ulcer Agents; Benzimidazoles; Esophagitis, Peptic; Gas | 1995 |
Prevention and treatment of ulcers induced by nonsteroidal anti-inflammatory drugs: an update.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Clinical Trials as Topic; Histamine H2 Antagonists; Humans; | 1995 |
[How to use proton pump inhibitors and histamine H2 antagonists in the therapy of peptic ulcer].
Topics: Gastritis; Helicobacter Infections; Helicobacter pylori; Histamine H2 Antagonists; Humans; Omeprazol | 1995 |
[Conservative therapy of peptic ulcer].
Topics: Ampicillin; Gastric Acidity Determination; Helicobacter pylori; Histamine H2 Antagonists; Humans; Om | 1995 |
The potential value of lansoprazole in Helicobacter pylori eradication.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Ulcer Agents; Drug Therapy, Combination; Helicobacter | 1995 |
[New therapy of peptic ulcer].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Alprostadil; Anti-Ulcer Agents; Histamine H2 Antagonists; H | 1995 |
Therapy of gastrointestinal ulcers.
Topics: Animals; Antacids; Anti-Ulcer Agents; Histamine H2 Antagonists; Misoprostol; Omeprazole; Peptic Ulce | 1995 |
Helicobacter pylori: the place of the new macrolides in the eradication of the bacteria in peptic ulcer disease.
Topics: Anti-Bacterial Agents; Bismuth; Clarithromycin; Drug Resistance, Microbial; Drug Therapy, Combinatio | 1995 |
The role of omeprazole and antibiotic combinations in the eradication of Helicobacter pylori--an update.
Topics: Amoxicillin; Anti-Bacterial Agents; Drug Therapy, Combination; Helicobacter Infections; Helicobacter | 1994 |
[Are proton pump inhibitors safe?].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Animals; Anti-Ulcer Agents; Benzimidazoles; Carcinogenicity | 1994 |
[Controversies and trends in ulcer therapy. 2: Prevention of recurrence].
Topics: Adult; Aged; Bismuth; Drug Therapy, Combination; Female; Helicobacter Infections; Helicobacter pylor | 1993 |
Antibacterial therapy of Helicobacter pylori-associated peptic ulcer disease: a new strategy. The Swedes go for it.
Topics: Amoxicillin; Anti-Ulcer Agents; Bismuth; Clarithromycin; Drug Therapy, Combination; Helicobacter Inf | 1994 |
Helicobacter pylori in peptic ulcer disease.
Topics: Amoxicillin; Anti-Bacterial Agents; Bismuth; Drug Therapy, Combination; Helicobacter Infections; Hel | 1994 |
[Helicobacter pylori therapy with omeprazole and clarithromycin: current status].
Topics: Clarithromycin; Drug Therapy, Combination; Helicobacter Infections; Helicobacter pylori; Humans; Ome | 1994 |
Review article: treatments that impact favourably upon the eradication of Helicobacter pylori and ulcer recurrence.
Topics: Anti-Bacterial Agents; Drug Administration Schedule; Drug Therapy, Combination; Helicobacter Infecti | 1994 |
Review article: Helicobacter pylori eradication--understandable caution but no excuse for inertia.
Topics: Anti-Bacterial Agents; Attitude of Health Personnel; Clinical Trials as Topic; Drug Administration S | 1994 |
Nonsteroidal antiinflammatory drugs and the gastrointestinal tract.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Rheumatoid; Digestive System; Gastrointestinal H | 1994 |
The role of acid inhibition in the treatment of Helicobacter pylori infection.
Topics: Amoxicillin; Depression, Chemical; Drug Administration Schedule; Drug Therapy, Combination; Gastric | 1994 |
The role of Helicobacter pylori in peptic ulcer disease.
Topics: Anti-Bacterial Agents; Bismuth; Drug Therapy, Combination; Gastritis; Helicobacter Infections; Helic | 1994 |
Emerging strategies for managing peptic ulcer disease.
Topics: Amoxicillin; Anti-Inflammatory Agents, Non-Steroidal; Depression, Chemical; Drug Therapy, Combinatio | 1994 |
Healing and prevention of NSAID-induced peptic ulcers.
Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Female; Humans; Male; Omeprazole; Peptic Ulcer; Risk | 1994 |
[Current therapy of Helicobacter pylori infection].
Topics: Amoxicillin; Clarithromycin; Drug Therapy, Combination; Gastric Mucosa; Gastritis; Helicobacter Infe | 1994 |
Safety of proton pump inhibitors--an overview.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Animals; Benzimidazoles; Cytochrome P-450 Enzyme System; Di | 1994 |
Hp and pH: implications for the eradication of Helicobacter pylori.
Topics: Amoxicillin; Drug Synergism; Duodenum; Gastric Acid; Helicobacter pylori; Humans; Hydrogen-Ion Conce | 1993 |
Compliance, adverse events and antibiotic resistance in Helicobacter pylori treatment.
Topics: Amoxicillin; Bismuth; Cimetidine; Drug Resistance, Microbial; Helicobacter Infections; Helicobacter | 1993 |
Eradication of Helicobacter pylori and its effect in peptic ulcer disease.
Topics: Amoxicillin; Anti-Bacterial Agents; Bismuth; Campylobacter Infections; Drug Therapy, Combination; Hu | 1993 |
[Risk for developing tumors in therapy with the proton pump inhibitor omeprazole].
Topics: Animals; Carcinogenicity Tests; Carcinoid Tumor; Esophagitis, Peptic; Humans; Omeprazole; Peptic Ulc | 1993 |
[Omeprazole and the cytochrome P450 system of the liver].
Topics: Acetaminophen; Carcinogenicity Tests; Cytochrome P-450 CYP1A1; Cytochrome P-450 Enzyme Inhibitors; C | 1993 |
Surgery for acid suppression in the 1990s.
Topics: Anti-Ulcer Agents; Female; Gastric Acid; Gastric Mucosa; Helicobacter pylori; Humans; Intestinal Muc | 1993 |
Is there any acid peptic disease that is refractory to proton pump inhibitors?
Topics: Clinical Trials as Topic; Drug Resistance; Duodenal Ulcer; Gastric Acid; Gastroesophageal Reflux; Hu | 1993 |
Review article: the continuing development of proton pump inhibitors with particular reference to pantoprazole.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Benzimidazoles; Duodenal Ulcer; Enzyme Inhibitors; Humans; | 1995 |
Clarithromycin and omeprazole as helicobacter pylori eradication therapy in patients with H. pylori-associated gastric disorders.
Topics: Anti-Bacterial Agents; Anti-Ulcer Agents; Clarithromycin; Drug Therapy, Combination; Helicobacter In | 1996 |
Strategies for Helicobacter pylori eradication in 1995: a review of international and Belgian experience.
Topics: Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Belgium; Clarithromycin; Drug Therapy, Combin | 1996 |
Cost-effectiveness of H. pylori eradication.
Topics: Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Clarithromycin; Duodenal Ulcer; Helicobacter | 1996 |
Lansoprazole and omeprazole in the treatment of acid peptic disorders.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Ulcer Agents; Clinical Trials as Topic; Drug Interacti | 1996 |
[Losek (omeprazole), a new therapeutic agent in the treatment of peptic ulcer and hyperacidity states].
Topics: Animals; Anti-Ulcer Agents; Duodenal Ulcer; Gastric Acid; Humans; Omeprazole; Peptic Ulcer; Rats; Re | 1995 |
[Helicobacter pylori eradication: triple therapy versus dual therapy].
Topics: Amoxicillin; Anti-Ulcer Agents; Bismuth; Clarithromycin; Clinical Trials as Topic; Drug Therapy, Com | 1996 |
A risk-benefit assessment of drugs used in the eradication of Helicobacter pylori infection.
Topics: Amoxicillin; Anti-Bacterial Agents; Bismuth; Clarithromycin; Drug Therapy, Combination; Dyspepsia; H | 1996 |
Helicobacter pylori infection. The importance of eradication in patients with gastric disease.
Topics: Antacids; Anti-Bacterial Agents; Anti-Ulcer Agents; Bismuth; Drug Therapy, Combination; Helicobacter | 1996 |
[Prevention and therapy of NSAID-induced ulcers: fact versus myth].
Topics: Anti-Inflammatory Agents, Non-Steroidal; Anti-Ulcer Agents; Comorbidity; Humans; Misoprostol; Omepra | 1996 |
The changing role of H2-receptor antagonists in acid-related diseases.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Ulcer Agents; Benzimidazoles; Clinical Trials as Topic | 1996 |
Pantoprazole, a new proton-pump inhibitor, has a precise and predictable profile of activity.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Animals; Anti-Bacterial Agents; Anti-Ulcer Agents; Benzimid | 1996 |
Triple therapy as a cure for Helicobacter pylori infection.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Antacids; Anti-Bacterial Agents; Anti-Ulcer Agents; Benzimi | 1996 |
Efficacy of clarithromycin in eradicating Helicobacter pylori.
Topics: Anti-Bacterial Agents; Anti-Ulcer Agents; Clarithromycin; Drug Therapy, Combination; Enzyme Inhibito | 1996 |
Lansoprazole: a proton pump inhibitor.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Ulcer Agents; Drug Interactions; Esophagitis; Humans; | 1996 |
[What is the current therapeutic role of omeprazole in gastroduodenal ulcer disease?].
Topics: Anti-Ulcer Agents; Drug Therapy, Combination; Helicobacter Infections; Helicobacter pylori; Humans; | 1997 |
[Helicobacter pylori eradication: modified triple therapy with lansoprazole].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Ulcer Agents; Drug Therapy, Combination; Helicobacter | 1996 |
Helicobacter pylori: new developments and treatments.
Topics: Algorithms; Anti-Bacterial Agents; Anti-Ulcer Agents; Clarithromycin; Drug Therapy, Combination; Hel | 1997 |
Treatment strategies for Helicobacter pylori infection.
Topics: Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Bismuth; Clarithromycin; Drug Therapy, Combin | 1997 |
Lansoprazole. An update of its pharmacological properties and clinical efficacy in the management of acid-related disorders.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Ulcer Agents; Esophagitis; Gastrointestinal Diseases; | 1997 |
Clarithromycin dual therapy regimens for eradication of Helicobacter pylori: a review.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Bacterial Agents; Anti-Ulcer Agents; Clarithromycin; C | 1997 |
Proton-pump inhibitors for gastric acid-related disease.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Ulcer Agents; Esophagitis; Gastric Acid; Helicobacter | 1998 |
Rabeprazole.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Ulcer Agents; Benzimidazoles; Clinical Trials as Topic | 1998 |
[Gastric lesion caused by NSAID and inflammation due to Helicobacter pylori. Is there potentiation or attenuation?].
Topics: Anti-Bacterial Agents; Anti-Inflammatory Agents, Non-Steroidal; Anti-Ulcer Agents; Clinical Trials a | 1998 |
New data on healing of nonsteroidal anti-inflammatory drug-associated ulcers and erosions. Omeprazole NSAID Steering Committee.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Anti-Ulcer Agents; Humans; Multicenter Studies as Topic; Om | 1998 |
Healing of nonsteroidal anti-inflammatory drug-associated ulcers and erosions, and relief of dyspeptic symptoms: a commentary on the new data.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Anti-Ulcer Agents; Dyspepsia; Humans; Misoprostol; Omeprazo | 1998 |
Prophylaxis against nonsteroidal anti-inflammatory drug-associated ulcers and erosions: a commentary on the new data.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Anti-Ulcer Agents; Humans; Misoprostol; Omeprazole; Peptic | 1998 |
Management of nonsteroidal anti-inflammatory drug-associated lesions: a cost-effectiveness perspective.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Anti-Ulcer Agents; Cost-Benefit Analysis; Humans; Misoprost | 1998 |
Non steroidal anti-inflammatory drugs. Minimising the harm, maximising the benefit.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Anti-Ulcer Agents; Cyclooxygenase 1; Cyclooxygenase 2; Gast | 1998 |
[Peptic ulcer due to Helicobacter pylori].
Topics: Animals; Anti-Bacterial Agents; Anti-Ulcer Agents; Gastric Acid; Gastric Mucosa; Helicobacter Infect | 1998 |
The impact of Helicobacter pylori eradication on peptic ulcer healing.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Antacids; Anti-Ulcer Agents; Benzimidazoles; Duodenal Ulcer | 1998 |
Efficacy of lansoprazole in eradicating Helicobacter pylori: a meta-analysis.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Clar | 1998 |
Antisecretory therapy for bleeding peptic ulcer.
Topics: Anti-Ulcer Agents; Gastrointestinal Hemorrhage; Histamine H2 Antagonists; Humans; Omeprazole; Peptic | 1998 |
[Lansoprazol ++ : a new proton pump inhibitor].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Ulcer Agents; Lansoprazole; Omeprazole; Peptic Ulcer | 1998 |
Omerprazole and other proton pump inhibitors: pharmacology, efficacy, and safety, with special reference to use in children.
Topics: Barrett Esophagus; Child; Enzyme Inhibitors; Esophagitis; Humans; Lung Diseases; Omeprazole; Peptic | 1998 |
Agents used in the prevention and treatment of nonsteroidal anti-inflammatory drug-associated symptoms and ulcers.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Anti-Ulcer Agents; Gastric Mucosa; Histamine H2 Antagonists | 1998 |
[History of the treatment of Helicobacter pylori and clinical efficacy].
Topics: Anti-Bacterial Agents; Anti-Ulcer Agents; Bismuth; Clinical Trials as Topic; Drug Therapy, Combinati | 1999 |
[Eradication rate and side effect from a point of view of Helicobacter pylori eradication of peptic ulcer disease in dual therapy or new triple therapy].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Clar | 1999 |
[Effect of the eradication of Helicobacter pylori on peptic ulcer healing].
Topics: Gastroscopy; Helicobacter Infections; Helicobacter pylori; Histamine H2 Antagonists; Histological Te | 1999 |
[Effects of Helicobacter pylori eradication therapy on the healing process of peptic ulcers].
Topics: Anti-Bacterial Agents; Anti-Ulcer Agents; Drug Therapy, Combination; Helicobacter Infections; Helico | 1999 |
Safety profile of Lansoprazole: the US clinical trial experience.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Ulcer Agents; Clinical Trials as Topic; Esophageal Dis | 1999 |
Management of nonsteroidal anti-inflammatory drug-induced gastroduodenal disease by acid suppression.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Anti-Ulcer Agents; Duodenal Ulcer; Famotidine; Gastric Juic | 1999 |
[Proton pump inhibitors in pediatrics].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Anti-Ulcer Agents; Benzimidazoles; Child; Enzyme Inh | 1999 |
Rabeprazole: a review of its use in acid-related gastrointestinal disorders.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Ulcer Agents; Benzimidazoles; Clinical Trials as Topic | 1999 |
Use of proton-pump inhibitors in complicated ulcer disease and upper gastrointestinal tract bleeding.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Bacterial Agents; Anti-Inflammatory Agents, Non-Steroi | 1999 |
Pantoprazole, Prout and the proton pump.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Ulcer Agents; Benzimidazoles; Drug Interactions; Femal | 1999 |
[25 years of gastric acid blockers].
Topics: Anti-Ulcer Agents; Cimetidine; Dyspepsia; Gastroesophageal Reflux; Histamine H2 Antagonists; Humans; | 1999 |
[Indications and use of omeprazole in esophago-gastro-duodenal diseases].
Topics: Anti-Ulcer Agents; Double-Blind Method; Duodenal Ulcer; Esophageal Diseases; Esophagitis; Gastritis; | 1999 |
Microbial ecology and treatment of Helicobacter pylori infections: review.
Topics: Adenocarcinoma; Adult; Aged; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Clarithromycin; | 2000 |
[Lansoprazole: an analysis of the clinical trials in the 3 years of 1997-1999].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Inflammatory Agents, Non-Steroidal; Anti-Ulcer Agents; | 2000 |
[Antisecretory drugs and prophylaxis of secondary gastrointestinal effects associated with the consumption of non steroid anti-inflammatory drugs].
Topics: Adolescent; Adult; Anti-Inflammatory Agents, Non-Steroidal; Enzyme Inhibitors; Female; Gastrointesti | 2000 |
[Gastroesophageal reflux disease: new data on the mechanisms of esophageal ulcer lesion healing].
Topics: Anti-Ulcer Agents; Esophagus; Gastroesophageal Reflux; Humans; Laser Therapy; Mucous Membrane; Omepr | 2000 |
Helicobacter pylori and nonsteroidal anti-inflammatory drugs: interaction with proton pump inhibitor therapy for prevention of nonsteroidal anti-inflammatory drug ulcers and ulcer complications--future research needs.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Anti-Ulcer Agents; Clinical Trials as Topic; Enzyme Inhibit | 2001 |
[Selection of antibiotics and planning of eradication for H. pylori infection].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Amoxicillin; Benzimidazoles; Clarithromycin; Drug Administr | 2001 |
A review of omeprazole use in the treatment of acid-related disorders in children.
Topics: Administration, Oral; Adolescent; Adult; Anti-Ulcer Agents; Biological Availability; Child; Child, P | 2001 |
Proton-pump inhibitors for acute peptic ulcer bleeding.
Topics: Acute Disease; Anti-Ulcer Agents; Hemorrhage; Humans; Omeprazole; Peptic Ulcer; Proton Pump Inhibito | 2001 |
Intravenous omeprazole after endoscopic treatment of bleeding peptic ulcers.
Topics: Anti-Ulcer Agents; Chemotherapy, Adjuvant; Double-Blind Method; Endoscopy, Gastrointestinal; Gastroi | 2001 |
Lansoprazole: an update of its place in the management of acid-related disorders.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Animals; Anti-Inflammatory Agents, Non-Steroidal; Anti-Ulce | 2001 |
Gastro-duodenal protection in an era of cyclo-oxygenase-2-selective nonsteroidal anti-inflammatory drugs.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Inflammatory Agents, Non-Steroidal; Anti-Ulcer Agents; | 2001 |
[Progress of tailor-made treatment of peptic ulcer].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Amoxicillin; Anti-Ulcer Agents; Aryl Hydrocarbon Hydroxylas | 2002 |
Clinical pharmacology and safety profile of esomeprazole, the first enantiomerically pure proton pump inhibitor.
Topics: Anti-Ulcer Agents; Drug Interactions; Esomeprazole; Humans; Omeprazole; Peptic Ulcer; Proton Pump In | 2001 |
Lansoprazole: pharmacokinetics, pharmacodynamics and clinical uses.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Animals; Anti-Ulcer Agents; Enzyme Inhibitors; Esophagitis, | 2001 |
Review article: rabeprazole-based therapy in Helicobacter pylori eradication.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Ulcer Agents; Benzimidazoles; Clinical Trials as Topic | 2002 |
[The outline of medical treatment of peptic ulcer].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Amoxicillin; Anti-Inflammatory Agents, Non-Steroidal; Clari | 2002 |
[Dual therapy for Helicobacter pylori resistance to anti microbial agents].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Amoxicillin; Benzimidazoles; Clarithromycin; Clinical Trial | 2002 |
[Acute mucosal lesion of the upper-gastrointestinal tract observed after H. pylori-eradication].
Topics: Acute Disease; Amoxicillin; Clarithromycin; Esophagitis, Peptic; Gastric Acid; Gastric Mucosa; Helic | 2002 |
[H. pylori eradication therapy and natural history of peptic ulcer].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Amoxicillin; Clarithromycin; Drug Therapy, Combination; Enz | 2002 |
[Continuation of acid suppression therapy after H. pylori eradication].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Antacids; Benzimidazoles; Clinical Trials as Topic; Enzyme | 2002 |
[Intractable ulcer].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Inflammatory Agents, Non-Steroidal; Diagnosis, Differe | 2002 |
[Prophylaxis against non-steroidal anti-inflammatory drug-associated ulcers and erosions].
Topics: Anti-Inflammatory Agents, Non-Steroidal; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Cyclooxygena | 2002 |
[Peptic ulcer in the elderly].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Aged; Amoxicillin; Anti-Inflammatory Agents, Non-Steroidal; | 2002 |
[Proton pump inhibitors: Tenatoprazole (TU-199)].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Animals; Anti-Ulcer Agents; Clinical Trials as Topic; Depre | 2002 |
[Sucralfate].
Topics: Anti-Ulcer Agents; Clarithromycin; Drug Resistance, Bacterial; Drug Therapy, Combination; Gastric Ac | 2002 |
[Plaunotol].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Amoxicillin; Anti-Ulcer Agents; Clarithromycin; Diterpenes; | 2002 |
[Sofalcone].
Topics: Amoxicillin; Anti-Ulcer Agents; Chalcone; Chalcones; Clarithromycin; Drug Resistance, Bacterial; Dru | 2002 |
[Ecabet sodium].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Abietanes; Amoxicillin; Animals; Anti-Ulcer Agents; Diterpe | 2002 |
[Polaprezinc].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Amoxicillin; Animals; Anti-Ulcer Agents; Carnosine; Clarith | 2002 |
Potent versus mild acid suppression in peptic ulcer disease.
Topics: Adenosine Triphosphatases; Anti-Ulcer Agents; H(+)-K(+)-Exchanging ATPase; Histamine H2 Antagonists; | 1992 |
[The medical therapy of peptic ulcer. The state of the art].
Topics: Anti-Ulcer Agents; Duodenal Ulcer; Histamine H2 Antagonists; Humans; Omeprazole; Peptic Ulcer; Stoma | 1992 |
Control of gastric acid secretion. Histamine H2-receptor antagonists and H+K(+)-ATPase inhibitors.
Topics: Absorption; Adenosine Triphosphatases; Benzimidazoles; Cytochrome P-450 Enzyme System; Gastric Acid; | 1992 |
Lansoprazole. A review of its pharmacodynamic and pharmacokinetic properties and its therapeutic efficacy in acid-related disorders.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Ulcer Agents; Biological Availability; Duodenal Ulcer; | 1992 |
Refractory peptic ulcers.
Topics: Anti-Ulcer Agents; Chronic Disease; Cimetidine; Gastric Mucosa; Humans; Meta-Analysis as Topic; Omep | 1992 |
Helicobacter pylori, peptic ulcer disease and inhibition of gastric acid secretion.
Topics: Amoxicillin; Clinical Trials as Topic; Drug Synergism; Drug Therapy, Combination; Gastric Acid; Gast | 1992 |
Safety experience from long-term treatment with omeprazole.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Cimetidine; Clinical Trials as Topic; Esophagitis, Pepti | 1992 |
[Omeprazole].
Topics: Esophagitis, Peptic; Helicobacter Infections; Helicobacter pylori; Humans; Omeprazole; Peptic Ulcer | 1992 |
[Proton pump blockade and Helicobacter pylori: status of current knowledge and clinical importance].
Topics: Amoxicillin; Helicobacter Infections; Helicobacter pylori; Humans; Omeprazole; Peptic Ulcer; Proton | 1992 |
Omeprazole in the treatment of peptic ulcers and gastroesophageal reflux disease.
Topics: Gastroesophageal Reflux; Humans; Omeprazole; Peptic Ulcer | 1992 |
Proton-pump inhibition for acid-related disease.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adenosine Triphosphatases; Animals; Anti-Ulcer Agents; Gast | 1991 |
Medical treatment of peptic ulcer disease.
Topics: Antacids; Duodenal Ulcer; Histamine H2 Antagonists; Humans; Omeprazole; Peptic Ulcer; Prostaglandins | 1991 |
Update: gastroenterology and hepatology.
Topics: Chronic Disease; Esophageal Diseases; Gastrointestinal Diseases; Humans; Interferons; Liver Diseases | 1991 |
Omeprazole.
Topics: Animals; Gastroesophageal Reflux; Humans; Omeprazole; Peptic Ulcer | 1991 |
Acid suppression as treatment for NSAID-related peptic ulcers.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Gastric Acid; Humans; Omeprazole; Peptic Ulcer; Ranitidine; | 1991 |
Treatment of acid-related disorders with gastric acid inhibitors: the state of the art.
Topics: Gastric Acid; Histamine H2 Antagonists; Humans; Meta-Analysis as Topic; Omeprazole; Peptic Ulcer; Re | 1990 |
Clinical development programme for omeprazole.
Topics: Drug Administration Schedule; Esophagitis, Peptic; Humans; Omeprazole; Peptic Ulcer; Peptic Ulcer He | 1990 |
The clinical safety of omeprazole.
Topics: Humans; Omeprazole; Peptic Ulcer; Product Surveillance, Postmarketing; Zollinger-Ellison Syndrome | 1990 |
Omeprazole: blocks gastric acid secretion completely.
Topics: Esophagitis, Peptic; Gastric Acid; Humans; Omeprazole; Peptic Ulcer | 1990 |
[Omeprazole. A new substance for inhibiting acid production].
Topics: Animals; Esophagitis, Peptic; Gastric Acid; Humans; Omeprazole; Peptic Ulcer; Zollinger-Ellison Synd | 1990 |
Omeprazole: a novel antisecretory agent for the treatment of acid-peptic disorders.
Topics: Animals; Gastric Acid; Humans; Omeprazole; Peptic Ulcer | 1990 |
Clinical experience with omeprazole: assessment of efficacy and safety.
Topics: Duodenal Ulcer; Esophagitis, Peptic; Humans; Omeprazole; Peptic Ulcer; Stomach Ulcer; Zollinger-Elli | 1989 |
Biological basis of omeprazole therapy.
Topics: Adenosine Triphosphatases; Gastric Acid; H(+)-K(+)-Exchanging ATPase; Humans; Omeprazole; Peptic Ulc | 1989 |
[Is strong inhibition of gastric acid in the treatment of peptic ulcer sensible?].
Topics: Cimetidine; Clinical Trials as Topic; Double-Blind Method; Gastric Acid; Histamine H2 Antagonists; H | 1989 |
[Drugs used in the therapy of peptic ulcer with special reference to H2 receptor blockaders].
Topics: Antacids; Anti-Ulcer Agents; Cimetidine; Famotidine; Female; Histamine H2 Antagonists; Humans; Male; | 1989 |
Drug therapy in peptic ulcer disease.
Topics: Cimetidine; Histamine Antagonists; Humans; Omeprazole; Peptic Ulcer; Pirenzepine; Prostaglandins; Ra | 1989 |
Clinical utility and safety of omeprazole.
Topics: Animals; Duodenal Ulcer; Esophagitis, Peptic; Humans; Omeprazole; Peptic Ulcer; Stomach Ulcer; Zolli | 1989 |
Therapeutic achlorhydria and risk of gastric cancer.
Topics: Animals; Biomechanical Phenomena; Carcinogens; Esophagitis; Gastric Acid; Humans; Omeprazole; Peptic | 1989 |
Effect of omeprazole on gastric acid secretion and plasma gastrin in man.
Topics: Dose-Response Relationship, Drug; Gastric Acid; Gastric Mucosa; Gastrins; Humans; Omeprazole; Pariet | 1989 |
Ulcer-healing drugs and endogenous prostaglandins.
Topics: Aluminum; Animals; Anti-Ulcer Agents; Benzimidazoles; Benzodiazepinones; Carbenoxolone; Cimetidine; | 1985 |
Pharmacological management of patients with peptic ulcer disease: prospects for the late 1980's.
Topics: Alprostadil; Antacids; Anti-Ulcer Agents; Cimetidine; Drug Resistance; Enprostil; Famotidine; Histam | 1987 |
Medical treatment of peptic ulcer disease.
Topics: Anti-Ulcer Agents; Histamine H2 Antagonists; Humans; Omeprazole; Peptic Ulcer; Wound Healing | 1988 |
[Pathophysiologic bases of the pharmacotherapy of peptic ulcer].
Topics: Anti-Ulcer Agents; Histamine H2 Antagonists; Humans; Omeprazole; Organometallic Compounds; Peptic Ul | 1988 |
[Therapy of peptic ulcer. ATPase inhibitors].
Topics: Adenosine Triphosphatases; Humans; Omeprazole; Peptic Ulcer | 1988 |
[Omeprazole].
Topics: Chemical Phenomena; Chemistry; Clinical Trials as Topic; Dose-Response Relationship, Drug; Esophagit | 1987 |
Omeprazole. A preliminary review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in peptic ulcer disease and Zollinger-Ellison syndrome.
Topics: Animals; Anti-Ulcer Agents; Benzimidazoles; Biological Availability; Drug Interactions; Gastric Acid | 1986 |
[Omeprazole in peptic ulcer--pros and cons].
Topics: Gastric Acid; Humans; Omeprazole; Peptic Ulcer; Wound Healing | 1986 |
Medical treatment of peptic ulcers.
Topics: Aluminum; Antacids; Anti-Ulcer Agents; Benzimidazoles; Bismuth; Cimetidine; Humans; Omeprazole; Para | 1985 |
Treatment of ulcer disease.
Topics: Aluminum; Antacids; Anti-Ulcer Agents; Benzimidazoles; Cimetidine; Clinical Trials as Topic; Gastric | 1985 |
253 trials available for omeprazole and Gastroduodenal Ulcer
| Article | Year |
|---|---|
Poliprotect vs Omeprazole in the Relief of Heartburn, Epigastric Pain, and Burning in Patients Without Erosive Esophagitis and Gastroduodenal Lesions: A Randomized, Controlled Trial.
Topics: Abdominal Pain; Anti-Ulcer Agents; Double-Blind Method; Dyspepsia; Esophagitis; Heartburn; Humans; O | 2023 |
Intravenous versus oral omeprazole on patients with high risk bleeding peptic ulcers: A prospective randomized clinical trial protocol.
Topics: Administration, Intravenous; Administration, Oral; Adult; Humans; Omeprazole; Peptic Ulcer; Peptic U | 2021 |
Omeprazole Absorption and Fasting Gastrinemia After Roux-en-Y Gastric Bypass.
Topics: Adult; Anastomosis, Roux-en-Y; Fasting; Female; Gastric Bypass; Gastrins; Humans; Male; Middle Aged; | 2017 |
Efficacy and safety of the use of rebamipide in the scheme of triple eradication therapy of Helicobacter pylori infection: a prospective randomized comparative study.
Topics: Adult; Alanine; Amoxicillin; Anti-Infective Agents; Anti-Ulcer Agents; Clarithromycin; Drug Administ | 2018 |
Evaluation of the efficacy and safety of the hybrid scheme for eradication therapy of Helicobacter pylori infection.
Topics: Adult; Amoxicillin; Antacids; Anti-Infective Agents; Anti-Ulcer Agents; Bismuth; Clarithromycin; Dru | 2018 |
Penbactam for Helicobacter pylori eradication: a randomised comparison of quadruple and triple treatment schedules in an Iranian population.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Amoxicillin; Ampicillin; Analysis of Variance; Anti-Bact | 2013 |
Randomised clinical trial comparing sequential and concomitant therapies for Helicobacter pylori eradication in routine clinical practice.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; B | 2014 |
Preventive effect of irsogladine or omeprazole on non-steroidal anti-inflammatory drug-induced esophagitis, peptic ulcers, and small intestinal lesions in humans, a prospective randomized controlled study.
Topics: Adult; Anti-Inflammatory Agents, Non-Steroidal; Anti-Ulcer Agents; Diclofenac; Endoscopy, Gastrointe | 2013 |
Effect of clopidogrel with or without omeprazole in patients with carotid artery stenting.
Topics: Angiography; Aspirin; Breath Tests; Carotid Arteries; Carotid Stenosis; Clopidogrel; Drug Interactio | 2013 |
Impact of creatinine clearance on Helicobacter pylori eradication rate in patients with peptic ulcer disease.
Topics: Adult; Amoxicillin; Anti-Bacterial Agents; Breath Tests; Clarithromycin; Creatinine; Drug Therapy, C | 2015 |
Long-Term Safety of a Coordinated Delivery Tablet of Enteric-Coated Aspirin 325 mg and Immediate-Release Omeprazole 40 mg for Secondary Cardiovascular Disease Prevention in Patients at GI Risk.
Topics: Aged; Aspirin; Cardiovascular Diseases; Dosage Forms; Drug Combinations; Female; Humans; Male; Middl | 2016 |
[Effect of Yiqi Huoxue Qingre Huashi Recipe on the Eradication Rate of Hp in Peptic Ulcer Patients].
Topics: Breath Tests; Drug Therapy, Combination; Drugs, Chinese Herbal; Gastric Mucosa; Helicobacter Infecti | 2015 |
Proton-Pump Inhibitors Reduce Gastrointestinal Events Regardless of Aspirin Dose in Patients Requiring Dual Antiplatelet Therapy.
Topics: Aged; Aspirin; Clopidogrel; Dose-Response Relationship, Drug; Drug Therapy, Combination; Dyspepsia; | 2016 |
Quadruple therapy with furazolidone for retreatment in patients with peptic ulcer disease.
Topics: Adult; Aged; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Drug Administration Schedule; Dr | 2008 |
[Interleukin-1beta gene polymorphism as a predictor of eradication treatment efficacy in gastric and duodenal ulcer associated with Helicobacter pylori].
Topics: Adolescent; Adult; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Clarithromycin; Endoscopy, | 2008 |
Does Helicobacter pylori eradication therapy for peptic ulcer prevent gastric cancer?
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adolescent; Adult; Aged; Aged, 80 and over; Amoxicillin; An | 2009 |
[Effect of CYP2C19 gene polymorphism on eradication treatment efficacy of Helicobacter pylori infection].
Topics: Adult; Amoxicillin; Aryl Hydrocarbon Hydroxylases; Breath Tests; Clarithromycin; Cohort Studies; Cyt | 2009 |
[Effect of yiqi huoxue formula on healing quality and recurrence rate of peptic ulcer].
Topics: Adult; Anti-Ulcer Agents; Drugs, Chinese Herbal; Female; Fibroblast Growth Factor 2; Humans; Male; M | 2009 |
Celecoxib versus omeprazole and diclofenac in patients with osteoarthritis and rheumatoid arthritis (CONDOR): a randomised trial.
Topics: Adult; Anti-Inflammatory Agents, Non-Steroidal; Anti-Ulcer Agents; Arthritis, Rheumatoid; Celecoxib; | 2010 |
The effect of cytochrome P2C19 and interleukin-1 polymorphisms on H. pylori eradication rate of 1-week triple therapy with omeprazole or rabeprazole, amoxycillin and clarithromycin in Chinese people.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Anti-Bacterial Agents; Anti-Ulcer Agents; Aryl | 2010 |
Clarithromycin-based triple therapy for Helicobacter pylori treatment in peptic ulcer patients.
Topics: Adult; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Brazil; Clarithromycin; Drug Therapy, | 2010 |
Melatonin or L-tryptophan accelerates healing of gastroduodenal ulcers in patients treated with omeprazole.
Topics: Adult; Drug Therapy, Combination; Female; Humans; Male; Melatonin; Middle Aged; Omeprazole; Peptic U | 2011 |
Prophylactic use of omeprazole associated with a reduced risk of peptic ulcer disease among maintenance hemodialysis patients.
Topics: Aged; Anti-Ulcer Agents; Cost-Benefit Analysis; Female; Humans; Kidney Failure, Chronic; Male; Middl | 2011 |
Furazolidone, amoxicillin and omeprazole with or without bismuth for eradication of Helicobacter pylori in peptic ulcer disease.
Topics: Adult; Amoxicillin; Antacids; Anti-Bacterial Agents; Anti-Infective Agents, Local; Anti-Ulcer Agents | 2011 |
Efficacy of levofloxacin and rifaximin based quadruple therapy in Helicobacter pylori associated gastroduodenal disease: a double-blind, randomized controlled trial.
Topics: Adult; Aged; Amoxicillin; Anti-Bacterial Agents; Clarithromycin; Diarrhea; Double-Blind Method; Drug | 2011 |
Second-line levofloxacin-based triple therapy's efficiency for Helicobacter pylori eradication in patients with peptic ulcer.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; D | 2011 |
Molecular pharmacological approaches to effects of capsaicinoids and of classical antisecretory drugs on gastric basal acid secretion and on indomethacin-induced gastric mucosal damage in human healthy subjects (mini review).
Topics: Adult; Afferent Pathways; Animals; Anti-Inflammatory Agents, Non-Steroidal; Anti-Ulcer Agents; Atrop | 2013 |
Randomized open trial for comparison of proton pump inhibitors in triple therapy for Helicobacter pylori infection in relation to CYP2C19 genotype.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Aged, 80 and over; Amoxicillin; Anti-Ulcer Age | 2002 |
Comparison of oral omeprazole and endoscopic ethanol injection therapy for prevention of recurrent bleeding from peptic ulcers with nonbleeding visible vessels or fresh adherent clots.
Topics: Administration, Oral; Endoscopy, Gastrointestinal; Enzyme Inhibitors; Ethanol; Female; Gastrointesti | 2002 |
One-week triple vs. quadruple therapy for Helicobacter pylori infection - a randomized trial.
Topics: Adult; Aged; Amoxicillin; Anti-Bacterial Agents; Breath Tests; Clarithromycin; Drug Administration S | 2002 |
Primary prevention of diclofenac associated ulcers and dyspepsia by omeprazole or triple therapy in Helicobacter pylori positive patients: a randomised, double blind, placebo controlled, clinical trial.
Topics: Adult; Amoxicillin; Anti-Inflammatory Agents, Non-Steroidal; Anti-Ulcer Agents; Clarithromycin; Dicl | 2002 |
Efficacy of quadruple therapy with pantoprazole, bismuth, tetracycline and metronidazole as rescue treatment for Helicobacter pylori infection.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Anti-Bacterial Agents; Anti-Ulcer Agents; Benz | 2002 |
Patients have treatment preferences: a multicentre, double-blind, crossover study comparing rabeprazole and omeprazole.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Anti-Ulcer Agents; Benzimidazoles; Chi-Square | 2002 |
Effect of H. pylori status on gastric ulcer healing in patients continuing nonsteroidal anti-inflammatory therapy and receiving treatment with lansoprazole or ranitidine.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Anti-Inflammatory Agents, Non-Steroidal; Anti- | 2002 |
[Antisecretory effect of losec and pariet in peptic ulcer therapy].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Anti-Ulcer Agents; Benzimidazoles; Female; Gastric A | 2002 |
The effects of nocturnal acid breakthrough on Helicobacter pylori eradication.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agent | 2002 |
Effect of different proton pump inhibitors, differences in CYP2C19 genotype and antibiotic resistance on the eradication rate of Helicobacter pylori infection by a 1-week regimen of proton pump inhibitor, amoxicillin and clarithromycin.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer | 2003 |
Impact of clarithromycin resistance and CYP2C19 genetic polymorphism on treatment efficacy of Helicobacter pylori infection with lansoprazole- or rabeprazole-based triple therapy in Japan.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer | 2003 |
Safety and efficacy of 7-day rabeprazole- and omeprazole-based triple therapy regimens for the eradication of Helicobacter pylori in patients with documented peptic ulcer disease.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adolescent; Adult; Aged; Amoxicillin; Anti-Ulcer Agents; Be | 2003 |
Follow-up survey of a large-scale multicenter, double-blind study of triple therapy with lansoprazole, amoxicillin, and clarithromycin for eradication of Helicobacter pylori in Japanese peptic ulcer patients.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer | 2003 |
Do Japanese and Swedish peptic ulcer patients respond differently to Helicobacter pylori eradication therapies and what are their histological features?
Topics: Adult; Aged; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Asian People; Clarithromycin; Dr | 2003 |
Effect of short-term treatment with regular or high doses of omeprazole on the detection of Helicobacter pylori in bleeding peptic ulcer patients.
Topics: Anti-Ulcer Agents; Diagnostic Techniques, Digestive System; Dose-Response Relationship, Drug; Double | 2003 |
Helicobacter pylori eradication and peptic ulcer healing: the impact of deleting the proton pump inhibitor and using a once-daily treatment.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adolescent; Adult; Aged; Aged, 80 and over; Anti-Bacterial | 2003 |
[Efficacy of antihelicobacter therapy in NSAID-induced gastropathies].
Topics: Anti-Inflammatory Agents, Non-Steroidal; Anti-Ulcer Agents; Female; Helicobacter Infections; Humans; | 2003 |
[A prospective study on rabeprazole-based triple therapy for Helicobacter pylori eradication in patients with peptic ulcer].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Benz | 2003 |
Lansoprazole reduces ulcer relapse after eradication of Helicobacter pylori in nonsteroidal anti-inflammatory drug users--a randomized trial.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adolescent; Adult; Aged; Aged, 80 and over; Amoxicillin; An | 2003 |
Effect of a single oral dose of rabeprazole on nocturnal acid breakthrough and nocturnal alkaline amplitude.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Administration, Oral; Adult; Alkalies; Anti-Ulcer Agents; B | 2003 |
Eradication of Helicobacter pylori by 7-day triple-therapy regimens combining pantoprazole with clarithromycin, metronidazole, or amoxicillin in patients with peptic ulcer disease: results of two double-blind, randomized studies.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adolescent; Adult; Aged; Aged, 80 and over; Amoxicillin; An | 2003 |
Comparable Helicobacter pylori eradication rates obtained with 4- and 7-day rabeprazole-based triple therapy: a preliminary study.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Bacterial Agents; Anti-Infective Agents; Anti-Ulcer Ag | 2003 |
Sequential treatment for Helicobacter pylori does not share the risk factors of triple therapy failure.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agent | 2004 |
[Efficacy of anti-Helicobacter therapy in children with ulcer-like functional dyspepsia].
Topics: Adolescent; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Child; Clarithromycin; Drug Thera | 2003 |
Comparison of rabeprazole-based four- and seven-day triple therapy and omeprazole-based seven-day triple therapy for Helicobacter pylori infection in patients with peptic ulcer.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agent | 2003 |
Clopidogrel plus omeprazole compared with aspirin plus omeprazole for aspirin-induced symptomatic peptic ulcers/erosions with low to moderate bleeding/re-bleeding risk -- a single-blind, randomized controlled study.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anti-Ulcer Agents; Aspirin; Clopidogrel; Female; Humans; | 2004 |
Polymorphism of interleukin-1beta affects the eradication rates of Helicobacter pylori by triple therapy.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Amoxicillin; Anti-Bacterial Agents; Anti-Infective A | 2004 |
Does the 'test-and-treat' strategy work in primary health care for management of uninvestigated dyspepsia? A prospective two-year follow-up study of 1552 patients.
Topics: Adult; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Dyspepsia; Endoscopy, Gastrointestinal | 2004 |
[Clinical effectiveness of omeprazole, azithromycin and amoxicillin in ulcer healing and eradication of Helicobacter pylori infection].
Topics: Adult; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Azithromycin; Drug Therapy, Combinatio | 2003 |
Use of imidazole-based eradication regimens for Helicobacter pylori should be abandoned in North India regardless of in vitro antibiotic sensitivity.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Amoxicillin; Anti-Bacterial Agents; Anti-Infective Agents; | 2004 |
Efficacy of two rabeprazole/gatifloxacin-based triple therapies for Helicobacter pylori infection.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Amoxicillin; Anti-Infective Agents; Anti-Ulcer Agent | 2004 |
The prolongation of triple therapy for Helicobacter pylori does not allow reaching therapeutic outcome of sequential scheme: a prospective, randomised study.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Anti | 2004 |
The importance of the level of metronidazole resistance for the success of Helicobacter pylori eradication.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Bacterial Agents; Anti-Ulcer Agents; Clarithromycin; D | 2004 |
Effect of Helicobacter pylori eradication on anti-thrombotic dose aspirin-induced gastroduodenal mucosal injury.
Topics: Adult; Aged; Amoxicillin; Anti-Bacterial Agents; Anti-Inflammatory Agents, Non-Steroidal; Anti-Ulcer | 2004 |
Helicobacter pylori eradication decreases blood neutrophil and monocyte counts.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Amoxicillin; Anti-Ulcer Agents; Clarithromycin; Gastritis; | 2004 |
The influence of pretreatment on cure rates of Helicobacter pylori eradication.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Antacids; Anti-Infective Agents; Anti-Ulcer Agents; Bismuth | 2004 |
Celecoxib versus diclofenac plus omeprazole in high-risk arthritis patients: results of a randomized double-blind trial.
Topics: Adult; Aged; Arthritis; Celecoxib; Diclofenac; Double-Blind Method; Drug Therapy, Combination; Dyspe | 2004 |
Helicobacter pylori infection and the prevention of peptic ulcer with proton pump inhibitors in elderly subjects taking low-dose aspirin.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Aged; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Ben | 2004 |
The safety of proton pump inhibitors in pregnancy: a multicentre prospective controlled study.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Abnormalities, Drug-Induced; Adult; Anti-Ulcer Agents; Benz | 2005 |
Effects of killing Helicobacter pylori quadruple therapy on peptic ulcer: a randomized double-blind clinical trial.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agent | 2005 |
Sofalcone, a mucoprotective agent, increases the cure rate of Helicobacter pylori infection when combined with rabeprazole, amoxicillin and clarithromycin.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer | 2005 |
Impact of stress ulcer prophylaxis algorithm study.
Topics: Adult; Aged; Aged, 80 and over; Algorithms; Anti-Ulcer Agents; Drug Administration Schedule; Famotid | 2005 |
Efficacy of omeprazole and amoxicillin with either clarithromycin or metronidazole on eradication of Helicobacter pylori in Chinese peptic ulcer patients.
Topics: Adult; Anti-Bacterial Agents; Anti-Infective Agents; Anti-Ulcer Agents; Asian People; Clarithromycin | 2005 |
Effect of high-dose aspirin on Helicobacter pylori eradication.
Topics: Adult; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Aspirin; Chronic Disease; Clarithromyc | 2005 |
[The clinical applications of rabeprazole either alone or combined with anti-Helicobacter pylori agents in peptic ulcer patients].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adolescent; Adult; Aged; Aged, 80 and over; Anti-Bacterial | 2005 |
Preventive therapy for non-steroidal anti-inflammatory drug-induced ulcers in Japanese patients with rheumatoid arthritis: the current situation and a prospective controlled-study of the preventive effects of lansoprazole or famotidine.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Aged; Anti-Inflammatory Agents, Non-Steroidal; Anti-Ulcer A | 2005 |
High rate of Helicobacter pylori eradication with sequential therapy in elderly patients with peptic ulcer: a prospective controlled study.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Aged; Aged, 80 and over; Amoxicillin; Benzimidazoles; Clari | 2005 |
High rate of Helicobacter pylori eradication with sequential therapy in elderly patients with peptic ulcer: a prospective controlled study.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Aged; Aged, 80 and over; Amoxicillin; Benzimidazoles; Clari | 2005 |
High rate of Helicobacter pylori eradication with sequential therapy in elderly patients with peptic ulcer: a prospective controlled study.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Aged; Aged, 80 and over; Amoxicillin; Benzimidazoles; Clari | 2005 |
High rate of Helicobacter pylori eradication with sequential therapy in elderly patients with peptic ulcer: a prospective controlled study.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Aged; Aged, 80 and over; Amoxicillin; Benzimidazoles; Clari | 2005 |
Seven versus ten days of rabeprazole triple therapy for Helicobacter pylori eradication: a multicenter randomized trial.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Benz | 2005 |
Seven versus ten days of rabeprazole triple therapy for Helicobacter pylori eradication: a multicenter randomized trial.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Benz | 2005 |
Seven versus ten days of rabeprazole triple therapy for Helicobacter pylori eradication: a multicenter randomized trial.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Benz | 2005 |
Seven versus ten days of rabeprazole triple therapy for Helicobacter pylori eradication: a multicenter randomized trial.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Benz | 2005 |
Long-term follow-up after eradication of Helicobacter pylori with omeprazole, clarithromycin, and tinidazole (OCT regimen) in a Japanese population.
Topics: Adult; Anti-Bacterial Agents; Anti-Ulcer Agents; Breath Tests; Clarithromycin; Drug Therapy, Combina | 2005 |
Celecoxib compared with lansoprazole and naproxen to prevent gastrointestinal ulcer complications.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Anti-Inflammatory Agents, Non-Steroidal; Anti- | 2005 |
Should we eradicate Helicobacter pylori before prescribing an NSAID? Result of a placebo-controlled study.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Aged, 80 and over; Amoxicillin; Anti-Bacterial | 2005 |
Effectiveness of minocycline-based triple therapy for eradication of Helicobacter pylori infection.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Benz | 2006 |
[Comparison of the effectiveness of tri- and quadricomponent eradication therapy in patients with peptic ulcer].
Topics: Adult; Aged; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Clarithromycin; Drug Administrat | 2005 |
[Double blind randomized multicentre study of a seven-day eradication regime of Helicobacter pylori by omeprazole, clarithromycin and ornidazole vs. omeprazole, clarithromycin and metronidazole].
Topics: Adolescent; Adult; Aged; Anti-Bacterial Agents; Anti-Ulcer Agents; Clarithromycin; Double-Blind Meth | 2002 |
Comparison of the efficacy of rabeprazole 10 mg and omeprazole 20 mg for the healing rapidity of peptic ulcer diseases.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Anti-Ulcer Agents; Aryl Hydrocarbon Hydroxylases; Cy | 2006 |
Does delayed gastric emptying shorten the H pylori eradication period? A double blind clinical trial.
Topics: Antacids; Anti-Bacterial Agents; Anti-Infective Agents; Anti-Ulcer Agents; Bismuth; Dopamine Agents; | 2006 |
Oral health status and oral hygiene practices of patients with peptic ulcer and how these affect Helicobacter pylori eradication from the stomach.
Topics: Amoxicillin; Anti-Bacterial Agents; Anti-Infective Agents; Anti-Ulcer Agents; Clarithromycin; Drug T | 2007 |
Eradication of Helicobacter pylori does not reduce the incidence of gastroduodenal ulcers in patients on long-term NSAID treatment: double-blind, randomized, placebo-controlled trial.
Topics: Aged; Amoxicillin; Anti-Bacterial Agents; Anti-Inflammatory Agents, Non-Steroidal; Anti-Ulcer Agents | 2007 |
Clinical trial: knowledge of negative Helicobacter pylori status reduces subsequent dyspepsia-related resource use.
Topics: Adult; Alkylating Agents; Anti-Bacterial Agents; Anti-Ulcer Agents; Clarithromycin; Cost-Benefit Ana | 2007 |
Evaluation of three different proton pump inhibitors with amoxicillin and metronidazole in retreatment for Helicobacter pylori infection.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Amoxicillin; Anti-Infective Agents; Drug Therapy, Co | 2008 |
Effect of Helicobacter pylori eradication and antisecretory maintenance therapy on peptic ulcer recurrence in cirrhotic patients: a prospective, cohort 2-year follow-up study.
Topics: Aged; Anti-Bacterial Agents; Anti-Ulcer Agents; Cohort Studies; Endoscopy; Follow-Up Studies; Greece | 2008 |
[Role of anti-secretory treatment in addition to Helicobacter pylori eradication triple therapy in the treatment of peptic ulcer].
Topics: Adult; Anti-Bacterial Agents; Anti-Ulcer Agents; Drug Therapy, Combination; Female; Helicobacter Inf | 2008 |
Effect of a community screening for Helicobacter pylori: a 5-Yr follow-up study.
Topics: Adult; Amoxicillin; Anti-Ulcer Agents; Clarithromycin; Community Health Services; Cost-Benefit Analy | 2008 |
[Substituted benzimidazoles--a new dimension in ulcer therapy?].
Topics: Benzimidazoles; Clinical Trials as Topic; Dose-Response Relationship, Drug; Enzyme Inhibitors; Esoph | 1984 |
[Treatment of acute peptic gastroduodenal ulcer: omeprazole is superior to ranitidine especially in the early phase of ulcer healing. A prospective controlled randomized serial endoscopy study].
Topics: Adult; Aged; Anti-Ulcer Agents; Dose-Response Relationship, Drug; Drug Administration Schedule; Endo | 1995 |
Clinical efficacy of lansoprazole-amoxicillin treatment in eradicating Helicobacter pylori: evaluation by the polymerase chain reaction method.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Amoxicillin; Anti-Ulcer Agents; Base Sequence; Drug | 1995 |
Clinical efficacy of lansoprazole in eradication of Helicobacter pylori.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Amoxicillin; Anti-Ulcer Agents; Drug Administration | 1995 |
13C-UBT using an infrared spectrometer for detection of Helicobacter pylori and for monitoring the effects of lansoprazole.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Ulcer Agents; Breath Tests; Carbon Dioxide; Carbon Iso | 1995 |
Effects of lansoprazole with or without amoxicillin on ulcer healing: relation to eradication of Helicobacter pylori.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Amoxicillin; Anti-Ulcer Agents; Duodenal Ulcer; Gastric Jui | 1995 |
Quality of peptic ulcer healing induced by lansoprazole and roxatidine.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Aged, 80 and over; Anti-Ulcer Agents; Duodenal | 1995 |
Clinical evaluation of lansoprazole in the treatment of peptic ulcers: initial healing and prevention of relapse. Tohoku Peptic Ulcer Study Group.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Ulcer Agents; Atrophy; Duodenal Ulcer; Gastric Mucosa; | 1995 |
Lansoprazole for maintenance therapy of peptic ulcer disease: weekend full-dose or everyday half-dose administration?
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Anti-Ulcer Agents; Drug Administration Schedule; Duo | 1995 |
The effect of lansoprazole treatment on the healing and relapse of peptic ulcer and serum levels of IgG anti-Helicobacter pylori antibody.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Aged, 80 and over; Anti-Ulcer Agents; Antibodi | 1995 |
Effect of lansoprazole on peptic ulcers.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Ulcer Agents; Duodenal Ulcer; Female; Helicobacter Inf | 1995 |
Therapeutic effects of lansoprazole on peptic ulcers in elderly patients.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Aged; Aged, 80 and over; Amoxicillin; Ampicillin; Anti-Ulce | 1995 |
Peptic ulcer therapy with lansoprazole and Helicobacter pylori eradication.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Ulcer Agents; Duodenal Ulcer; Helicobacter Infections; | 1995 |
Treatment of Helicobacter pylori infection with omeprazole-amoxicillin combination therapy versus ranitidine/sodium bicarbonate-amoxicillin.
Topics: Amoxicillin; Biopsy; Drug Administration Schedule; Drug Therapy, Combination; Female; Gastric Mucosa | 1995 |
Proton pump inhibitors for Helicobacter pylori eradication in patients with peptic ulcer.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Anti-Ulcer Agents; Biopsy; Endoscopy, Digestive Syst | 1995 |
Pharmacological effects of metronidazole+tetracycline+bismuth subcitrate versus omeprazole+amoxycillin+bismuth subcitrate in Helicobacter pylori-related gastritis and peptic ulcer disease.
Topics: Adult; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Double-Blind Method; Drug Therapy, Com | 1994 |
Effect of plaunotol on hypergastrinemia induced by long-term omeprazole administration in humans.
Topics: Adult; Aged; Anti-Ulcer Agents; Diterpenes; Fatty Alcohols; Female; Gastrins; Gastrointestinal Hormo | 1995 |
One-week low-dose triple therapy for the eradication of Helicobacter pylori infection.
Topics: Adult; Aged; Aged, 80 and over; Clarithromycin; Drug Administration Schedule; Drug Therapy, Combinat | 1995 |
Effect of acid suppression on efficacy of treatment for Helicobacter pylori infection.
Topics: Adult; Aged; Anti-Ulcer Agents; Drug Administration Schedule; Drug Therapy, Combination; Female; Hel | 1995 |
Causal role of Helicobacter pylori in peptic ulcer relapse.
Topics: Aged; Amoxicillin; Bismuth; Chi-Square Distribution; Drug Therapy, Combination; Gastric Mucosa; Heli | 1994 |
Omeprazole 40 mg o.m. combined with amoxycillin alone or with amoxycillin and metronidazole in the eradication of Helicobacter pylori.
Topics: Adult; Aged; Amoxicillin; Double-Blind Method; Drug Therapy, Combination; Female; Follow-Up Studies; | 1994 |
[Reduced ex vivo production of superoxide anion by polymorphonuclear leukocytes during therapy with omeprazole. A pharmacological effect?].
Topics: Adult; Esophagitis, Peptic; Female; Humans; Male; Middle Aged; Neutrophils; Omeprazole; Peptic Ulcer | 1994 |
Serum gastrin levels following administration of omeprazole alone or in combination with pirenzepine.
Topics: Drug Therapy, Combination; Duodenal Ulcer; Gastrins; Humans; Omeprazole; Peptic Ulcer; Pirenzepine; | 1994 |
[24-hour gastric pH profile with 2 x 20 mg and 2 x 40 mg omeprazole in patients with Helicobacter pylori-associated gastroduodenal ulcer disease].
Topics: Adult; Aged; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Gastric Acidity | 1994 |
Short report: omeprazole-tetracycline combinations are inadequate as therapy for Helicobacter pylori infection.
Topics: Adult; Aged; Aged, 80 and over; Bismuth; Dose-Response Relationship, Drug; Drug Therapy, Combination | 1994 |
[Omeprazole/amoxicillin: impaired eradication of Helicobacter pylori in smoking but not in premedication with omeprazole].
Topics: Adult; Aged; Amoxicillin; Drug Therapy, Combination; Female; Helicobacter Infections; Helicobacter p | 1994 |
Long-term therapy with pantoprazole in patients with peptic ulceration resistant to extended high-dose ranitidine treatment.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Benzimidazoles; Duodenal Ulcer; Enterochromaffin Cells; Eso | 1994 |
[Omeprazole modified antibiotic therapy of Helicobacter pylori infection: can clarithromycin be replaced by roxithromycin?].
Topics: Adult; Aged; Aged, 80 and over; Clarithromycin; Drug Therapy, Combination; Dyspepsia; Female; Helico | 1994 |
Medium-term results of oral and intravenous omeprazole/amoxicillin Helicobacter pylori eradication therapy.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Amoxicillin; Breath Tests; Drug Administration | 1994 |
Omeprazole ameliorates aspirin-induced gastroduodenal injury.
Topics: Adult; Aspirin; Double-Blind Method; Duodenum; Female; Gastric Mucosa; Humans; Male; Omeprazole; Pep | 1994 |
Duodenal bacterial overgrowth during treatment in outpatients with omeprazole.
Topics: Adult; Aged; Aged, 80 and over; Bacteria; Duodenum; Female; Humans; Intestinal Secretions; Male; Mid | 1994 |
An open trial of long-term therapy with lansoprazole in patients with peptic ulceration resistant to extended high-dose ranitidine treatment.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Ulcer Agents; Dose-Response Relationship, Drug; Drug A | 1993 |
Cure of Helicobacter pylori infection: role of duration of treatment with omeprazole and amoxicillin.
Topics: Adult; Aged; Amoxicillin; Anti-Bacterial Agents; Drug Therapy, Combination; Female; Gastric Mucosa; | 1996 |
Efficacy and optimum dose of omeprazole in a new 1-week triple therapy regimen to eradicate Helicobacter pylori.
Topics: Adult; Aged; Anti-Bacterial Agents; Anti-Ulcer Agents; Biopsy; Clarithromycin; Drug Resistance, Micr | 1995 |
Omeprazole-based antimicrobial therapies: results in 198 Helicobacter pylori-positive patients.
Topics: Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Biopsy; Clarithromycin; Drug Therapy, Combina | 1995 |
Dual therapy with lansoprazole and clarithromycin for eradication of Helicobacter pylori.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Bacterial Agents; Anti-Ulcer Agents; Biopsy; Clarithro | 1995 |
Effect of Helicobacter pylori eradication on the healing and recurrence of peptic ulcer: combination therapy with low-dose omeprazole and clarithromycin.
Topics: Adult; Anti-Bacterial Agents; Anti-Ulcer Agents; Biopsy; Clarithromycin; Drug Therapy, Combination; | 1995 |
Lansoprazole capsules and amoxicillin oral suspension in the treatment of peptic ulcer disease.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Administration, Oral; Amoxicillin; Anti-Ulcer Agents; Capsu | 1995 |
Effects of pirenzepine on omeprazole-induced hypergastrinemia and acid suppression in peptic ulcer patients.
Topics: Adult; Aged; Anti-Ulcer Agents; Drug Therapy, Combination; Duodenal Ulcer; Female; Gastric Acid; Gas | 1996 |
Treatment of Helicobacter pylori infection with low or high dose omeprazole combined with amoxycillin and the effect of early retreatment.
Topics: Adolescent; Adult; Aged; Amoxicillin; Anti-Ulcer Agents; Double-Blind Method; Drug Therapy, Combinat | 1996 |
Quadruple therapy compared with dual therapy for eradication of Helicobacter pylori in ulcer patients: results of a randomized prospective single-centre study.
Topics: Adult; Aged; Aged, 80 and over; Amoxicillin; Antacids; Anti-Bacterial Agents; Anti-Ulcer Agents; Ant | 1995 |
Only four days of quadruple therapy can effectively cure Helicobacter pylori infection.
Topics: Adult; Aged; Aged, 80 and over; Antacids; Anti-Bacterial Agents; Anti-Ulcer Agents; Bismuth; Drug Th | 1995 |
Misoprostol and omeprazole in the prevention of chemotherapy-induced acute gastroduodenal mucosal injury. A randomized, placebo-controlled pilot study.
Topics: Adult; Aged; Anti-Ulcer Agents; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Female; F | 1996 |
One-week triple therapy with omeprazole, amoxycillin and clarithromycin for treatment of Helicobacter pylori infection.
Topics: Adult; Aged; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Clarithromycin; Drug Administrat | 1996 |
Long-term follow-up after cure of Helicobacter pylori infection with 4 days of quadruple therapy.
Topics: Adult; Anti-Bacterial Agents; Anti-Ulcer Agents; Bismuth; Drug Therapy, Combination; Dyspepsia; Heli | 1996 |
Prevention of peptic ulcer and dyspeptic symptoms with omeprazole in patients receiving continuous non-steroidal anti-inflammatory drug therapy. A Nordic multicentre study.
Topics: Adult; Aged; Anti-Inflammatory Agents, Non-Steroidal; Anti-Ulcer Agents; Double-Blind Method; Dyspep | 1996 |
Role of Helicobacter pylori in ulcer healing and recurrence of gastric and duodenal ulcers in longterm NSAID users. Response to omeprazole dual therapy.
Topics: Amoxicillin; Anti-Inflammatory Agents, Non-Steroidal; Anti-Ulcer Agents; Arthritis; Drug Therapy, Co | 1996 |
Bacterial overgrowth during treatment with omeprazole compared with cimetidine: a prospective randomised double blind study.
Topics: Adult; Aged; Anti-Ulcer Agents; Bacteria; Cimetidine; Double-Blind Method; Duodenum; Female; Humans; | 1996 |
Therapeutic options after failed Helicobacter pylori eradication therapy.
Topics: Adult; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Clarithromycin; Drug Therapy, Combinat | 1996 |
Omeprazole plus amoxicillin versus triple therapy eradicates Helicobacter pylori in the Chinese with peptic ulcer disease.
Topics: Adult; Aged; Amoxicillin; Anti-Ulcer Agents; Drug Therapy, Combination; Female; Helicobacter pylori; | 1996 |
Randomised controlled trial of ranitidine versus omeprazole in combination with antibiotics for eradication of Helicobacter pylori.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anti-Bacterial Agents; Anti-Ulcer Agents; Drug Resistanc | 1996 |
Omeprazole, amoxicillin and bismuth for peptic ulcer healing and Helicobacter pylori eradication.
Topics: Adult; Amoxicillin; Anti-Ulcer Agents; Drug Interactions; Drug Therapy, Combination; Female; Helicob | 1997 |
One-day intensified lansoprazole-quadruple therapy for cure of Helicobacter pylori infection.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Aged, 80 and over; Anti-Bacterial Agents; Anti | 1997 |
Transforming growth factor-alpha (TGF-alpha) levels in human proximal gastrointestinal epithelium. Effect of mucosal injury and acid inhibition.
Topics: Adult; Anti-Inflammatory Agents, Non-Steroidal; Anti-Ulcer Agents; Aspirin; Biopsy, Needle; Cimetidi | 1997 |
Immediate repeat course of amoxycillin, metronidazole and omeprazole to eradicate Helicobacter pylori.
Topics: Adult; Aged; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Drug Therapy, Combination; Femal | 1997 |
Randomized study comparing omeprazole plus amoxycillin versus omeprazole plus clarithromycin for eradication of Helicobacter pylori.
Topics: Adolescent; Adult; Aged; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Clarithromycin; Drug | 1997 |
Does pretreatment with omeprazole decrease the chance of eradication of Helicobacter pylori in peptic ulcer patients?
Topics: Adult; Aged; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Drug Administration Schedule; Fe | 1997 |
Omeprazole-based dual and triple regimens for Helicobacter pylori eradication in children.
Topics: Adolescent; Adult; Anti-Bacterial Agents; Anti-Ulcer Agents; Antibodies, Bacterial; Biopsy; Child; C | 1997 |
[Studies on the protective effect of lansoprazole on human gastric mucosa against low-dose acetylsalicylic acid. An endoscopic controlled double-blind study].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Anti-Ulcer Agents; Aspirin; Double-Blind Method; Duo | 1997 |
Bismuth subsalicylate instead of metronidazole with lansoprazole and clarithromycin for Helicobacter pylori infection: a randomized trial.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Abdominal Pain; Anti-Bacterial Agents; Anti-Ulcer Agents; B | 1997 |
Omeprazole plus clarithromycin and either tinidazole or tetracycline for Helicobacter pylori infection: a randomized prospective study.
Topics: Adolescent; Adult; Aged; Anti-Bacterial Agents; Anti-Ulcer Agents; Clarithromycin; Drug Therapy, Com | 1997 |
Pantoprazole versus omeprazole in one-week low-dose triple therapy for curve of H. pylori infection.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Bacterial Agents; Anti-Ulcer Agents; Benzimidazoles; C | 1997 |
Quadruple therapy: the golden bullet or a drug too far?
Topics: Antacids; Drug Therapy, Combination; Enzyme Inhibitors; Famotidine; Helicobacter Infections; Helicob | 1996 |
Effectiveness of quadruple therapy using lansoprazole, instead of omeprazole, in curing Helicobacter pylori infection.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Antacids; Anti-Ulcer Agents; Bacterial Protein | 1996 |
One week triple therapy for Helicobacter pylori: does high-dose clarithromycin confer additional benefit?
Topics: Adult; Aged; Aged, 80 and over; Anti-Bacterial Agents; Anti-Ulcer Agents; Antitrichomonal Agents; Cl | 1997 |
A prospective randomized comparative trial showing that omeprazole prevents rebleeding in patients with bleeding peptic ulcer after successful endoscopic therapy.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anti-Ulcer Agents; Blood Transfusion; Cimetidine; Female | 1998 |
Are we correctly using the inhibitors of gastric acid secretion and cytoprotective drugs? Results of a multicentre study.
Topics: Acute Disease; Anti-Ulcer Agents; Cohort Studies; Cytoprotection; Drug Prescriptions; Drug Utilizati | 1997 |
Does Helicobacter pylori eradication depend on the period of amoxicillin treatment? A retrospective study.
Topics: Adult; Aged; Aged, 80 and over; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Diterpenes; D | 1998 |
Augmented eradication rates of Helicobacter pylori by new combination therapy with lansoprazole, amoxicillin, and rebamipide.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Alanine; Amoxicillin; Anti-Infective Agents; A | 1998 |
Lansoprazole elevates the ratio of serum pepsinogen I v.s. pepsinogen II.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Anti-Ulcer Agents; Helicobacter Infections; He | 1997 |
Eradicating Helicobacter pylori reduces hypergastrinaemia during long-term omeprazole treatment.
Topics: Adult; Alginates; Aluminum Hydroxide; Amoxicillin; Antacids; Anti-Ulcer Agents; Drug Combinations; D | 1998 |
Lansoprazole, amoxicillin, and clarithromycin triple therapy in vagotomized patients with dyspeptic complaints. A randomized, double-blind, placebo-controlled, clinical study without pretreatment diagnostic upper endoscopy.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer | 1998 |
Lansoprazole triple therapy for Helicobacter pylori--is 5 days enough?
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adolescent; Adult; Aged; Aged, 80 and over; Anti-Bacterial | 1998 |
Bismuth-containing single-antibiotic 1-week triple therapy for Helicobacter pylori eradication.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Abdominal Pain; Adolescent; Adult; Aged; Aged, 80 and over; | 1998 |
New data on healing of nonsteroidal anti-inflammatory drug-associated ulcers and erosions. Omeprazole NSAID Steering Committee.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Anti-Ulcer Agents; Humans; Multicenter Studies as Topic; Om | 1998 |
One-week proton pump inhibitor-based triple therapy eradicates residual Helicobacter pylori after failed dual therapy.
Topics: Adult; Ampicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Clarithromycin; Drug Resistance, Microb | 1998 |
Prevention of gastroduodenal damage with omeprazole in patients receiving continuous NSAIDs treatment. A double blind placebo controlled study.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Anti-Ulcer Agents; Diclofenac; Double-Blind Method; Endosco | 1998 |
[The action of the proton pump inhibitor pantoprazol against acetylsalicylic acid-induced gastroduodenopathy in comparison to ranitidine. An endoscopic controlled, double blind comparison].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Anti-Ulcer Agents; Aspirin; Benzimidazoles; Cyclooxy | 1998 |
Two-day quadruple therapy for cure of Helicobacter pylori infection: a comparative, randomized trial.
Topics: Adolescent; Adult; Aged; Amoxicillin; Anti-Ulcer Agents; Bismuth; Drug Administration Schedule; Fema | 1998 |
Omeprazole 20 or 40 mg daily for healing gastroduodenal ulcers in patients receiving non-steroidal anti-inflammatory drugs.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Anti-Ulcer Agents; Double-Blind Method; Endoscopy, Gastroin | 1998 |
Dose-response relationship of lansoprazole to gastric acid antisecretory effects.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Administration, Oral; Adult; Anti-Ulcer Agents; Cross-Over | 1998 |
[Eradication therapies for Helicobacter pylori].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer | 1998 |
Factors influencing Helicobacter pylori eradication with 2 week combination therapy of lansoprazole and amoxycillin: intragastric distribution of colonization and gastric mucosal atrophy.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Amoxicillin; Anti-Bacterial Agents; Drug Administration Sch | 1998 |
Lansoprazole quadruple therapy is effective in curing Helicobacter pylori infection.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Aged, 80 and over; Anti-Bacterial Agents; Anti | 1998 |
Cure of H. pylori infection using a 7-day triple therapy combining pantoprazole with two antibiotics.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adolescent; Adult; Aged; Amoxicillin; Anti-Bacterial Agents | 1998 |
Effect of rebamipide on Helicobacter pylori infection in patients with peptic ulcer.
Topics: Adult; Aged; Alanine; Amoxicillin; Anti-Ulcer Agents; Drug Therapy, Combination; Duodenal Ulcer; Fem | 1998 |
Randomised controlled trial of Helicobacter pylori eradication in patients on non-steroidal anti-inflammatory drugs: HELP NSAIDs study. Helicobacter Eradication for Lesion Prevention.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Amoxicillin; Anti-Inflammatory Agents, Non-Steroidal; Cl | 1998 |
Helicobacter pylori eradication and ulcer healing with daily lansoprazole, plus 1 or 2 weeks co-therapy with amoxycillin and clarithromycin.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adolescent; Adult; Aged; Amoxicillin; Anti-Bacterial Agents | 1998 |
Safety and efficacy of rabeprazole in combination with four antibiotic regimens for the eradication of Helicobacter pylori in patients with chronic gastritis with or without peptic ulceration.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Amoxicillin; Anti-Ulcer Agents; Benzimidazoles; Clarithromy | 1998 |
A new quadruple therapy for the eradication of Helicobacter pylori. Effect of pretreatment with omeprazole on the cure rate.
Topics: Adult; Aged; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Drug Therapy, Combination; Dyspe | 1998 |
Dual versus triple therapy: comparison of five antibiotic regimens for eradication of Helicobacter pylori in a prospective, randomized study.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anti-Bacterial Agents; Anti-Ulcer Agents; Dose-Response | 1998 |
Triple regimens using lansoprazole or ranitidine bismuth citrate for Helicobacter pylori eradication.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adolescent; Adult; Aged; Anti-Ulcer Agents; Clarithromycin; | 1998 |
Preliminary study on a novel quadruple eradication therapy with a mucoprotective drug, sofalcone, for Helicobacter pylori infection.
Topics: Adolescent; Adult; Aged; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Chalcone; Chalcones; | 1998 |
Double-blind comparison [correction of Double-blind, placebo-controlled comparison] of rabeprazole 20 mg vs. omeprazole 20 mg in the treatment of erosive or ulcerative gastro-oesophageal reflux disease. The European Rabeprazole Study Group.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Aged, 80 and over; Anti-Ulcer Agents; Benzimid | 1999 |
[Recurrence rate of H. pylori after successful eradication and second eradication therapy after initial failure of treatment].
Topics: Amoxicillin; Anti-Ulcer Agents; Clarithromycin; Drug Therapy, Combination; Follow-Up Studies; Helico | 1999 |
[Evaluation of the efficacy and the cost-effectiveness of proton pump inhibitor-based dual and triple therapy regimens for H. pylori eradication in peptic ulcer disease].
Topics: Amoxicillin; Anti-Ulcer Agents; Clarithromycin; Cost-Benefit Analysis; Drug Evaluation; Drug Therapy | 1999 |
[Four kinds of new triple therapy regiments for Helicobacter pylori eradication in patients with peptic ulcer].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Amoxicillin; Anti-Ulcer Agents; Clarithromycin | 1999 |
[A comparative study; one week treatment versus two weeks treatment with lansoprazol, amoxycillin and clarythromycin for the eradication of Helicobacter pylori in patient with gastric and duodenal ulcer].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Amoxicillin; Anti-Ulcer Agents; Clarithromycin; Drug Admini | 1999 |
[Triple therapy regimens involving H2 blockaders for therapy of Helicobacter pylori infections].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Aged, 80 and over; Anti-Bacterial Agents; Anti | 1999 |
Reliability of the omeprazole hydroxylation index for CYP2C19 phenotyping: possible effect of age, liver disease and length of therapy.
Topics: Adult; Age Factors; Aryl Hydrocarbon Hydroxylases; Cytochrome P-450 CYP2C19; Cytochrome P-450 Enzyme | 1999 |
Efficacy of 1 week omeprazole or lansoprazole-amoxycillin-clarithromycin therapy for Helicobacter pylori infection in the Japanese population.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Clar | 1999 |
Helicobacter pylori as a possible bacterial focus of chronic urticaria.
Topics: Adult; Amoxicillin; Anti-Ulcer Agents; Chronic Disease; Drug Therapy, Combination; Female; Gastritis | 1999 |
Efficacy of 7 day lansoprazole-based triple therapy for Helicobacter pylori infection in elderly patients.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Aged; Aged, 80 and over; Amoxicillin; Antibodies, Bacterial | 1999 |
Short-term triple therapy with lansoprazole 30 mg or 60 mg, amoxycillin and clarithromycin to eradicate Helicobacter pylori.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adolescent; Adult; Aged; Aged, 80 and over; Amoxicillin; An | 1999 |
Comparison of two 3-day Helicobacter pylori eradication regimens with a standard 1-week regimen.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Aged, 80 and over; Amoxicillin; Anti-Bacterial | 1999 |
Randomized trial of omeprazole and clarithromycin combined with either metronidazole or amoxycillin in patients with metronidazole-resistant or -susceptible Helicobacter pylori strains.
Topics: Adolescent; Adult; Aged; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Clarithromycin; Drug | 1999 |
Prevalence of resistance to clarithromycin and its clinical impact on the efficacy of Helicobacter pylori eradication.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Aged, 80 and over; Amoxicillin; Anti-Bacterial | 1999 |
Helicobacter treatment with quadruple therapy in primary health care for patients with a history of ulcer disease.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Anti-Bacterial Agents; Drug Therapy, Combinati | 1999 |
Quadruple therapy is effective for eradicating Helicobacter pylori after failure of triple proton-pump inhibitor-based therapy: a detailed, prospective analysis of 21 consecutive cases.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Anti-Bacterial Agents; Clarithromycin; Drug Re | 1999 |
Eradication of Helicobacter pylori using 30 mg or 60 mg lansoprazole combined with amoxicillin and metronidazole: one and two weeks of a new triple therapy.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer | 1999 |
Comparison of 1-week and 2-week triple therapy with omeprazole, amoxicillin, and clarithromycin in peptic ulcer patients with Helicobacter pylori infection: results of a randomized controlled trial.
Topics: Adolescent; Adult; Aged; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Clarithromycin; Drug | 1999 |
Effect of Helicobacter pylori eradication on peptic ulcer disease complicated with outlet obstruction.
Topics: Administration, Oral; Adult; Aged; Anti-Bacterial Agents; Anti-Ulcer Agents; Bismuth; Drug Therapy, | 2000 |
Importance of Helicobacter pylori cagA and vacA status for the efficacy of antibiotic treatment.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Aged, 80 and over; Anti-Bacterial Agents; Anti | 2000 |
Effect of ornidazole and clarithromycin resistance on eradication of Helicobacter pylori in peptic ulcer disease.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adolescent; Adult; Aged; Amoxicillin; Anti-Bacterial Agents | 2000 |
Pharmacokinetics of clarithromycin in Helicobacter pylori eradication therapy in patients with liver cirrhosis.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Aged; Anti-Bacterial Agents; Anti-Ulcer Agents; Clarithromy | 2000 |
Eradication of Helicobacter pylori with lansoprazole based triple therapy in peptic ulcer disease.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Aged, 80 and over; Amoxicillin; Antitrichomona | 2000 |
[Effectiveness of omeprazole, clarithromycin and amoxycillin therapy to eradicate Helicobacter pylori in patients with active peptic ulcer. Preliminary results of GENPY study].
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; C | 2000 |
Effect of population screening and treatment for Helicobacter pylori on dyspepsia and quality of life in the community: a randomised controlled trial. Leeds HELP Study Group.
Topics: Adult; Anti-Ulcer Agents; Clarithromycin; Double-Blind Method; Drug Therapy, Combination; Dyspepsia; | 2000 |
Effect of intravenous omeprazole on recurrent bleeding after endoscopic treatment of bleeding peptic ulcers.
Topics: Aged; Anti-Ulcer Agents; Combined Modality Therapy; Double-Blind Method; Electrocoagulation; Endosco | 2000 |
Intravenous eradication therapy for bleeding gastroduodenal ulcer associated with Helicobacter pylori infection.
Topics: Adult; Aged; Ampicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Drug Administration Schedule; Fem | 2000 |
[Triple therapy of short-term with azithromycin, amoxycillin and omeprazole for the eradication of Helicobacter pylori].
Topics: Amoxicillin; Anti-Ulcer Agents; Azithromycin; Drug Administration Schedule; Drug Therapy, Combinatio | 2000 |
Changes in Helicobacter pylori-induced gastritis in the antrum and corpus during long-term acid-suppressive treatment in Japan.
Topics: Anti-Ulcer Agents; Enzyme Inhibitors; Famotidine; Gastric Mucosa; Gastritis; Gastroscopy; Helicobact | 2000 |
Influence of Helicobacter pylori eradication therapy on 13C aminopyrine breath test: comparison among omeprazole-, lansoprazole-, or pantoprazole-containing regimens.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Aminopyrine; Anti-Ulcer Agents; Benzimidazoles | 2000 |
Identifying responders to acid suppression in dyspepsia using a random starting day trial.
Topics: Adult; Aged; Anti-Ulcer Agents; Drug Administration Schedule; Dyspepsia; Female; Gastroesophageal Re | 2000 |
Eradication of Helicobacter pylori prevents ulcer development in patients with ulcer-like functional dyspepsia.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Aged, 80 and over; Anti-Ulcer Agents; Double-B | 2001 |
Eradication of Helicobacter pylori prevents ulcer development in patients with ulcer-like functional dyspepsia.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Aged, 80 and over; Anti-Ulcer Agents; Double-B | 2001 |
Eradication of Helicobacter pylori prevents ulcer development in patients with ulcer-like functional dyspepsia.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Aged, 80 and over; Anti-Ulcer Agents; Double-B | 2001 |
Eradication of Helicobacter pylori prevents ulcer development in patients with ulcer-like functional dyspepsia.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Aged, 80 and over; Anti-Ulcer Agents; Double-B | 2001 |
Eradication of Helicobacter pylori prevents ulcer development in patients with ulcer-like functional dyspepsia.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Aged, 80 and over; Anti-Ulcer Agents; Double-B | 2001 |
Eradication of Helicobacter pylori prevents ulcer development in patients with ulcer-like functional dyspepsia.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Aged, 80 and over; Anti-Ulcer Agents; Double-B | 2001 |
Eradication of Helicobacter pylori prevents ulcer development in patients with ulcer-like functional dyspepsia.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Aged, 80 and over; Anti-Ulcer Agents; Double-B | 2001 |
Eradication of Helicobacter pylori prevents ulcer development in patients with ulcer-like functional dyspepsia.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Aged, 80 and over; Anti-Ulcer Agents; Double-B | 2001 |
Eradication of Helicobacter pylori prevents ulcer development in patients with ulcer-like functional dyspepsia.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Aged, 80 and over; Anti-Ulcer Agents; Double-B | 2001 |
Eradication of Helicobacter pylori prevents ulcer development in patients with ulcer-like functional dyspepsia.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Aged, 80 and over; Anti-Ulcer Agents; Double-B | 2001 |
Eradication of Helicobacter pylori prevents ulcer development in patients with ulcer-like functional dyspepsia.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Aged, 80 and over; Anti-Ulcer Agents; Double-B | 2001 |
Eradication of Helicobacter pylori prevents ulcer development in patients with ulcer-like functional dyspepsia.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Aged, 80 and over; Anti-Ulcer Agents; Double-B | 2001 |
Eradication of Helicobacter pylori prevents ulcer development in patients with ulcer-like functional dyspepsia.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Aged, 80 and over; Anti-Ulcer Agents; Double-B | 2001 |
Eradication of Helicobacter pylori prevents ulcer development in patients with ulcer-like functional dyspepsia.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Aged, 80 and over; Anti-Ulcer Agents; Double-B | 2001 |
Eradication of Helicobacter pylori prevents ulcer development in patients with ulcer-like functional dyspepsia.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Aged, 80 and over; Anti-Ulcer Agents; Double-B | 2001 |
Eradication of Helicobacter pylori prevents ulcer development in patients with ulcer-like functional dyspepsia.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Aged, 80 and over; Anti-Ulcer Agents; Double-B | 2001 |
Comparison of the efficacy and safety of different formulations of omeprazole-based triple therapies in the treatment of Helicobacter pylori-positive peptic ulcer.
Topics: Adult; Amoxicillin; Anti-Bacterial Agents; Capsules; Clarithromycin; Drug Therapy, Combination; Fema | 2001 |
A randomized, pharmacokinetic and pharmacodynamic, cross-over study of duodenal or jejunal administration compared to nasogastric administration of omeprazole suspension in patients at risk for stress ulcers.
Topics: Adult; Anti-Ulcer Agents; Critical Illness; Cross-Over Studies; Duodenum; Female; Humans; Intubation | 2001 |
Comparison of two regimens on eradication of Helicobacter pylori.
Topics: Amoxicillin; Clarithromycin; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Th | 2000 |
The effect of culture results for Helicobacter pylori on the choice of treatment following failure of initial eradication.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Aged; Amoxicillin; Antacids; Anti-Bacterial Agents; Anti-Ul | 2001 |
Pantoprazole therapy in the long-term management of severe acid peptic disease: clinical efficacy, safety, serum gastrin, gastric histology, and endocrine cell studies.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adolescent; Adult; Aged; Anti-Ulcer Agents; Benzimidazoles; | 2001 |
Modified seven-day, quadruple therapy as a first line Helicobacter pylori treatment.
Topics: Administration, Oral; Adult; Aged; Anti-Bacterial Agents; Anti-Ulcer Agents; Drug Administration Sch | 2001 |
A randomized open trial for comparison of proton pump inhibitors, omeprazole versus rabeprazole, in dual therapy for Helicobacter pylori infection in relation to CYP2C19 genetic polymorphism.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Amoxicillin; Anti-Ulcer Agents; Benzimidazoles | 2001 |
Effect of intravenous omeprazole on recurrent bleeding after endoscopic treatment of bleeding peptic ulcers.
Topics: Aged; Double-Blind Method; Endoscopy, Digestive System; Epinephrine; Female; Humans; Hyperthermia, I | 2001 |
[Optimization of the anti-Helicobacter therapy of peptic ulcer on the basis of modern methods of pharmacokinetic analysis].
Topics: Anti-Bacterial Agents; Anti-Ulcer Agents; Drug Monitoring; Drug Therapy, Combination; Female; Helico | 2000 |
Famotidine versus omeprazole, in combination with amoxycillin and tinidazole, for eradication of Helicobacter pylori infection.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Amoxicillin; Anti-Bacterial Agents; Drug Therapy, Combin | 2001 |
Intragastric distribution of Helicobacter pylori during short-term omeprazole therapy: study using Carnoy's fixation and immunohistochemistry for detection of bacteria.
Topics: Acetic Acid; Adult; Aged; Aged, 80 and over; Anti-Ulcer Agents; Chloroform; Ethanol; Female; Gastric | 2001 |
Intravenous omeprazole in critically ill patients: a randomized, crossover study comparing 40 with 80 mg plus 8 mg/hour on intragastric pH.
Topics: Adult; Critical Illness; Cross-Over Studies; Dose-Response Relationship, Drug; Enzyme Inhibitors; Fe | 2001 |
A multicenter, double-blind study on triple therapy with lansoprazole, amoxicillin and clarithromycin for eradication of Helicobacter pylori in Japanese peptic ulcer patients.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agent | 2001 |
Clinical outcome and influencing factors of a new short-term quadruple therapy for Helicobacter pylori eradication: a randomized controlled trial (MACLOR study).
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer | 2002 |
Eradication of Helicobacter pylori and risk of peptic ulcers in patients starting long-term treatment with non-steroidal anti-inflammatory drugs: a randomised trial.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Anti-Ulcer Agents; Arthritis; Delayed-Action Preparations; | 2002 |
The cost-effectiveness of population Helicobacter pylori screening and treatment: a Markov model using economic data from a randomized controlled trial.
Topics: Adult; Anti-Bacterial Agents; Clarithromycin; Cost-Benefit Analysis; Dyspepsia; Female; Health Care | 2002 |
Relation between alcohol consumption and the success of Helicobacter pylori eradication therapy using omeprazole, clarithromycin and amoxicillin for 1 week.
Topics: Adult; Aged; Alcohol Drinking; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Clarithromycin | 2002 |
Lansoprazole for the prevention of recurrences of ulcer complications from long-term low-dose aspirin use.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Aged; Anti-Inflammatory Agents, Non-Steroidal; Anti-Ulcer A | 2002 |
Lansoprazole. A review of its pharmacodynamic and pharmacokinetic properties and its therapeutic efficacy in acid-related disorders.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Ulcer Agents; Biological Availability; Duodenal Ulcer; | 1992 |
The potential clinical role of intravenous omeprazole.
Topics: Critical Illness; Decision Trees; Female; Gastric Acidity Determination; Gastrointestinal Hemorrhage | 1992 |
Two weeks treatment with amoxicillin/omeprazole for eradication of Helicobacter pylori.
Topics: Amoxicillin; Biopsy; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Therapy, C | 1992 |
[Short-term therapy with high dosage omeprazole and amoxicillin for Helicobacter pylori eradication. A pilot study].
Topics: Amoxicillin; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Therapy, Combinati | 1992 |
Treatment of refractory peptic ulcer with omeprazole or continued H2 receptor antagonists: a controlled clinical trial.
Topics: Cimetidine; Double-Blind Method; Duodenal Ulcer; Female; Histamine H2 Antagonists; Humans; Male; Mid | 1991 |
H2-receptor antagonist-refractory ulcer: its pathophysiology and treatment.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Ulcer Agents; Dinoprostone; Female; Gastric Mucosa; Hi | 1991 |
Nocturnal intragastric acidity during and after a period of dosing with either ranitidine or omeprazole.
Topics: Adult; Circadian Rhythm; Double-Blind Method; Gastric Acid; Gastric Mucosa; Humans; Hydrogen-Ion Con | 1991 |
The clinical safety of omeprazole.
Topics: Humans; Omeprazole; Peptic Ulcer; Product Surveillance, Postmarketing; Zollinger-Ellison Syndrome | 1990 |
Omeprazole.
Topics: Animals; Carcinoid Tumor; Clinical Trials as Topic; Gastric Acid; Gastroesophageal Reflux; Humans; O | 1990 |
Treatment of peptic ulcer in general practice and in hospital: a comparison of omeprazole and cimetidine.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Cimetidine; Double-Blind Method; Family Practice; Female | 1990 |
Clinical experience with omeprazole: assessment of efficacy and safety.
Topics: Duodenal Ulcer; Esophagitis, Peptic; Humans; Omeprazole; Peptic Ulcer; Stomach Ulcer; Zollinger-Elli | 1989 |
Qualitative studies of gastric endocrine cells in patients treated long-term with omeprazole.
Topics: Biopsy; Carcinoid Tumor; Cell Division; Cell Transformation, Neoplastic; Enterochromaffin Cells; Eso | 1989 |
[Is strong inhibition of gastric acid in the treatment of peptic ulcer sensible?].
Topics: Cimetidine; Clinical Trials as Topic; Double-Blind Method; Gastric Acid; Histamine H2 Antagonists; H | 1989 |
Omeprazole in acute and long-term treatment of Asian patients with peptic ulcer refractory to H2-antagonists.
Topics: Adult; Aged; Drug Evaluation; Duodenal Ulcer; Female; Histamine H2 Antagonists; Humans; Male; Middle | 1989 |
The clinical safety of omeprazole.
Topics: Cimetidine; Clinical Trials as Topic; Esophagitis, Peptic; Humans; Liver Function Tests; Omeprazole; | 1989 |
[Omeprazole in the therapy of acid-induced diseases].
Topics: Clinical Trials as Topic; Dose-Response Relationship, Drug; Double-Blind Method; Duodenal Ulcer; Eso | 1987 |
Treatment of acid-peptic diseases by inhibition of gastric H+,K+-ATPase.
Topics: Adenosine Triphosphatases; Anti-Ulcer Agents; Benzimidazoles; Clinical Trials as Topic; Duodenal Ulc | 1986 |
[Drug therapy of peptic ulcer. What is coming up?].
Topics: Alprostadil; Anti-Ulcer Agents; Cimetidine; Clinical Trials as Topic; Double-Blind Method; Drug Admi | 1987 |
[Omeprazole].
Topics: Chemical Phenomena; Chemistry; Clinical Trials as Topic; Dose-Response Relationship, Drug; Esophagit | 1987 |
Treatment of ulcer disease.
Topics: Aluminum; Antacids; Anti-Ulcer Agents; Benzimidazoles; Cimetidine; Clinical Trials as Topic; Gastric | 1985 |
307 other studies available for omeprazole and Gastroduodenal Ulcer
| Article | Year |
|---|---|
Stress ulcer prophylaxis for critically ill children: routine use needs to be re-examined.
Topics: Acute Disease; Child; Critical Illness; Gastrointestinal Hemorrhage; Humans; Omeprazole; Peptic Ulce | 2022 |
Patient journey in erosive oesophagitis: real-world perspectives from US physicians and patients.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Ulcer Agents; Benzimidazoles; Esophagitis; Gastroesoph | 2022 |
Clinical effect of Anwei Qingyou recipe on peptic ulcer and its effect on the levels of EGF and PGE2: A retrospective study.
Topics: Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Clarithromycin; Dinoprostone; Drug Therapy, C | 2022 |
Treatment effects of Shilajit on aspirin-induced gastric lesions in rats.
Topics: Animals; Antioxidants; Aspirin; Gastric Mucosa; Male; Minerals; Omeprazole; Oxidative Stress; Peptic | 2021 |
Reliving 25 years of Experience with Omeprazole in Acid-peptic Diseases.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Anti-Ulcer Agents; Gastroesophageal Reflux; Humans; Omepraz | 2018 |
Gastric acid-dependent diseases: a twentieth-century revolution.
Topics: Anti-Bacterial Agents; Anti-Ulcer Agents; Drug Therapy, Combination; Gastric Acid; Gastroesophageal | 2014 |
Comparison of proton pump inhibitor and histamine-2 receptor antagonist in the prevention of recurrent peptic ulcers/erosions in long-term low-dose aspirin users: a retrospective cohort study.
Topics: Aged; Aged, 80 and over; Aspirin; Cohort Studies; Drug-Related Side Effects and Adverse Reactions; F | 2014 |
[THE EFFECTIVENESS OF ERADICATION IN PATIENTS WITH PEPTIC ULCER DISEASE ASSOCIATED WITH HELICOBACTER PYLORI, DEPENDING ON THE GENOTYPE OF THE DRUGMETABOLISM OF PROTON PUMP INHIBITORS].
Topics: Cytochrome P-450 CYP2C19; Female; Genotype; Helicobacter Infections; Helicobacter pylori; Humans; Ma | 2015 |
Asymmetric Dimethylarginine versus Proton Pump Inhibitors Usage in Patients with Stable Coronary Artery Disease: A Cross-Sectional Study.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Aged; Arginine; Coronary Artery Disease; Cross-Sectional St | 2016 |
French comment on article: High-dose omeprazole infusion compared with scheduled second-look endoscopy for prevention of peptic ulcer rebleeding: a randomized controlled trial.
Topics: Anti-Ulcer Agents; Endoscopy; Humans; Omeprazole; Peptic Ulcer; Peptic Ulcer Hemorrhage; Recurrence; | 2016 |
Proton pump inhibitors, purple gastric juice and peptic ulcer disease.
Topics: Aged, 80 and over; Endoscopy, Digestive System; Esomeprazole; Female; Gastric Juice; Humans; Omepraz | 2017 |
Continuous radiotelemetric monitoring of intragastric pH in a dog with peptic ulceration.
Topics: Animals; Anti-Ulcer Agents; Dog Diseases; Dogs; Drug Therapy, Combination; Hydrogen-Ion Concentratio | 2017 |
Short-term triple therapy with azithromycin for Helicobacter pylori eradication: low cost, high compliance, but low efficacy.
Topics: Adult; Aged; Aged, 80 and over; Amoxicillin; Azithromycin; Brazil; Drug Administration Schedule; Dru | 2008 |
[Gastroduodenal ulcers in the practice of joint endoprosthesis].
Topics: Anti-Inflammatory Agents, Non-Steroidal; Anti-Ulcer Agents; Arthroplasty, Replacement, Hip; Arthropl | 2008 |
[Comparison of Helicobacter pylori eradication rate in patients with non-ulcer dyspepsia and peptic ulcer diseases according to proton pump inhibitors].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agent | 2008 |
Effect of rebamipide on quality of peptic ulcer healing in rat.
Topics: Alanine; Animals; Anti-Ulcer Agents; Dinoprostone; Drug Therapy, Combination; Gastric Mucosa; Interl | 2009 |
Proton-pump inhibitors in peptic ulcer disease.
Topics: Humans; Omeprazole; Peptic Ulcer; Peptic Ulcer Hemorrhage; Proton Pump Inhibitors; Randomized Contro | 2008 |
Antiulcerogenic and anti-inflammatory activities of the essential oil from Pterodon emarginatus seeds.
Topics: Administration, Oral; Alkyl and Aryl Transferases; Animals; Anti-Inflammatory Agents; Anti-Ulcer Age | 2009 |
Evaluation of use of proton pump inhibitors in Greece.
Topics: Adult; Anti-Inflammatory Agents, Non-Steroidal; Drug Prescriptions; Drug Utilization; Gastroesophage | 2009 |
Helicobacter pylori infection in patients with chronic urticaria: correlation with pathologic findings in gastric biopsies.
Topics: Adult; Aged; Amoxicillin; Anti-Infective Agents; Biopsy; Case-Control Studies; Chronic Disease; Fema | 2009 |
Efficacy of an intravenous proton pump inhibitor after endoscopic therapy with epinephrine injection for peptic ulcer bleeding in patients with uraemia: a case-control study.
Topics: Aged; Anti-Ulcer Agents; Blood Transfusion; Case-Control Studies; Drug Administration Schedule; Epin | 2009 |
[Antihelicobacteric therapy for the patients with recurrent complicated postoperative gastroduodenal ulcer: indications, principles of conduction, efficacy].
Topics: Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Clarithromycin; Drug Administration Schedule; | 2009 |
Recurrent peptic ulcer disease in a pediatric patient with type 1 neurofibromatosis and primary ciliary dyskinesia.
Topics: Adult; Age Factors; Anti-Ulcer Agents; Child, Preschool; Ciliary Motility Disorders; Female; Follow- | 2009 |
Gedunin and photogedunin of Xylocarpus granatum show significant anti-secretory effects and protect the gastric mucosa of peptic ulcer in rats.
Topics: Acids; Animals; Anti-Ulcer Agents; Disease Models, Animal; Female; Fruit; Gastric Mucosa; Guinea Pig | 2010 |
Case report: peptic ulcer disease in a professional athlete.
Topics: Amoxicillin-Potassium Clavulanate Combination; Anti-Bacterial Agents; Anti-Ulcer Agents; Clarithromy | 2009 |
[Prevalence of rebleeding from peptic ulcer in patients treated with proton pump inhibitors].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Aged; Drug Costs; Female; Health Resources; Hospital Costs; | 2010 |
Protective effect of lafutidine, a histamine H2 receptor antagonist, against loxoprofen-induced small intestinal lesions in rats.
Topics: 16,16-Dimethylprostaglandin E2; Acetamides; Ampicillin; Animals; Anti-Bacterial Agents; Anti-Ulcer A | 2010 |
Quadruple therapy with ecabet sodium, omeprazole, amoxicillin and metronidazole is effective for eradication of Helicobacter pylori after failure of first-line therapy (KDOG0201 Study).
Topics: Abietanes; Adult; Aged; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Drug Therapy, Combina | 2010 |
Late-onset omeprazole-associated acute interstitial nephritis.
Topics: Acute Disease; Aged; Anti-Ulcer Agents; Biopsy; Female; Humans; Nephritis, Interstitial; Omeprazole; | 2010 |
Proton pump inhibitor co-therapy with clopidogrel: is there GI benefit or cardiovascular harm?
Topics: Atherosclerosis; Clopidogrel; Drug Interactions; Humans; Omeprazole; Peptic Ulcer; Platelet Aggregat | 2011 |
Proton pump inhibitors exacerbate NSAID-induced small intestinal injury by inducing dysbiosis.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Actinobacteria; Animals; Anti-Inflammatory Agents, Non-Ster | 2011 |
Helicobacter pylori infection: is sequential therapy superior to standard triple therapy? A single-centre Italian study in treatment-naive and non-treatment-naive patients.
Topics: Anti-Bacterial Agents; Anti-Ulcer Agents; Breath Tests; Drug Administration Schedule; Drug Resistanc | 2011 |
[Primary antibiotic resistance of Helicobacter pylori strains and eradication rate according to gastroduodenal disease in Korea].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Amoxicillin; Anti-Bacterial Agents; Chronic Di | 2011 |
Clinical update on nursing home medicine: 2011.
Topics: Anti-Ulcer Agents; Anticoagulants; Atrial Fibrillation; Clopidogrel; Clostridioides difficile; Delir | 2011 |
I've taken aspirin for years to prevent heart attack, and now I've developed an ulcer. My doctor told me to keep taking aspirin along with Prilosec. Why keep taking aspirin if it caused my ulcer?
Topics: Anti-Ulcer Agents; Aspirin; Humans; Myocardial Infarction; Omeprazole; Peptic Ulcer; Platelet Aggreg | 2012 |
Factors modulating the outcome of treatment for the eradication of Helicobacter pylori infection.
Topics: Adult; Aged; Aged, 80 and over; Amoxicillin; Antibodies, Bacterial; Antigens, Bacterial; Bacterial P | 2012 |
Melatonin protects against gastric ulceration and increases the efficacy of ranitidine and omeprazole in reducing gastric damage.
Topics: Animals; Anti-Ulcer Agents; Dose-Response Relationship, Drug; Free Radical Scavengers; Gastric Mucos | 2002 |
Proton pump inhibitors: an update.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Benzimidazoles; Drug Interactions; Esomeprazole; Gastroesop | 2002 |
Efficacy of a 1-week course of proton-pump inhibitor-based triple therapy for eradicating Helicobacter pylori in patients with and without chronic renal failure.
Topics: Amoxicillin; Anti-Ulcer Agents; Clarithromycin; Drug Administration Schedule; Drug Therapy, Combinat | 2002 |
Sequential eradicating therapy: a treatment that does not discriminate Helicobacter pylori strains in patients with nonulcer dyspepsia?
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Anti | 2002 |
A new serum antibody test kit (E plate) for evaluation of Helicobacter pylori eradication.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Anti | 2002 |
[Concerning the discussion article by I. A. Morozov "Choice of the gastroenterologist"].
Topics: Anti-Ulcer Agents; Duodenal Ulcer; Gastric Acid; Gastric Acidity Determination; Gastric Juice; Gastr | 2002 |
Lansoprazole for the prevention of recurrences of ulcer complications from long-term low-dose aspirin.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Inflammatory Agents, Non-Steroidal; Anti-Ulcer Agents; | 2002 |
NSAIDs, Helicobacter pylori, and Pandora's Box.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Anti-Ulcer Agents; Arthritis; Celecoxib; Cyclooxygenase 2; | 2002 |
[Visual documentation of the stability of intravenous solutions of omeprazole (Losec) and pantoprazole (Pantoloc)].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Ulcer Agents; Benzimidazoles; Drug Stability; Drug Sto | 2002 |
Seven-day proton pump inhibitor, amoxicillin and clarithromycin triple therapy. factors that influence Helicobacter pylori eradications success.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Amoxicillin; Benzimidazoles; Clarithromycin; Drug Therapy, | 2003 |
The clinical role of cytochrome p450 genotypes in Helicobacter pylori management.
Topics: Adult; Aged; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Aryl Hydrocarbon Hydroxylases; C | 2003 |
Low frequency of upper gastrointestinal complications in a cohort of high-risk patients taking low-dose aspirin or NSAIDS and omeprazole.
Topics: Adult; Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Anti-Ulcer Agents; Aspirin; | 2003 |
A retrospective study on efficacy of proton-pump inhibitor-based triple therapy for eradication of Helicobacter pylori in patients with chronic renal failure.
Topics: Aged; Amoxicillin; Anti-Ulcer Agents; Clarithromycin; Creatinine; Drug Therapy, Combination; Endosco | 2003 |
Banishing bleeding ulcers. Direct treatment helps--and long-term follow-up therapy may be unnecessary.
Topics: Anti-Ulcer Agents; Combined Modality Therapy; Epinephrine; Gastroscopy; Humans; Omeprazole; Peptic U | 2003 |
Intragastric pH during continuous infusion with pantoprazole in patients with bleeding peptic ulcer.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Aged, 80 and over; Anti-Ulcer Agents; Benzimid | 2003 |
Dosage of intravenous pantoprazole.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Ulcer Agents; Benzimidazoles; Gastrointestinal Hemorrh | 2003 |
Life cycle of a block buster drug: discovery and development of omeprazole (Prilosec).
Topics: Anti-Ulcer Agents; History, 20th Century; History, 21st Century; Omeprazole; Peptic Ulcer | 2002 |
[Long-term course of reflux symptoms following Helicobacter pylori eradication].
Topics: Adult; Aged; Aged, 80 and over; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Clarithromyci | 2004 |
[Selective cox-2 inhibitors. Better tolerance than NSAID plus antacid].
Topics: Adolescent; Adult; Aged; Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Rheumatoid; Celecoxib; | 2004 |
COX-2-specific inhibitor or proton pump inhibitor plus traditional NSAID: is either approach sufficient for patients at highest risk of NSAID-induced ulcers?
Topics: Anti-Inflammatory Agents, Non-Steroidal; Arthritis; Aspirin; Celecoxib; Cyclooxygenase 2; Cyclooxyge | 2004 |
Accuracy of a monoclonal antibody-based stool antigen test in the diagnosis of Helicobacter pylori infection.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adolescent; Adult; Aged; Antibodies, Monoclonal; Antigens, | 2004 |
Pantoprazole in severe acid-peptic disease: the effectiveness and safety of 5 years' continuous treatment.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Anti-Ulcer Agents; Benzimidazoles; Cell Count; | 2005 |
Desmodium gangeticum: a potent anti-ulcer agent.
Topics: Alcohols; Animals; Anti-Ulcer Agents; Aspirin; Cold Temperature; Duodenal Ulcer; Ethanol; Fabaceae; | 2005 |
Efficacy of local omeprazoles in the treatment of peptic ulcer disease.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anti-Ulcer Agents; Humans; Middle Aged; Omeprazole; Pept | 2005 |
Helicobacter pylori and recurrent pain abdomen.
Topics: Abdominal Pain; Adolescent; Anti-Bacterial Agents; Anti-Ulcer Agents; Child; Child, Preschool; Endos | 2005 |
Combined use of omeprazole and a novel antioxidative cytoprotectant for the treatment of peptic ulcer. Facilitation of ulcer healing in experimental animals.
Topics: Acetic Acid; Animals; Anti-Inflammatory Agents, Non-Steroidal; Anti-Ulcer Agents; Antioxidants; Arte | 2005 |
[Antisecretory therapy as a component of hemostasis in acute gastroduodenal ulcer bleedings].
Topics: Acute Disease; Anti-Ulcer Agents; Famotidine; Gastrointestinal Agents; Histamine H2 Antagonists; Hum | 2005 |
Helicobacter pylori eradication decreases the expression of glycosylphosphatidylinositol-anchored complement regulators, decay-accelerating factor and homologous restriction factor 20, in human gastric epithelium.
Topics: Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; CD55 Antigens; CD59 Antigens; Clarithromycin; | 2005 |
CagA status and Helicobacter pylori eradication among dyspeptic patients.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adolescent; Adult; Aged; Amoxicillin; Anti-Bacterial Agents | 2005 |
Helicobacter pylori: factors affecting eradication and recurrence.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Benz | 2005 |
[Medical, social, and economic effectiveness of treatment of day-case patients with peptic ulcer].
Topics: Adolescent; Adult; Anti-Bacterial Agents; Anti-Ulcer Agents; Biopsy; Clarithromycin; Cost-Benefit An | 2006 |
Drug injury in the upper gastrointestinal tract: nonsteroidal anti-inflammatory drugs.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Female; Gastrointestinal Tract; Humans; M | 2006 |
Helicobacter pylori eradication in peptic dyspepsia.
Topics: Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Bismuth; Clarithromycin; Drug Administration | 2005 |
Helicobacter pylori eradication prior to initiation of long-term non-steroidal anti-inflammatory drug therapy in Chinese patients-a cost-effectiveness analysis.
Topics: Aged; Amoxicillin; Anti-Bacterial Agents; Anti-Inflammatory Agents, Non-Steroidal; Anti-Ulcer Agents | 2006 |
The management of upper gastrointestinal symptoms: is endoscopy indicated?
Topics: Age Factors; Antacids; Anti-Ulcer Agents; Dyspepsia; Endoscopy, Digestive System; Gastroesophageal R | 2007 |
[Pharmacological efficacy of bismuth tripotassium dicitrate in peptic ulcer].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Antacids; Anti-Ulcer Agents; Cost-Benefit Analysis; Drug Th | 2007 |
Omeprazole inhibits natural killer cell functions.
Topics: Adult; Anti-Ulcer Agents; Cytotoxicity Tests, Immunologic; Female; Humans; Killer Cells, Natural; Ma | 2008 |
Eradication rates of helicobacter pylori infection with second-line treatment: non-ulcer dyspepsia compared to peptic ulcer disease.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Anti-Bacterial Agents; Anti-Ulcer Agents; Dysp | 2007 |
Prospective Acid Reflux Study of Iran (PARSI): methodology and study design.
Topics: Biopsy; Comorbidity; Drug Administration Schedule; Esophagogastric Junction; Esophagus; Feasibility | 2007 |
[Endoscopic changes in the stomach and duodenal mucosa caused by minidose acetylsalicylic acid therapy and their prevention].
Topics: Adult; Aged; Anti-Inflammatory Agents, Non-Steroidal; Anti-Ulcer Agents; Aspirin; Duodenum; Endoscop | 2007 |
Response to Ray and colleagues: the called-for large clinical trial is already ongoing.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Anti-Ulcer Agents; Arthritis; Celecoxib; Diclofenac; Humans | 2008 |
[New approach to the treatment and prophylaxis of NSAID-induced gastropathies in ambulatory practics].
Topics: Aged; Ambulatory Care; Anti-Inflammatory Agents, Non-Steroidal; Anti-Ulcer Agents; Humans; Male; Ome | 2007 |
Pump blockers and ulcer disease.
Topics: Adenosine Triphosphatases; Anti-Ulcer Agents; Benzimidazoles; Gastric Acid; Humans; Omeprazole; Pept | 1984 |
The SSAT-AGA (Society for Surgery of the Alimentary Tract-American Gastroenterological Association). New Orleans, May 20-23, 1984.
Topics: Animals; Benzimidazoles; Colitis, Ulcerative; Colon; Common Bile Duct; Crohn Disease; Digestive Syst | 1984 |
[Anti-ulcer agents. Clinico-experimental findings].
Topics: Antacids; Anti-Ulcer Agents; Benzimidazoles; Benzodiazepinones; Cimetidine; Histamine Antagonists; H | 1984 |
[A case report of prosthetic valve replacement for malfunction of the Hancock valve in mitral position associated with recurrent peptic ulcer and renal dysfunction].
Topics: Female; Heart Valve Prosthesis; Humans; Kidney Diseases; Middle Aged; Mitral Valve; Omeprazole; Pept | 1995 |
[Helicobacter pylori and peptic ulcer--1995 therapeutic indications and recommendations of a Munster Expert Group].
Topics: Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Bismuth; Dose-Response Relationship, Drug; Dr | 1995 |
Zollinger-Ellison syndrome. Advances in treatment of gastric hypersecretion and the gastrinoma.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Ulcer Agents; Blood Chemical Analysis; Combined Modali | 1994 |
[Once again: "A sick federal health office watches over health!"].
Topics: Anti-Ulcer Agents; Drug Approval; Germany; Humans; Omeprazole; Peptic Ulcer | 1995 |
[Federal health office commentaries: false, misleading citations].
Topics: Adverse Drug Reaction Reporting Systems; Anti-Ulcer Agents; Blindness; Germany; Humans; Omeprazole; | 1995 |
[Who is affected by blindness?].
Topics: Adverse Drug Reaction Reporting Systems; Anti-Ulcer Agents; Blindness; Deafness; Drug Approval; Huma | 1995 |
[We hope that the responsible persons learn from the experience!].
Topics: Adverse Drug Reaction Reporting Systems; Anti-Ulcer Agents; Blindness; Deafness; Drug Approval; Germ | 1995 |
[What can be learned from this case?].
Topics: Adverse Drug Reaction Reporting Systems; Anti-Ulcer Agents; Drug Approval; Germany; Humans; Omeprazo | 1995 |
Suppression of Acid Secretion by Lansoprazole and its Effects on Helicobacter pylori. II. Poster presentations from the 2nd International Colloquium on Proton Pump Inhibitors. Houston, Texas, September 29, 1994.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Animals; Anti-Ulcer Agents; Enzyme Inhibitors; Helicobacter | 1995 |
Clinical study on the pathophysiology and treatment of PPI-resistant ulcers.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Ulcer Agents; Drug Resistance; Duodenal Ulcer; Gastric | 1995 |
Factors affecting quality of ulcer healing after lansoprazole treatment.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Age Factors; Alcohol Drinking; Anti-Ulcer Agents; Duodenal | 1995 |
[Usefulness of every-other day administration of proton pump inhibitors from the standpoint of continuous 48-hour pH measurements-- Comparison of cimetidine, omeprazole, and lansoprazole].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Ulcer Agents; Cimetidine; Drug Administration Schedule | 1995 |
[Progress on therapy of peptic ulcer (discussion)].
Topics: Anti-Inflammatory Agents, Non-Steroidal; Gastritis; Helicobacter Infections; Helicobacter pylori; Hi | 1995 |
90% cure: which anti-Helicobacter therapy can achieve this treatment goal?
Topics: Amoxicillin; Bismuth; Drug Therapy, Combination; Helicobacter Infections; Helicobacter pylori; Human | 1995 |
[Therapy of Helicobacter pylori associated diseases].
Topics: Amoxicillin; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Therapy, Combinati | 1995 |
[Peptic ulcer: changing indications for gastric resection during the last 15 years].
Topics: Histamine H2 Antagonists; Humans; Omeprazole; Peptic Ulcer; Peptic Ulcer Hemorrhage; Peptic Ulcer Pe | 1994 |
[Drug of the month. Lansoprazole (DakaR)].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Ulcer Agents; Humans; Lansoprazole; Omeprazole; Peptic | 1995 |
Toward an optimal treatment of Helicobacter pylori-positive peptic ulcers.
Topics: Bismuth; Clarithromycin; Helicobacter Infections; Helicobacter pylori; Humans; Omeprazole; Peptic Ul | 1995 |
Low dose, short-term triple therapy for cure of Helicobacter pylori infection and healing of peptic ulcers.
Topics: Adult; Aged; Aged, 80 and over; Clarithromycin; Drug Administration Schedule; Drug Therapy, Combinat | 1995 |
Helicobacter pylori eradication and reinfection.
Topics: Clarithromycin; Drug Administration Schedule; Drug Therapy, Combination; Helicobacter Infections; He | 1995 |
Helicobacter pylori eradication and reinfection.
Topics: Anti-Bacterial Agents; Bismuth; Drug Administration Schedule; Drug Therapy, Combination; Helicobacte | 1995 |
Helicobacter pylori eradication and reinfection.
Topics: Anti-Ulcer Agents; Bismuth; Drug Therapy, Combination; Helicobacter Infections; Helicobacter pylori; | 1995 |
[A case of bronchial asthma associated with reflux esophagitis, whose peak expiratory flow rate improved with omeprazole and cisapride].
Topics: Asthma; Cisapride; Esophagitis, Peptic; Humans; Male; Middle Aged; Omeprazole; Peak Expiratory Flow | 1994 |
Acute interstitial nephritis, omeprazole and antineutrophil cytoplasmic antibodies.
Topics: Aged; Antibodies, Antineutrophil Cytoplasmic; Autoantibodies; Biomarkers; Humans; Male; Nephritis, I | 1994 |
Omeprazole treatment of children with peptic esophagitis refractory to ranitidine therapy.
Topics: Abdominal Pain; Adolescent; Child; Chronic Disease; Drug Resistance; Esophagitis, Peptic; Gastritis; | 1995 |
One-week low-dose triple therapy: new standards for Helicobacter pylori treatment.
Topics: Clarithromycin; Drug Administration Schedule; Drug Therapy, Combination; Helicobacter Infections; He | 1995 |
[Possibilities of the use of present-day antisecretory preparation omeprazole].
Topics: Adult; Aged; Aluminum Hydroxide; Antacids; Benzilates; Benzocaine; Choline; Cimetidine; Drug Combina | 1994 |
Hitting H pylori for four.
Topics: Anti-Ulcer Agents; Drug Administration Schedule; Drug Therapy, Combination; Helicobacter Infections; | 1995 |
[The use of ulcer medication in Iceland].
Topics: Adult; Aged; Anti-Ulcer Agents; Drug Utilization; Endoscopy, Gastrointestinal; Female; Histamine H2 | 1994 |
Management of Acid-Related Diseases: Focus on Pantoprazole. Proceedings of the 1st International Symposium on Pantoprazole. Berlin, Germany, 1 May 1993.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adenosine Triphosphatases; Animals; Benzimidazoles; Gastroe | 1994 |
Drugs for treatment of peptic ulcers.
Topics: Antacids; Anti-Bacterial Agents; Helicobacter Infections; Helicobacter pylori; Histamine H2 Antagoni | 1994 |
Effective treatment after failure of omeprazole plus amoxycillin to eradicate Helicobacter pylori infection in peptic ulcer disease.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Amoxicillin; Bismuth; Drug Therapy, Combinatio | 1994 |
[A Norwegian conference on updating of the treatment of Helicobacter pylori in peptic ulcer. Interessegruppe for Gastroenterologi].
Topics: Amoxicillin; Bismuth; Drug Therapy, Combination; Follow-Up Studies; Helicobacter Infections; Helicob | 1994 |
Highly significant change of the clinical course of relapsing and complicated peptic ulcer disease after cure of Helicobacter pylori infection.
Topics: Adult; Aged; Aged, 80 and over; Anti-Bacterial Agents; Cohort Studies; Drug Therapy, Combination; Fe | 1994 |
[Antibiotics in the treatment of peptic ulcer].
Topics: Anti-Bacterial Agents; Humans; Omeprazole; Peptic Ulcer | 1994 |
Omeprazole and reflux oesophagitis.
Topics: Esophagitis, Peptic; Humans; Omeprazole; Peptic Ulcer | 1994 |
Economic evaluation of new medical technology.
Topics: Canada; Cost-Benefit Analysis; Drug Costs; Europe; Health Expenditures; Hospital Costs; Humans; Japa | 1994 |
Acid-peptic disease: Helicobacter pylori and omeprazole: great advances but clinical problems remain.
Topics: Aged; Esophagitis, Peptic; Female; Helicobacter Infections; Helicobacter pylori; Humans; Omeprazole; | 1993 |
Short-term omeprazole oral/amoxicillin intravenous therapy for Helicobacter pylori eradication: a lack of therapeutic effect.
Topics: Adult; Aged; Aged, 80 and over; Amoxicillin; Drug Administration Schedule; Drug Therapy, Combination | 1994 |
Treatment of acid peptic disease: focus on proton pump inhibitors. Proceedings of the 1st International Symposium on Lansoprazole. Athens, Greece, 24 September 1992.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Animals; Anti-Ulcer Agents; Humans; Lansoprazole; Omeprazol | 1993 |
Role of Helicobacter pylori eradication in the prevention of peptic ulcer bleeding relapse.
Topics: Adult; Aged; Aged, 80 and over; Amoxicillin; Bismuth; Drug Therapy, Combination; Duodenal Ulcer; Fem | 1994 |
Four-week treatment with omeprazole increases the metabolism of caffeine.
Topics: Caffeine; Cytochrome P-450 CYP1A2; Cytochrome P-450 Enzyme System; Enzyme Induction; Esophagitis; Fe | 1994 |
[What are the indications for proton pump inhibitors? R. Arnold, Marburg, elaborates on the clinical aspects of the controversy regarding lansoprazole. Interview by Gerrit Lichtenberg].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Animals; Anti-Ulcer Agents; Carcinogenicity Tests; Carcinoi | 1994 |
The safety of omeprazole: true or false?
Topics: Esophagitis, Peptic; Humans; Omeprazole; Peptic Ulcer | 1994 |
[Quality assurance in everyday routines].
Topics: Amoxicillin; Anti-Inflammatory Agents, Non-Steroidal; Helicobacter Infections; Helicobacter pylori; | 1994 |
Long-term omeprazole therapy in peptic ulcer disease.
Topics: Animals; Gastritis, Atrophic; Humans; Omeprazole; Peptic Ulcer; Rats | 1993 |
Effects of omeprazole therapy on peptic disease and serum gastrin levels in hemodialysis patients. A preliminary study.
Topics: Adult; Drug Administration Schedule; Female; Gastrins; Humans; Male; Middle Aged; Omeprazole; Peptic | 1993 |
Helicobacter pylori eradication.
Topics: Adult; Amoxicillin; Drug Therapy, Combination; Helicobacter Infections; Helicobacter pylori; Humans; | 1993 |
One-day therapy for treatment of Helicobacter pylori infection.
Topics: Adult; Amoxicillin; Anti-Ulcer Agents; Chronic Disease; Drug Administration Schedule; Drug Therapy, | 1993 |
Omeprazole: is it the answer of peptic ulcer disease?
Topics: Adenosine Triphosphatases; Drug Administration Schedule; Duodenal Ulcer; Humans; Omeprazole; Peptic | 1993 |
[Omeprazole prevention of the recurrence of peptic ulcer: the efficacy of treatment with 20 mg on alternate days].
Topics: Adult; Aged; Aged, 80 and over; Drug Evaluation; Female; Gastrins; Humans; Male; Middle Aged; Omepra | 1993 |
Successful Helicobacter pylori eradication: a systemic effect of antibiotics?
Topics: Adult; Amoxicillin; Drug Therapy, Combination; Female; Helicobacter Infections; Helicobacter pylori; | 1993 |
Long-term omeprazole therapy in peptic ulcer disease: gastrin, endocrine cell growth, and gastritis.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Cell Division; Female; Gastrins; Gastritis; Helicobacter | 1993 |
Comparative evaluation of ulcer prevention efficacy of orally, rectally and sublingually administered omeprazole in three acute gastric ulcer models in rats.
Topics: Administration, Oral; Administration, Rectal; Administration, Sublingual; Animals; Aspirin; Female; | 1993 |
Colonization in patients receiving and not receiving topical antimicrobial prophylaxis.
Topics: Antacids; Anti-Ulcer Agents; Antibiotic Prophylaxis; Cross Infection; Histamine H2 Antagonists; Huma | 1996 |
Phenocopies of poor metabolizers of omeprazole caused by liver disease and drug treatment.
Topics: Administration, Oral; Adolescent; Adult; Aged; Aged, 80 and over; Analysis of Variance; Anti-Ulcer A | 1995 |
Proton-pump inhibitors or H2-receptor antagonists for Helicobacter pylori eradication-a meta-analysis.
Topics: Anti-Bacterial Agents; Anti-Ulcer Agents; Drug Therapy, Combination; Enzyme Inhibitors; Helicobacter | 1996 |
Cell kinetics of the gastric mucosa of patients treated with omeprazole.
Topics: Adult; Anti-Ulcer Agents; Cytokines; Female; Gastric Mucosa; Humans; Male; Middle Aged; Omeprazole; | 1996 |
[Pantoprazole. A new acid pump inhibitor against peptic ulcer and reflux esophagitis].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Ulcer Agents; Benzimidazoles; Esophagitis, Peptic; Hum | 1996 |
Prevalence of metronidazole resistant Helicobacter pylori strains among Chinese peptic ulcer disease patients and normal controls in Hong Kong.
Topics: Anti-Ulcer Agents; Antitrichomonal Agents; Biopsy; Case-Control Studies; China; Drug Resistance, Mic | 1996 |
Effects of the novel histamine H2-receptor antagonist (+/-)-(E)-1-[2-hydroxy-2-(4-hydroxyphenyl)ethyl]-3-[2-[[[5- (methylamino)methyl-2-furyl]methyl]thio]ethyl]-2-(methylsulfonyl) guanidine on gastric secretion and gastroduodenal ulcers in rats.
Topics: Animals; Anti-Ulcer Agents; Dose-Response Relationship, Drug; Epirizole; Gastric Acid; Gastric Mucos | 1996 |
Suppression of Helicobacter pylori colonization with omeprazole.
Topics: Anti-Bacterial Agents; Anti-Ulcer Agents; Drug Therapy, Combination; Helicobacter Infections; Helico | 1996 |
High effectiveness and safety of one-week antibiotic regimen in Helicobacter pylori eradication.
Topics: Adult; Aged; Aged, 80 and over; Anti-Bacterial Agents; Anti-Ulcer Agents; Antitrichomonal Agents; Cl | 1996 |
One-week triple therapy with omeprazole, amoxycillin and either clarithromycin or metronidazole for cure of Helicobacter pylori infection.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; A | 1996 |
Side effects of omeprazole.
Topics: Aged; Aged, 80 and over; Anti-Ulcer Agents; Dysgeusia; Female; Humans; Omeprazole; Peptic Ulcer; Sal | 1996 |
Metabolic interactions of the proton-pump inhibitors lansoprazole, omeprazole and pantoprazole with other drugs.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Ulcer Agents; Aryl Hydrocarbon Hydroxylases; Benzimida | 1996 |
Only one proton-pump inhibitor for formulary.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Enzyme Inhibitors; Formularies as Topic; Humans; Lansoprazo | 1996 |
Eradication of Helicobacter pylori followed by reinfection.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Blot | 1996 |
[What is the role of H2 receptor blockers today in ulcer therapy?].
Topics: Anti-Ulcer Agents; Drug Therapy, Combination; Helicobacter Infections; Histamine H2 Antagonists; Hum | 1996 |
[Do other proton pump blockers have advantages over Antra (omeprazole)?].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Ulcer Agents; Benzimidazoles; Humans; Lansoprazole; Om | 1996 |
[2 new proton pump inhibitors. Possibilities of pantoprazole and lansoprazole].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Ulcer Agents; Benzimidazoles; Humans; Lansoprazole; Om | 1996 |
Eradication of helicobacter pylori among patients from a primary care practice.
Topics: Adult; Anti-Bacterial Agents; Anti-Ulcer Agents; Chronic Disease; Drug Therapy, Combination; Endosco | 1996 |
[Anti-Helicobacter pylori therapy. Who should be treated, how, how long?].
Topics: Anti-Bacterial Agents; Anti-Ulcer Agents; Bismuth; Dose-Response Relationship, Drug; Drug Administra | 1996 |
Eradication of Helicobacter pylori in patients with end-stage renal disease under dialysis treatment.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Comb | 1997 |
A one-week quadruple eradication regimen for Helicobacter pylori in routine clinical practice.
Topics: Adult; Aged; Aged, 80 and over; Anti-Bacterial Agents; Anti-Ulcer Agents; Bismuth; Breath Tests; Dru | 1997 |
Patient factors that predict failure of omeprazole, clarithromycin, and tinidazole to eradicate Helicobacter pylori.
Topics: Adult; Age Factors; Aged; Alcohol Drinking; Anti-Bacterial Agents; Anti-Ulcer Agents; Clarithromycin | 1997 |
[Helicobacter pylori eradication: finally clarity].
Topics: Amoxicillin; Anti-Ulcer Agents; Clarithromycin; Drug Therapy, Combination; Gastritis; Helicobacter I | 1996 |
Antisecretory and antiulcer effect of T-330, a novel reversible proton pump inhibitor, in rats.
Topics: Animals; Anti-Ulcer Agents; Enzyme Inhibitors; Esophagitis, Peptic; Gastric Acid; Gastric Fistula; G | 1997 |
H2 blockers in the intensive care unit: ignoring the evidence? Telephone survey.
Topics: Anti-Ulcer Agents; Critical Care; Decision Making; Drug Utilization Review; Health Care Surveys; His | 1997 |
Proton-pump inhibitors: three of a kind?
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Ulcer Agents; Benzimidazoles; Enzyme Inhibitors; Human | 1997 |
Evaluation of the dyspeptic patient: a cost-utility study.
Topics: Adult; Ambulatory Care; Amoxicillin; Antacids; Anti-Bacterial Agents; Anti-Ulcer Agents; Antibodies, | 1997 |
[Toxic megacolon after Helicobacter pylori eradication therapy].
Topics: Aged; Amoxicillin; Anti-Ulcer Agents; Colon; Diagnosis, Differential; Drug Therapy, Combination; Ent | 1997 |
[Lansoprazol: acid blocking in peptic disorders].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Enzyme Inhibitors; Humans; Lansoprazole; Omeprazole; Peptic | 1994 |
[NSAID-induced ulcer and its complications].
Topics: Age Factors; Aged; Anti-Inflammatory Agents, Non-Steroidal; Anti-Ulcer Agents; Contraindications; Fe | 1997 |
Development of duodenal ulcer concomitant with successful Helicobacter pylori eradication.
Topics: Adult; Amoxicillin; Anti-Ulcer Agents; Drug Therapy, Combination; Duodenal Ulcer; Female; Helicobact | 1997 |
[Two step therapy for education of Helicobacter pylori].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Amoxicillin; Anti-Bacterial Agents; Clarithromycin; Drug Ad | 1997 |
Effect of enprostil on omeprazole-induced hypergastrinemia and inhibition of gastric acid secretion in peptic ulcer patients.
Topics: Adult; Aged; Anti-Ulcer Agents; Drug Therapy, Combination; Enprostil; Female; Gastric Acid; Gastric | 1997 |
Lack of effect of omeprazole in oral acenocoumarol anticoagulant therapy.
Topics: Acenocoumarol; Administration, Oral; Aged; Anti-Ulcer Agents; Anticoagulants; Case-Control Studies; | 1997 |
Low dose, short-term, triple therapy for helicobacter pylori associated peptic ulcer.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Anti-Bacterial Agents; Anti-Ulcer Agents; Clarithrom | 1997 |
[Short-term (6 days) eradication of Helicobacter pylori infection in the practice of a health insurance physician].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Ulcer Agents; Azithromycin; Benzimidazoles; Female; He | 1998 |
[Efficacy of the triple therapy in the eradication of H. pylori in peptic ulcer].
Topics: Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Clarithromycin; Drug Therapy, Combination; Du | 1997 |
Human gastric carcinoid detected during long-term antiulcer therapy of H2 receptor antagonist and proton pump inhibitor.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Anti-Ulcer Agents; Carcinoid Tumor; Famotidine; Hist | 1998 |
One-week triple therapy with lansoprazole, clarithromycin, and metronidazole to cure Helicobacter pylori infection in peptic ulcer disease in Korea.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Anti-Bacterial Agents; Clarithromycin; Drug Administ | 1998 |
The use of omeprazole in the pediatric population.
Topics: Adolescent; Anti-Ulcer Agents; Child; Child, Preschool; Esophagitis; Female; Humans; Male; Omeprazol | 1998 |
Predictive factors for rebleeding in patients with peptic ulcer bleeding after multipolar electrocoagulation: a retrospective analysis.
Topics: Anti-Ulcer Agents; Blood Transfusion; Electrocoagulation; Endoscopy, Digestive System; Female; Follo | 1998 |
Synergic interactions of macrolides and proton-pump inhibitors against Helicobacter pylori: a comparative in-vitro study.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Bacterial Agents; Anti-Ulcer Agents; Azithromycin; Dru | 1998 |
Studies support use of omeprazole for NSAID-induced ulcers.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Anti-Ulcer Agents; Humans; Omeprazole; Peptic Ulcer | 1998 |
The long-term clinical outcome of elderly patients with Helicobacter pylori-associated peptic ulcer disease.
Topics: Aged; Aging; Anti-Bacterial Agents; Anti-Ulcer Agents; Drug Therapy, Combination; Female; Gastritis; | 1998 |
Influence of the NIH Consensus Conference on Helicobacter pylori on physician prescribing among a Medicaid population.
Topics: Adult; Aged; Anti-Inflammatory Agents, Non-Steroidal; Anti-Ulcer Agents; Cohort Studies; Consensus D | 1998 |
A study on the relation between proton pump inhibitor and gastric giardiasis.
Topics: Adult; Animals; Anti-Ulcer Agents; Female; Gastric Mucosa; Gastritis; Giardia lamblia; Giardiasis; H | 1998 |
[Sensitivity of Helicobacter pylori to amoxicillin and clarythromycin with special reference to eradication therapy].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Clar | 1998 |
Assessment of symptomatic response as predictor of Helicobacter pylori status following eradication therapy in patients with ulcer.
Topics: Adult; Aged; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Antitrichomonal Agents; Breath T | 1998 |
Four-day quadruple therapy as a routine treatment for Helicobacter pylori infection.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adolescent; Adult; Aged; Anti-Bacterial Agents; Anti-Ulcer | 1997 |
Antacid (A02A) and antiulcer (A02B) drug prescription patterns: predicting factors, dosage and treatment duration.
Topics: Adolescent; Adult; Age Distribution; Aged; Aluminum Hydroxide; Analysis of Variance; Antacids; Anti- | 1998 |
Therapies for ulcers associated with nonsteroidal antiinflammatory drugs.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Anti-Ulcer Agents; Helicobacter Infections; Helicobacter py | 1998 |
Therapies for ulcers associated with nonsteroidal antiinflammatory drugs.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Anti-Ulcer Agents; Histamine H2 Antagonists; Humans; Misopr | 1998 |
Therapies for ulcers associated with nonsteroidal antiinflammatory drugs.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Anti-Ulcer Agents; Humans; Misoprostol; Omeprazole; Peptic | 1998 |
Therapies for ulcers associated with nonsteroidal antiinflammatory drugs.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Anti-Ulcer Agents; Humans; Omeprazole; Peptic Ulcer; Raniti | 1998 |
Omeprazole or misoprostol. Which works best for NSAID-induced ulcers?
Topics: Anti-Inflammatory Agents, Non-Steroidal; Anti-Ulcer Agents; Double-Blind Method; Female; Humans; Mal | 1998 |
Omeprazole for bleeding PUD: do we finally have evidence for effective medical therapy?
Topics: Anti-Ulcer Agents; Gastrointestinal Hemorrhage; Humans; Omeprazole; Peptic Ulcer; Prospective Studie | 1998 |
Treating Helicobacter pylori.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Bism | 1998 |
CYP2C19 genotype and phenotype determined with omeprazole in patients with acid-related disorders with and without Helicobacter pylori infection.
Topics: Anti-Ulcer Agents; Aryl Hydrocarbon Hydroxylases; Chromatography, High Pressure Liquid; Cytochrome P | 1998 |
Misoprostol vs omeprazole for ulcers associated with NSAIDs.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Anti-Ulcer Agents; Humans; Misoprostol; Omeprazole; Peptic | 1998 |
Fine structural and morphometric studies on gastric parietal cells of peptic ulcer patients after long-term treatment with omeprazole.
Topics: Adult; Anti-Ulcer Agents; Female; Humans; Male; Middle Aged; Omeprazole; Parietal Cells, Gastric; Pe | 1998 |
Effect of genetic differences in omeprazole metabolism on cure rates for Helicobacter pylori infection and peptic ulcer.
Topics: Adult; Amoxicillin; Anti-Ulcer Agents; Aryl Hydrocarbon Hydroxylases; Cytochrome P-450 CYP2C19; Cyto | 1998 |
One-week low-dose triple therapy is effective in treating Helicobacter pylori-infected patients with bleeding peptic ulcers.
Topics: Adult; Aged; Clarithromycin; Drug Therapy, Combination; Female; Follow-Up Studies; Gastrointestinal | 1998 |
Biochemical and pharmacological properties of a new proton pump inhibitor, 2-amino-4,5-dihydropyrido[1,2-a]thiazolo [5,4-g] benzimidazole (YJA20379-5).
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Anti-Ulcer Agents; Benzimidazoles; Epirizole; Etha | 1998 |
[Eradication of Helicobacter pylori by triple therapy in ulcerous patients: the role of endoscopy and antibiotic sensitivity].
Topics: Adult; Aged; Amoxicillin; Anti-Bacterial Agents; Clarithromycin; Drug Resistance, Microbial; Drug Th | 1998 |
New model of cytoprotection/adaptive cytoprotection in rats: endogenous small irritants, antiulcer agents and indomethacin.
Topics: Amino Acid Sequence; Anastomosis, Surgical; Animals; Anti-Ulcer Agents; Atropine; Cyclooxygenase Inh | 1999 |
Stress ulcer prevention and histamine-2-receptor antagonists: leaps of faith or back to the drawing board?
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Ulcer Agents; Histamine H2 Antagonists; Humans; Intens | 1999 |
Understanding peptic ulcer disease pharmacotherapeutics.
Topics: Anti-Bacterial Agents; Anti-Ulcer Agents; Clarithromycin; Drug Therapy, Combination; Female; Helicob | 1999 |
Quality of life in arthritis patients using nonsteroidal anti-inflammatory drugs.
Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Anti-Ulcer Agents; Arthritis; Female; Humans; Male; M | 1999 |
Effect of CYP2C19 polymorphism on serum levels of vitamin B12 in patients on long-term omeprazole treatment.
Topics: Anti-Ulcer Agents; Aryl Hydrocarbon Hydroxylases; Cytochrome P-450 CYP2C19; Cytochrome P-450 Enzyme | 1999 |
Omeprazole and bleeding peptic ulcer, or "how case-control studies can tell you what you suspected all along".
Topics: Anti-Inflammatory Agents, Non-Steroidal; Anti-Ulcer Agents; Case-Control Studies; Confounding Factor | 1999 |
Secondary prevention of upper gastrointestinal bleeding associated with maintenance acid-suppressing treatment in patients with peptic ulcer bleed.
Topics: Adult; Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Anti-Ulcer Agents; Cimetidi | 1999 |
Effects of TU-199, a novel H+, K(+)-ATPase inhibitor, on gastric acid secretion and gastroduodenal ulcers in rats.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Animals; Anti-Ulcer Agents; Drug Evaluation, Preclinical; G | 1999 |
Helicobacter pylori infection and persistent hyperemesis gravidarum.
Topics: Adolescent; Adult; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Clarithromycin; Famotidine | 1999 |
Impact of clarithromycin resistance on the effectiveness of a regimen for Helicobacter pylori: a prospective study of 1-week lansoprazole, amoxycillin and clarithromycin in active peptic ulcer.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Amoxicillin; Clarithromycin; Drug Resistance, | 1999 |
CYP2C19 genotype-related efficacy of omeprazole for the treatment of infection caused by Helicobacter pylori.
Topics: Amoxicillin; Antacids; Anti-Bacterial Agents; Anti-Ulcer Agents; Aryl Hydrocarbon Hydroxylases; Bism | 1999 |
Symptomatic benefit 1-3 years after H. pylori eradication in ulcer patients: impact of gastroesophageal reflux disease.
Topics: Adult; Aged; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Drug Therapy, Combination; Femal | 2000 |
Biochemical and pharmacological characteristics of a newly synthesized H+/K+-ATPase inhibitor, YJA20379-8, 3-butyryl-4-[R-1-methylbenzylamino]-8-ethoxy-1,7-naphthyridine, in pigs and rats.
Topics: Animals; Enzyme Inhibitors; Ethanol; Gastric Acid; Gastric Mucosa; Immersion; In Vitro Techniques; M | 1999 |
Concordance between use of proton pump inhibitors and prescribing guidelines.
Topics: Adult; Aged; Aged, 80 and over; Cohort Studies; Drug Utilization Review; Enzyme Inhibitors; Female; | 2000 |
Study of outcome after targeted intervention for peptic ulcer resistant to acid suppression therapy.
Topics: Adult; Antacids; Anti-Inflammatory Agents, Non-Steroidal; Anti-Ulcer Agents; Drug Resistance; Enzyme | 2000 |
Anaphylactic reactions to proton-pump inhibitors.
Topics: Anaphylaxis; Anti-Ulcer Agents; Female; Humans; Male; Middle Aged; Omeprazole; Peptic Ulcer; Proton | 2000 |
Concordance between use of proton pump inhibitors and prescribing guidelines.
Topics: Antacids; Anti-Ulcer Agents; Critical Care; Drug Prescriptions; Drug Utilization; Enzyme Inhibitors; | 2000 |
Omeprazole to prevent recurrent bleeding after endoscopic treatment of ulcers.
Topics: Anti-Ulcer Agents; Histamine H2 Antagonists; Humans; Injections, Intravenous; Omeprazole; Peptic Ulc | 2000 |
[Short-term intervention in ulcer and reflux. New acid blocker halves duration of therapy].
Topics: Anti-Ulcer Agents; Drug Administration Schedule; Esophagitis, Peptic; Helicobacter Infections; Helic | 2000 |
[Helicobacter pylori eradication in gastroduodenal ulcer: good, fine and not expensive].
Topics: Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Clarithromycin; Cost-Benefit Analysis; Drug T | 2000 |
Proton pump inhibitor therapy: preliminary results of a therapeutic interchange program.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Anti-Ulcer Agents; Drug Costs; Humans; Lansopr | 2000 |
Melatonin protects against stress-induced gastric lesions by scavenging the hydroxyl radical.
Topics: Animals; Anti-Ulcer Agents; Antioxidants; Cold Temperature; Dose-Response Relationship, Drug; Free R | 2000 |
[Upgrading efficiency and safety of combined antihelicobacterial treatment of ulcer patients using modern clinicopharmacological approaches].
Topics: Adult; Anti-Bacterial Agents; Anti-Ulcer Agents; Dose-Response Relationship, Drug; Drug Therapy, Com | 2000 |
Omeprazole and CYP2C19 polymorphism: effects of long-term treatment on gastrin, pepsinogen I, and chromogranin A in patients with acid related disorders.
Topics: Anti-Ulcer Agents; Aryl Hydrocarbon Hydroxylases; Biomarkers, Tumor; Chromogranin A; Chromogranins; | 2000 |
Effect of amoxicillin, clarithromycin, and rabeprazole, a new proton pump inhibitor, in eradication therapy for relapsing peptic ulcer diseases with Helicobacter pylori infection.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Aged, 80 and over; Amoxicillin; Anti-Bacterial | 2000 |
Current approaches to reducing gastrointestinal toxicity of low-dose aspirin.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Inflammatory Agents, Non-Steroidal; Anti-Ulcer Agents; | 2001 |
[Ulcer therapy with a new proton pump inhibitor. One week of treatment is enough].
Topics: Drug Administration Schedule; Drug Therapy, Combination; Helicobacter Infections; Helicobacter pylor | 2001 |
[Prevalence and treatment of Helicobacter pylori in gastro-duodenal ulcers. An experience in Liege].
Topics: Adult; Aged; Aged, 80 and over; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Belgium; Clar | 2001 |
Effects of lansoprazole, clarithromycin and pH gradient on uptake of [14C]amoxycillin into rat gastric tissue.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Amoxicillin; Animals; Anti-Ulcer Agents; Biological Transpo | 2001 |
Which patients with ulcer- or reflux-like dyspepsia will respond favorably to omeprazole?
Topics: Anti-Ulcer Agents; Gastroesophageal Reflux; Humans; Omeprazole; Patient Selection; Peptic Ulcer; Tre | 2001 |
Gastroprotective effect of aparisthman, a diterpene isolated from Aparisthmium cordatum, on experimental gastric ulcer models in rats and mice.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Animals; Anti-Inflammatory Agents, Non-Steroidal; Anti-Ulce | 2001 |
[Relations of acid-base balance and gastric secretion of hydrogen carbonate ions in patients with peptic ulcer].
Topics: Acid-Base Equilibrium; Acidosis; Adult; Anti-Ulcer Agents; Bicarbonates; Famotidine; Female; Gastric | 2001 |
Reversible pheripheral edema in female patients taking proton pump inhibitors for peptic acid diseases.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Anti-Ulcer Agents; Benzimidazoles; Edema; Female; Hu | 2001 |
4-day triple therapy with rabeprazole, amoxicillin and clarithromycin in the eradication of Helicobacter pylori in patients with peptic ulcer disease--A pilot study.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Amoxicillin; Anti-Ulcer Agents; Benzimidazoles | 2001 |
Strategy for retreatment of therapeutic failure of eradication of Helicobacter pylori infection.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agent | 2001 |
Drugs versus diets: disillusions with Dutch health care.
Topics: Adverse Drug Reaction Reporting Systems; Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Rheumat | 2001 |
[Current principles of the use of laparoscopic surgery in gastroduodenal ulcer].
Topics: Antacids; Anti-Bacterial Agents; Anti-Ulcer Agents; Clarithromycin; Drug Therapy, Combination; Duode | 2001 |
[The effectiveness of 7-day combined Helicobacter eradication therapy in patients with peptic ulcer and chronic gastritis].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Aged; Aged, 80 and over; Anti-Ulcer Agents; Chronic Disease | 2001 |
Recrudescence and reinfection with Helicobacter pylori after eradication therapy in Bangladeshi adults.
Topics: Adult; Amoxicillin; Anti-Ulcer Agents; Bangladesh; Body Mass Index; Breath Tests; Carbon Isotopes; D | 2001 |
Clarithromycin resistance of Helicobacter pylori has a major impact on the efficacy of the omeprazole-amoxicillin-clarithromycin therapy.
Topics: Adolescent; Adult; Aged; Amoxicillin; Anti-Ulcer Agents; Biopsy; Clarithromycin; DNA, Bacterial; Dru | 2001 |
Clarithromycin resistance, but not CYP2C-19 polymorphism, has a major impact on treatment success in 7-day treatment regimen for cure of H. pylori infection: a multiple logistic regression analysis.
Topics: Amoxicillin; Anti-Bacterial Agents; Aryl Hydrocarbon Hydroxylases; Clarithromycin; Cytochrome P-450 | 2001 |
The influence of commonly prescribed synthetic drugs for peptic ulcer on the pharmacokinetic fate of glycyrrhizin from Shaoyao-Gancao-tang.
Topics: Amoxicillin; Animals; Anti-Inflammatory Agents, Non-Steroidal; Anti-Ulcer Agents; Area Under Curve; | 2001 |
Does Helicobacter pylori eradication reduce the long-term requirements for acid suppressants in patients with a history of peptic ulcer disease in general practice? Results from a four-year longitudinal study.
Topics: Amoxicillin; Antacids; Clarithromycin; Drug Therapy, Combination; Follow-Up Studies; Helicobacter In | 2002 |
Critical effect of Helicobacter pylori infection on the effectiveness of omeprazole for prevention of gastric or duodenal ulcers among chronic NSAID users.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Anti-Ulcer Agents; Clinical Trials as Topic; Helicobacter I | 2002 |
[Gastroduodenal ulcer in childhood].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adolescent; Amoxicillin; Anti-Inflammatory Agents, Non-Ster | 2002 |
Failure of Helicobacter pylori eradication: is poor compliance the main cause?
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Amoxicillin; Anti-Bacterial Agents; Clarithrom | 2002 |
Proton pump inhibitors and stress ulcer prophylaxis: pause for thought?
Topics: Humans; Neutrophils; Omeprazole; Peptic Ulcer; Proton Pump Inhibitors; Stress, Physiological | 2002 |
[Management of dyspepsia, gastroduodenal ulcer and Helicobacter pylori infection in primary care].
Topics: Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Chi-Square Distribution; Clarithromycin; Drug | 2002 |
[Recurrent peptic ulcer after gastric surgery].
Topics: Adenosine Triphosphatases; Adult; Aged; Female; Gastrectomy; Gastric Acid; Gastrins; H(+)-K(+)-Excha | 1992 |
[Proton pump inhibitor for maintenance therapy of peptic ulcer].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adenosine Triphosphatases; Endoscopy, Gastrointestinal; H(+ | 1992 |
[Proton pump inhibitors in the treatment of peptic ulcers resistant to H2-receptor antagonists].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adenosine Triphosphatases; Depression, Chemical; Drug Resis | 1992 |
[Movement of gastric acid secretion and influence of proton pump inhibitors on histamine H2 receptor antagonist resistant ulcer].
Topics: Adenosine Triphosphatases; Adult; Depression, Chemical; Drug Resistance; Female; Gastric Acid; H(+)- | 1992 |
[Evaluation of the effect of proton pump inhibitors on stomal ulcer].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adenosine Triphosphatases; Drug Evaluation; Endoscopy, Gast | 1992 |
[Changes in the treatment of peptic ulcer following the development of proton pump inhibitors].
Topics: Adenosine Triphosphatases; Animals; Depression, Chemical; Gastric Acid; H(+)-K(+)-Exchanging ATPase; | 1992 |
[The influence of proton-pump inhibitors on the healing process of peptic ulcers--electronic endoscopic study].
Topics: Adenosine Triphosphatases; Electronics; Endoscopy, Gastrointestinal; Gastric Mucosa; H(+)-K(+)-Excha | 1992 |
Use of cimetidine and other peptic ulcer drugs in Denmark 1977-1990 with analysis of the risk of gastric cancer among cimetidine users.
Topics: Adult; Age Factors; Aged; Aged, 80 and over; Cimetidine; Cohort Studies; Denmark; Female; Histamine | 1992 |
[Drug therapy of peptic ulcer disease].
Topics: Anti-Bacterial Agents; Anti-Ulcer Agents; Chronic Disease; Helicobacter Infections; Histamine H2 Ant | 1991 |
[Opinion on the drug treatment of peptic ulcer].
Topics: Histamine H2 Antagonists; Humans; Omeprazole; Peptic Ulcer | 1991 |
[Relapse of peptic ulcer after quick healing induced by proton pump inhibitors].
Topics: Adenosine Triphosphatases; Animals; Endoscopy, Gastrointestinal; Gastric Mucosa; H(+)-K(+)-Exchangin | 1992 |
Gastric endocrine cells and gastritis in patients receiving long-term omeprazole treatment.
Topics: Adult; Biopsy; Esophagitis, Peptic; Gastric Mucosa; Gastritis, Atrophic; Humans; Hyperplasia; Incide | 1992 |
Inter-relationship between serum gastrin levels, gastric mucosal histology and gastric endocrine cell growth.
Topics: Biopsy; Esophagitis, Peptic; Gastric Mucosa; Gastrins; Gastritis, Atrophic; Humans; Hyperplasia; Lon | 1992 |
Importance of gastric acid in gastric ulcer formation in rabbits with antibody-induced prostaglandin deficiency.
Topics: 6-Ketoprostaglandin F1 alpha; Analysis of Variance; Animals; Antibodies; Cross Reactions; Gastric Ac | 1992 |
[Modified combined omeprazole/amoxicillin therapy for Helicobacter pylori eradication: a pilot study].
Topics: Adult; Aged; Amoxicillin; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Thera | 1992 |
[Omeprazole: a step forward in the therapy of acido-peptic disease].
Topics: Humans; Omeprazole; Peptic Ulcer | 1992 |
[Omeprazole and misoprostol in acute gastroduodenal pathology. Physiopathological and therapeutic considerations in a surgical study].
Topics: Acute Disease; Humans; Misoprostol; Omeprazole; Peptic Ulcer | 1992 |
Controversies, dilemmas, and dialogues. Reduction of gastric acidity in the treatment of peptic ulcer disease: how low should we go?
Topics: Dose-Response Relationship, Drug; Esophagitis, Peptic; Gastric Acid; Histamine H2 Antagonists; Human | 1991 |
[Ulcer prevention in therapy with low-dose acetylsalicylic acid?].
Topics: Aspirin; Brain Ischemia; Coronary Disease; Drug Therapy, Combination; Histamine H2 Antagonists; Huma | 1991 |
Omeprazole.
Topics: Gastroesophageal Reflux; Histamine H2 Antagonists; Humans; Omeprazole; Peptic Ulcer; Risk Factors; S | 1991 |
Drugs for treatment of peptic ulcers.
Topics: Antacids; Anti-Infective Agents; Anti-Ulcer Agents; Bismuth; Histamine H2 Antagonists; Humans; Misop | 1991 |
The effect of Zollinger-Ellison syndrome and omeprazole therapy on gastric oxyntic endocrine cells.
Topics: Adult; Cell Count; Female; Gastric Mucosa; Gastrins; Humans; Male; Middle Aged; Omeprazole; Parietal | 1990 |
Resolving problems in the use of omeprazole.
Topics: Humans; Omeprazole; Peptic Ulcer | 1991 |
[Reply to the critique by Drs. Díaz de Rojas y Castelló Tapias].
Topics: Achlorhydria; Depression, Chemical; Gastric Acid; Humans; Omeprazole; Peptic Ulcer | 1991 |
[Proton-pump inhibitor].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adenosine Triphosphate; Animals; Anti-Ulcer Agents; Energy | 1991 |
[Treatment of peptic ulcer and reflux esophagitis with enzyme inhibitors].
Topics: Adult; Aged; Esophagitis, Peptic; Esters; Female; Gabexate; Gastric Acid; Guanidines; Humans; Omepra | 1991 |
[Ciprofloxacin-omeprazole combination therapy for eradication of Helicobacter pylori].
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Campylobacter Infections; Ciprofloxacin; Drug | 1991 |
[Comment on the contribution: "Effect of omeprazole on serum gastrin levels: influence of age and sex" by Koop et al].
Topics: Age Factors; Carcinoid Tumor; Esophagitis, Peptic; Female; Gastrins; Humans; Male; Middle Aged; Omep | 1991 |
Effects of a proton pump inhibitor, AG-1749 (lansoprazole), on reflux esophagitis and experimental ulcers in rats.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Animals; Anti-Ulcer Agents; Duodenal Ulcer; Duodenum; Esoph | 1991 |
Effect of omeprazole on nocturnal intragastric pH in cirrhotics with inadequate antisecretory response to ranitidine.
Topics: Female; Gastric Acid; Gastric Acidity Determination; Gastritis; Humans; Hydrogen-Ion Concentration; | 1991 |
Histology of gastric biopsies from peptic ulcer patients before and after short-term treatment with omeprazole or H2-receptor antagonists.
Topics: Adult; Cimetidine; Female; Gastric Mucosa; Histamine H2 Antagonists; Humans; Male; Middle Aged; Omep | 1990 |
Effect of omeprazole on serum gastrin levels: influence of age and sex.
Topics: Adolescent; Adult; Age Factors; Aged; Esophagitis, Peptic; Female; Gastrins; Histamine H2 Antagonist | 1990 |
Omeprazole in the treatment of peptic ulcers resistant to H2-receptor antagonists.
Topics: Adult; Aged; Drug Resistance; Female; Histamine H2 Antagonists; Humans; Male; Middle Aged; Omeprazol | 1990 |
Hemolytic anemia associated with the use of omeprazole.
Topics: Anemia, Hemolytic; Duodenitis; Esophagitis, Peptic; Female; Humans; Middle Aged; Omeprazole; Peptic | 1991 |
Omeprazole for peptic ulcer in Crohn's disease.
Topics: Adult; Crohn Disease; Humans; Male; Omeprazole; Peptic Ulcer | 1991 |
[Bullous pemphigoid secondary corticoresistant. Inhibitory role of omeprazole on corticosteroid metabolism?].
Topics: Adult; Drug Interactions; Drug Resistance; Female; Humans; Microsomes, Liver; Omeprazole; Pemphigoid | 1991 |
Efficacy and safety of omeprazole in the long-term treatment of peptic ulcer and reflux oesophagitis resistant to ranitidine.
Topics: Drug Resistance; Esophagitis, Peptic; Gastrins; Humans; Omeprazole; Peptic Ulcer; Ranitidine; Time F | 1990 |
Serum gastrin levels during long-term omeprazole treatment.
Topics: Esophagitis, Peptic; Gastric Acid; Gastrins; Humans; Omeprazole; Peptic Ulcer; Radioimmunoassay; Vag | 1990 |
Catatonic reaction to omeprazole and disulfiram in a patient with alcohol dependence.
Topics: Adult; Alcoholism; Catatonia; Disulfiram; Drug Interactions; Humans; Male; Omeprazole; Peptic Ulcer | 1990 |
Omeprazole treatment of severe peptic disease associated with antral G cell hyperfunction and hyperpepsinogenemia I in an infant.
Topics: Administration, Oral; Biopsy; Child, Preschool; Endoscopy, Gastrointestinal; Female; Gastrins; Human | 1990 |
Omeprazole, the first proton pump inhibitor for peptic ulcer disease. Proceedings of the symposium held during the 8th Asian Pacific Congress of Gastroenterology. Seoul, Korea, 11 October 1988.
Topics: Humans; Omeprazole; Peptic Ulcer | 1989 |
Antisecretory and antiulcer activities of a novel proton pump inhibitor AG-1749 in dogs and rats.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adenosine Triphosphatases; Animals; Anti-Ulcer Agents; Dogs | 1989 |
[Advances in the knowledge of peptic-acid dependent diseases].
Topics: Congresses as Topic; Esophagitis; Gastric Acid; Humans; Omeprazole; Peptic Ulcer | 1989 |
[Omeprazole. A new inhibitor of gastric secretion].
Topics: Gastric Acid; Humans; Omeprazole; Peptic Ulcer; Secretory Rate | 1989 |
[Omeprazole. An effective antisecretory agent in ulcerative disease and reflux esophagitis].
Topics: Esophagitis, Peptic; Humans; Omeprazole; Peptic Ulcer | 1989 |
[Recent developments in drugs antagonistic to factors causing peptic ulcer--clinical efficacy and problems; gastric mucosa proton pump inhibitors].
Topics: Animals; Dogs; Female; Gastric Acid; Gastric Mucosa; Humans; Male; Omeprazole; Peptic Ulcer; Protons | 1988 |
Advances in drug therapy for peptic ulcer disease.
Topics: Animals; Anti-Ulcer Agents; Bicarbonates; Diterpenes; Dogs; Gastric Acid; Gastric Mucosa; Omeprazole | 1987 |
Advances in the treatment of peptic ulcer disease.
Topics: Antacids; Anti-Ulcer Agents; Histamine H2 Antagonists; Humans; Omeprazole; Parasympatholytics; Pepti | 1987 |
[Perspectives in the drug therapy of peptic ulcer].
Topics: Gastric Mucosa; Histamine H2 Antagonists; Humans; Omeprazole; Oxygen Consumption; Peptic Ulcer; Pros | 1988 |
Omeprazole in peptic ulcers resistant to histamine H2-receptor antagonists.
Topics: Adult; Aged; Drug Resistance; Female; Histamine H2 Antagonists; Humans; Male; Middle Aged; Omeprazol | 1987 |
Biochemical and pharmacological analysis of 2-[(2-dimethylaminobenzyl)sulfinyl] benzimidazole (NC-1300), a new proton pump inhibitor.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Acetylcholine; Adenosine Triphosphatases; Animals; Anti-Ulc | 1986 |
[New developments in ulcer therapy: famotidine, omeprazole misoprostol].
Topics: Alprostadil; Anti-Ulcer Agents; Famotidine; Humans; Misoprostol; Omeprazole; Peptic Ulcer; Thiazoles | 1986 |
[Peptic ulcer. New H2 blockers, prostaglandins, benzimidazoles].
Topics: Alprostadil; Anti-Ulcer Agents; Famotidine; Humans; Misoprostol; Omeprazole; Peptic Ulcer; Thiazoles | 1987 |
Effects of prostaglandin D2 and omeprazole on indomethacin-induced gastric ulcers in rats.
Topics: Animals; Chromatography, High Pressure Liquid; Gastric Acid; Gastric Mucosa; Indomethacin; Male; Ome | 1988 |
Gastric surface epithelial cell damage induced by restraint and water-immersion stress in rats. Protective effects of 16,16-dimethyl-prostaglandin E2.
Topics: 16,16-Dimethylprostaglandin E2; 2-Pyridinylmethylsulfinylbenzimidazoles; Animals; Atropine; Benzimid | 1988 |
The effect of a new gastric proton pump inhibitor on serotonin-induced gastric mucosal lesions in rats.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Animals; Anti-Ulcer Agents; Benzimidazoles; Gastric Juice; | 1988 |
Long-term omeprazole treatment in man: effects on gastric endocrine cell populations.
Topics: Female; Gastric Mucosa; Gastrins; Humans; Male; Omeprazole; Parietal Cells, Gastric; Peptic Ulcer; R | 1988 |
Present experiences with omeprazole in the Zollinger-Ellison syndrome.
Topics: Anti-Ulcer Agents; Benzimidazoles; Gastric Acid; Gastrins; Humans; Omeprazole; Peptic Ulcer; Time Fa | 1986 |
Safety aspects of omeprazole.
Topics: Alanine Transaminase; Anti-Ulcer Agents; Benzimidazoles; Creatinine; Dose-Response Relationship, Dru | 1986 |
[Omeprazole and peptic ulcer. Profile of a new active agent].
Topics: Humans; Omeprazole; Peptic Ulcer; Zollinger-Ellison Syndrome | 1987 |